



[illegible]

that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The condensed consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiary, scPharmaceuticals Securities Corporation. Certain information and disclosures normally included in financial statements in accordance with U.S. GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company's audited financial statements and related notes for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 13, 2024. The Company has determined that it operates in one segment. The accompanying condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of operations and comprehensive loss and stockholders' equity for the three and nine months ended September 30, 2023 and 2024 and condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2024 are unaudited. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with that used to prepare the Company's audited annual financial statements and include, in the opinion of management, adjustments, consisting of normal recurring items, necessary for the fair statement of the condensed consolidated financial statements. The operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results expected for the full year ending December 31, 2024.

**Liquidity**As of September 30, 2024, the Company had an accumulated deficit of approximately \$347.6 million. Management expects to continue to incur operating losses for the foreseeable future. The Company has financed its operations to date from proceeds from the sale of common stock, preferred stock and the incurrence of debt. As of September 30, 2024, the Company had cash and cash equivalents of \$91.5 million. On October 13, 2022, the Company entered into a Credit Agreement and Guaranty (the "Oaktree Agreement") with, among others, the lenders from time to time party thereto and Oaktree Fund Administration, LLC, in its capacity as administrative agent for the lenders (Note 9). On August 9, 2024 (the "Closing Date"), the Company entered into a Credit Agreement and Guaranty (the "Credit Agreement") with the guarantors from time to time party thereto, the lenders from time to time party thereto (the "Lenders"), and Perceptive Credit Holdings IV, LP, in its capacity as administrative agent for the Lenders (in such capacity, the "Agent") (Note 9). On the Closing Date, the Company also entered into a Revenue Participation Right Purchase and Sale Agreement (the "Revenue Purchase and Sale Agreement") with Perceptive Credit Holdings IV, LP (the "Purchaser") (Note 9). The Company used the proceeds of the Credit Agreement and the Revenue Purchase and Sale Agreement to, on the Closing Date, prepay all outstanding obligations under the Oaktree Agreement, including the payment of fees and expenses associated with the Oaktree Agreement. In addition, on August 13, 2024, the Company completed an underwritten public offering of shares of its common stock (and, in lieu of such shares of common stock to selected investors, pre-funded warrants to purchase shares of its common stock) with net proceeds of \$53.5 million (Note 10). The Company's existing cash and cash equivalents will be sufficient to meet its cash commitments for at least the next 12 months after the date that the interim condensed consolidated financial statements are issued. Additionally, the Company expects to have access to funds pursuant to an at-the-market offering program with Cowen and Company, LLC (Note 10), or could otherwise seek \$9 additional funding through a combination of public or private equity offerings if it believes additional resources are needed. Additional financing may not be available on a timely basis on terms acceptable to the Company, or at all.

**2. Significant Accounting Policies****Use of Estimates**The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reported periods. Actual results could differ from those estimates.

**Cash and Cash Equivalents** Cash and cash equivalents consists of bank deposits and money market accounts with financial institutions. Cash equivalents are carried at cost which approximates fair value due to their short-term nature and which the Company believes do not have a material exposure to credit risk. The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. The Company's cash and cash equivalent accounts, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts.

**Accounts Receivable**Accounts receivable are recorded net of any estimated expected credit losses. The Company's measurement of expected credit losses is based on relevant information about past events, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material credit loss allowance for uncollectible trade receivables.

**Concentration of Credit Risk**Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to hold a minimum rating, thereby reducing credit risk exposure.

**Customer and Supplier Concentration**The Company has a limited number of specialty pharmacy customers and distributors. As of December 31, 2023 and September 30, 2024, three customers represented 99% and two customers represented 98% of accounts receivable, respectively. For the three and nine months ended September 30, 2024, two customers represented 98% and three customers represented 99% of revenue, respectively. For the three and nine months ended September 30, 2023, two customers represented 92% and one customer represented 88% of revenue, respectively. The Company has a limited number of suppliers and contract manufacturers utilized in the production of its product. As of December 31, 2023 and September 30, 2024, one supplier represented 47% and three suppliers represented 49% of accounts payable, respectively. For the three and nine months ended September 30, 2024, two suppliers represented 45% and 49% of purchases, respectively. For the three and nine months ended September 30, 2023, one supplier represented 29% and two suppliers represented 40% of purchases, respectively. The Company depends on suppliers for raw materials, active pharmaceutical ingredients, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers may take a substantial period of time, as suppliers must be approved by the FDA. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture its products, it could have a materially adverse effect on the Company's business, financial condition and results of operations.

**Investments**The Company invests excess cash balances in available-for-sale debt securities. The Company determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company reports available-for-sale investments at fair value at each balance sheet date and includes any unrealized gains and losses in accumulated other comprehensive income (loss), a component of stockholders' equity. Realized gains and losses are determined using the specific identification method and are included in other income. If any 9/10 adjustment to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is other than temporary, including the intention to sell and, if so, marks the investment to market through a charge to the Company's consolidated statements of operations and comprehensive loss.

**Inventory**Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company began capitalizing inventory costs following U.S. Food and Drug Administration ("FDA") approval of FUROSCIX on October 7, 2022. Inventory is sold on a first in, first out ("FIFO") basis. The Company periodically reviews inventory for expiry and obsolescence and writes it down accordingly, if necessary. Prior to FDA approval of FUROSCIX, the Company expensed all inventory-related costs, including that used for clinical development, to research and development ("R&D") costs in the period incurred.

**Leases**The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use ("ROU") lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets. ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

**Debt** Issuance Costs Debt issuance costs have been amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheet as of December 31, 2023.

**Fair Value**OptionAs permitted under Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 825, Financial Instruments ("ASC 825"), the Company elected the fair value option to account for the Credit Agreement and the Revenue Purchase and Sale Agreement (collectively, the "Perceptive Financing"). In accordance with ASC 825, the Company records these instruments at fair value with changes in fair value recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the Perceptive Financing were expensed as incurred and were not deferred. The Company elected to account for the Perceptive Financing using the fair value option, which allows for valuing the Credit Agreement and the Revenue Purchase and Sale Agreement in their entirety versus bifurcation of the embedded derivatives.

**Revenue Recognition**The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, Revenue from Contracts with Customer ("ASC Topic 606"), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. The Company has identified one performance obligation, the delivery of FUROSCIX to its customers. The Company has not incurred any incremental costs associated with obtaining contracts with customers. The Company's revenues consist solely of the sale of FUROSCIX to customers in the United States.

**10/11 Product Net Sales** FUROSCIX was approved by the FDA on October 7, 2022. The Company launched sales of FUROSCIX in the first quarter of 2023 and its customers consist of specialty pharmacies ("P&Ss") and specialty distributors ("SDs"). The Company recognizes revenue from product sales at a point in time, typically upon receipt of product at the SPs and SDs, the date at which the rights, title, interest and risk of loss are transferred. Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration that result from (a) sales discounts, (b) rebates (c) co-pay assistance, and (d) product returns. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves for variable consideration are reflected as either as a reduction to the related account receivable or as an accrued liability, depending on how the consideration is settled. The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results vary from its estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.

**Sales Discounts:** Sales discounts are agreed-upon discounts, from negotiated contracts, taken directly off the Company's sales invoices. Sales discounts are recorded as an offset to revenue based on contractual terms at the time revenue from the sale is recognized. **Rebates:** Allowance for rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare Part D prescription drug benefit, TRICARE program and contractual rebates with commercial payers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or statutory requirements. The allowance for rebates is based on contracted or statutory discount rates and expected utilization by benefit plan participants. The Company's estimates for expected utilization of rebates are based on utilization data received from the SPs since product launch. Rebates are generally included and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter's activity, plus an accrual balance for prior quarters' unpaid rebates. If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

**Co-Payment Assistance:** The Company offers co-payment assistance to commercially insured patients meeting certain eligibility requirements. Co-payment assistance is accrued at the time of product sale to SPs based on estimated patient participation and average co-pay benefit to be paid per a claim. The Company's estimated amounts are compared to actual program participation and co-pay amounts paid using data provided by third-party administrators. If actual amounts differ from the original estimates the assumptions being applied are updated and adjustment for prior period accruals will be adjusted in the current period.

**Product Returns:** Consistent with industry practice, the Company offers SPs and SDs limited product return rights for damages, shipment errors, and expiring product, provided that the return is within a specified period around the product expiration date as set forth in the applicable individual distribution agreement. The Company does not allow product returns for product that has been dispensed to a patient. As the Company receives inventory reports from the SPs and has the ability to control the amount of product that is sold to the SPs, it is able to make a reasonable estimate of future potential product returns based on this on-hand channel inventory data and sell-through data obtained from the SPs. Currently, sales to SDs are limited and there is no access to on-hand channel inventory or sell through data. As these arrangements mature, the Company will utilize any data that they can provide as part of this analysis. In arriving at its estimate, the Company also considers historical product returns, the underlying product demand, and industry data specific to the specialty pharmaceutical distribution industry.

**Research and Development Costs** Research and development costs are expensed as incurred. Nonrefundable advance payments, if any, for goods or services used in research and development are initially recorded as an asset and then recognized as an expense as the related goods are delivered or services are performed. Research and development expenses include contract services, consulting, salaries, materials and supplies and overhead.

**Income Taxes**The Company accounts for income taxes in accordance with the FASB ASC 740, Income Taxes. Deferred tax assets and liabilities are recorded to reflect the impact of temporary differences between amounts of assets and liabilities for financial reporting purposes and such amounts as measured under enacted tax laws. A valuation allowance is required to offset any net deferred tax assets if, based upon the available evidence, it is more likely than not that some or all of the deferred tax asset will not be realized.

**11/12** The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions. The tax benefits recorded are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any uncertainty related to the tax benefit, assuming that the matter in question will be raised by the tax authorities. Potential interest and penalties associated with such uncertain tax positions are recorded as a component of income tax expense. At September 30, 2024, the Company had no such accruals.

As part of the Tax Cuts and Jobs Act of 2017 ("TCJA"), beginning with the Company's fiscal year ended December 31, 2022, the Company is required to capitalize research and development expenses, as defined under section 174 of the Internal Revenue Code of 1986, as amended. For expenses that are incurred for research and development in the United States, the amounts will be amortized over 5 years, and expenses that are incurred for research and experimentation outside the United States will be amortized over 15 years.

**3. Net Loss per Share**Net Loss per Share Attributable to Common StockholdersThe following table sets forth the computation of basic and diluted net loss per share of common stock (in thousands, except share and per share data):

	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2023
Net loss	\$ (15,634)	\$ (35,105)	\$ (40,998)	\$ (66,303)
Weighted-average shares used in computing net loss per share	38,760,895	46,558,474	38,421,676	41,516,917
Net loss per share, basic and diluted	\$ (0.41)	\$ (0.75)	\$ (1.07)	\$ (1.60)

Basic and diluted weighted average shares of common stock outstanding for the three and nine months ended September 30, 2024 include the weighted average effect of outstanding pre-funded warrants for the purchase of shares of common stock for which the remaining unfunded exercise price is \$0.001 per share. The Company's potentially dilutive securities, which include unexercised stock options outstanding, unexercised warrants and unvested restricted stock units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect.

	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2023
Stock options to purchase common stock	4,722,050	5,445,475	4,722,050	5,445,475

Assets to purchase common stock at \$ 516,345 \$ 1,016,345 \$ 516,345 \$ 1,016,345 \$ Unvested restricted stock units \$ 339,556 \$ 721,766 \$ 339,556 \$ 721,766 \$ Total \$ 5,577,951 \$ 7,183,586 \$ 5,577,951 \$ 7,183,586 \$ 12 13 4. InvestmentsCash in excess of the Company's immediate requirements is invested in accordance with the Company's investment policy that primarily seeks to maintain adequate liquidity and preserve capital.A summary of the Company's available-for-sale classified investments as of December 31, 2023 consisted of the following (in thousands): At December 31, 2023 Investments - Current: Cost Basis \$ Accumulated Unrealized Gains \$ Accumulated Unrealized Losses \$ Fair Value United States Treasury securities \$ 13,967 \$ 2 \$ - \$ 13,969 Commercial paper \$ 9,427 \$ - \$ (2) \$ 9,425 \$ Corporate bonds \$ 3,815 \$ - \$ - \$ 3,815 United States Government Agency securities \$ 1,991 \$ - \$ - \$ 1,990 Total \$ 29,200 \$ 2 \$ 2 \$ (3) \$ 29,199 The Company did not have any investments as of September 30, 2024. 5. InventoryThe Company's inventory balance consists of the following (in thousands): At December 31, 2023 At September 30, 2024 Raw materials \$ 4,256 \$ 6,874 Work-in-process \$ 4,188 \$ 10,363 Finished goods \$ 396 \$ 870 \$ 8,840 \$ 18,107 \$ At Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company began capitalizing inventory costs following FDA approval of FUROSCIX in October 2022 and has not recorded any significant inventory write-downs since that time. At December 31, 2023 and September 30, 2024, the Company has an allowance for excess, damaged and obsolete inventory in the amount of \$0 and \$75,000, respectively. The Company currently uses a limited number of third-party contract manufacturing organizations ("CMOs") to produce its inventory. 6. Property and EquipmentPurchased property and equipment consist of the following (dollars in thousands): At ESTIMATEDUSEFUL LIFE At December 31, 2023 At September 30, 2024 Office equipment 5A years \$ 31 \$ 31 Office furniture 7A years \$ 64 \$ 73 Computer equipment 3A years \$ 15 \$ 15 Leasehold improvements A Life of lease \$ 9 \$ 9 \$ 119 \$ 128 Less: Accumulated depreciation \$ (61) \$ (77) Property and equipment, net \$ 58 \$ 51 \$ Depreciation expense for the three months ended September 30, 2023 and 2024 was \$6,000 and \$5,000, respectively. Depreciation expense for the nine months ended September 30, 2023 and 2024 was \$18,000 and \$16,000, respectively. At 13 14 7. Accrued ExpensesAccrued expenses consist of the following (in thousands): At December 31, 2023 At September 30, 2024 Employee compensation and related costs \$ 4,375 \$ 3,891 Manufacturing costs \$ 434 \$ 2,260 Sales returns and allowances and related costs \$ 1,418 \$ 1,477 Contract research and development \$ 1,202 \$ 1,240 Consulting and professional service fees \$ 945 \$ 658 Royalty \$ 249 \$ 259 Inventory in transit \$ 150 \$ 150 \$ Other \$ 128 \$ 83 Total accrued expenses \$ 8,901 \$ 9,868 \$ 8 Fair Value of Financial Instruments FASB ASC Topic 820, Fair Value Measurements and Disclosures (ASC 820), provides a fair value hierarchy, which classifies fair value measurements based on the inputs used in measuring fair value. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below: Level 1 "Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 "Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3 "Valuations that require inputs that reflect the Company's own assumptions that are both significant to the fair value measurement and observable. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying values of the Company's cash, prepaid expenses and deposits approximate their fair values due to their short-term nature. At 14 15 The following tables summarize the Company's assets that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands): At As of December 31, 2023 At TOTAL \$ Quoted Prices in Active Markets (Level 1) \$ Significant Other Observable Inputs (Level 2) \$ Significant Unobservable Inputs (Level 3) \$ Assets: Cash equivalents \$ 44,202 \$ 44,202 \$ \$ \$ Total cash equivalents \$ 44,202 \$ 44,202 \$ \$ \$ United States Treasury securities \$ 13,969 \$ 13,969 \$ - \$ Commercial paper \$ 9,425 \$ 9,425 \$ - \$ Corporate bonds \$ 3,815 \$ 3,815 \$ - \$ United States Treasury securities \$ 13,969 \$ 13,969 \$ - \$ Commercial paper \$ 9,425 \$ 9,425 \$ - \$ Investments \$ 29,199 \$ 13,969 \$ 15,230 \$ Derivative liability \$ 3,857 \$ 3,857 \$ - \$ Total \$ 73,401 \$ 58,171 \$ 15,230 \$ Liabilities: Derivative liability \$ 3,857 \$ 3,857 \$ - \$ Total \$ 3,857 \$ 3,857 \$ - \$ As of September 30, 2024 At TOTAL \$ Quoted Prices in Active Markets (Level 1) \$ Significant Other Observable Inputs (Level 2) \$ Significant Unobservable Inputs (Level 3) \$ Assets: Cash equivalents \$ 90,346 \$ 90,346 \$ \$ \$ Total \$ 90,346 \$ 90,346 \$ \$ \$ Cash equivalents \$ 90,346 \$ 90,346 \$ \$ \$ Total \$ 90,346 \$ 90,346 \$ \$ \$ Liabilities: Term loan \$ 51,099 \$ 51,099 \$ \$ \$ Revenue purchase and sale liability \$ 26,830 \$ 26,830 \$ \$ \$ Total \$ 77,929 \$ 77,929 \$ \$ \$ The Company measures the term loan and the revenue purchase and sale liability from the Perceptive Financing at fair value based on significant inputs not observable in the market, which causes them to be classified as Level 3 measurements within the fair value hierarchy. These valuations use assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an on-going basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value of the Perceptive Financing related to updated assumptions and estimates are recognized within the Consolidated Statements of Operations and Comprehensive Loss. The fair value of the term loan was measured as of September 30, 2024, using a binomial lattice model to account for the dynamic nature of interest rate fluctuations and the strategic exercise of the certain optional prepayment features. Three variations of such binomial lattice models were utilized: the Black-Derman-Toy ("BDT"), Hull-White, and Ho-Lee models, each incorporating assumptions of future interest rate curves. The fair value of the revenue purchase and sale liability was measured as of September 30, 2024, using a hybrid methodology between the discounted cash flow ("DCF") and Monte Carlo simulation method (MCS), utilizing future cash flow projections and assumptions of the timing and probability of certain contingent events, such as the occurrence of a change of control and the exercise of call and put options. A discount rate of 20.5% was used. At 15 16 The fair values of the term loan and the revenue purchase and sale liability may change significantly as additional data is obtained, impacting the Company's assumptions regarding probabilities of outcomes used to estimate the fair value of the liabilities. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company's results of operations in future periods. A Changes in the fair value of the Company's Level 3 liabilities for the nine months ended September 30, 2024 are as follows (in thousands): At Derivative Liability \$ Term Loan \$ Revenue purchase and sale liability \$ At December 31, 2023 \$ 3,857 \$ \$ \$ At Initial fair value \$ 48,145 \$ 25,000 \$ Change in fair value \$ (3,857) \$ 2,954 \$ 1,830 \$ At September 30, 2024 \$ 51,099 \$ \$ 26,830 \$ 9. Financial Liabilities Perceptive FinancingThe following table presents the fair value of the Company's debt balance as of September 30, 2024 (in thousands): At September 30, 2024 Par value of the term loan \$ 50,000 Initial fair value adjustment \$ (1,855) Fair value of the term loan at issuance \$ 48,145 Change in fair value of the term loan \$ 2,954 Total fair value of the term loan \$ 51,099 At On the Closing Date, the Company entered into the Credit Agreement. The Credit Agreement establishes a \$75.0 million term loan facility, consisting of (i) \$50.0 million funded on the Closing Date ("Tranche A Loan") and (ii) subject to satisfaction of certain conditions, \$25.0 million (together with the Tranche A Loan, collectively, the "Term Loan") that the Company may borrow in a single borrowing on or prior to March 31, 2026. A Borrowings under the Term Loan bear interest at a rate per annum equal to the one-month term SOFR (subject to a 3.25% floor), plus an applicable margin of 6.75%, payable monthly in arrears. There will be no scheduled repayments of outstanding principal on the Term Loan prior to August 9, 2029 (the "Maturity Date"). The Company may voluntarily prepay the outstanding Term Loan, subject to a yield protection premium equal to (i) 5.0% of the principal amount of the Term Loan prepaid, if prepaid on or prior to the first anniversary of the Closing Date, (ii) 3.0% of the principal amount of the Term Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, (iii) 1.0% of the principal amount of the Term Loan if prepaid after the second anniversary of the Closing Date through and including the third anniversary of the Closing Date, with no prepayment premium due after the third anniversary of the Closing date through the Maturity Date. At On the Closing Date, the Company was required to issue to the Lenders of such Term Loan warrants to purchase 300,000 of shares of the Company's common stock, in the aggregate (the "Warrant"), at an exercise price of \$4.902. Upon the completion of the sale of common stock on August 13, 2024 (Note 10), the exercise price of the warrants was adjusted to \$4.00 according to the terms of the agreement. Upon inception, the Company evaluated the warrants and determined that they met all the requirements for equity classification under ASC Topic 815 Derivatives and Hedging ("ASC 815"). This transaction was accounted for as a detachable warrant at its fair value, using the residual method, and is recorded as an increase to additional paid-in-capital on the consolidated statement of stockholder's equity in the amount of \$1.6 million. The Company used the Black-Scholes option pricing model to determine the fair value of the warrants. Assumptions included the fair market value per share of common stock on the valuation date of \$4.33, the exercise price per warrant equal to \$4.00, the expected volatility of 87.5%, the risk-free interest rate of 3.83%, the contractual term of 6 years and the absence of a dividend. The Warrant is immediately exercisable, and the exercise period will expire 6 years from the date of issuance. At In addition to the Warrant, the Company will be required to issue to the Lenders warrants to purchase 200,000 of shares of the Company's common stock (the "Tranche B Warrant") upon the draw down of the second tranche of the Term Loan on or prior to March 31, 2026. These warrants were accounted for using the residual method and were recorded on a relative fair value basis, resulting in an increase to additional paid-in-capital on the consolidated statement of stockholder's equity in the amount of \$0.2 million. The Company used the Black-Scholes option pricing model to determine the fair value of the warrants. Assumptions included the fair market value per share of common stock on the valuation date of \$4.33, the exercise price per warrant equal to \$4.00, the expected volatility of 82.5%, the risk-free interest rate of 3.87%, the contractual term of 7.64 years and the absence of a dividend. The Tranche B Warrant will expire 6 years from the date of issuance. At The Company's obligations under the Credit Agreement and the other Loan Documents (as defined in the Credit Agreement) will be guaranteed by any domestic subsidiaries of ours that become Guarantors (as defined in the Credit Agreement), subject to certain exceptions. The Borrowers' and the Guarantors' (collectively, the "Loan Parties") respective obligations under the Credit Agreement and the other Loan Documents are secured by first priority security interests in substantially all assets of the Loan Parties, subject to certain customary thresholds and exceptions. The Credit Agreement contains customary representations, warranties and affirmative and negative covenants, including financial covenants requiring the Company to (i) maintain certain levels of cash and cash equivalents in accounts subject to a control agreement in favor of the Agent of at least \$5.0 million at all times after the Closing Date and (ii) meet minimum quarterly net sales targets described in the Credit Agreement. In addition, the Credit Agreement contains customary events of default that entitle the Agent to cause the Company's indebtedness under the Credit Agreement to become immediately due and payable, and to exercise remedies against the Loan Parties and the collateral securing the Term Loan, including cash. Under the Credit Agreement, an event of default will occur if, among other things, the Company fails to make payments under the Credit Agreement (subject to specified periods), the Company or its subsidiaries breach any of the covenants under the Credit Agreement (subject to specified cure periods with respect to certain breaches), a material adverse change occurs, the Company, its subsidiaries or its respective assets become subject to certain legal proceedings, such as bankruptcy proceedings, the Company and/or its subsidiaries are unable to pay its debts as they become due or default on contracts with third parties which would permit the holder of indebtedness in excess of a certain threshold to accelerate the maturity of such indebtedness or that could cause a material adverse change. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 3.0% per annum may apply to all obligations owed under the Credit Agreement. At On the Closing Date, the Company also entered into the Revenue Purchase and Sale Agreement with the Purchaser. Under the Revenue Purchase and Sale Agreement, in exchange for the Purchaser's payment to the Company of a purchase price of up to \$50.0 million, in the aggregate, the Company has agreed to sell to the Purchaser its right to receive payment in full of a tiered single digit percentage of net sales of FUROSCIX. The initial sale of the Revenue Payment under the Revenue Purchase and Sale Agreement in the amount of \$25.0 million took place on the Closing Date. The Purchaser's right to receive the Revenue Payment terminates and the Company no longer has the obligation to pay Purchaser Revenue Payments once the Purch

payment or prepayment equal to 2.0% of the aggregate principal amount of the loans funded under the Oaktree Agreement. In connection with the Credit Agreement, the Company paid off all unpaid borrowings under the Oaktree Agreement on August 9, 2024, including the \$1.0 million exit fee and a prepayment premium of \$2.6 million. For the three months ended September 30, 2023 and 2024, the Company recorded \$521,000 and \$276,000 related to the amortization of the debt discount associated with the Oaktree Agreement, respectively. For the nine months ended September 30, 2023 and 2024, the Company recorded \$1.5 million and \$1.5 million related to the amortization of the debt discount associated with the Oaktree Agreement, respectively. For the three months ended September 30, 2023 and 2024, the Company recorded \$38,000 and \$20,000 related to the amortization of the exit fee associated with the Oaktree Agreement, respectively. For the nine months ended September 30, 2023 and 2024, the Company recorded \$108,000 and \$107,000 related to the amortization of the exit fee associated with the Oaktree Agreement, respectively.

10. Stockholders' Equity

18 19 2021 At-the-Market Issuance Sales Agreement

On March 23, 2021, the Company entered into an Open Market Sale Agreement (the "2021 ATM Agreement") with Cowen and Company, LLC (the "Cowen"), having an aggregate offering price of up to \$50.0 million through Cowen as its sales agent. The Company agreed to pay Cowen a commission up to 3.0% of the gross sales proceeds of such 2021 ATM Shares. On March 13, 2024, the Company amended and restated the 2021 ATM Agreement and entered into a new \$50.0 million Open Market Sales Agreement with Cowen (the "2024 ATM Agreement"). As of March 13, 2024, the Company had sold a total of 1,726,043 2021 ATM Shares under the 2021 ATM Program at a weighted average gross selling price of \$9.01 per share for net proceeds of \$15.2 million. 2024 At-the-Market Issuance Sales Agreement Pursuant to the 2024 ATM Agreement, the Company could offer and sell shares of its common stock (the "2024 ATM Shares"), having an aggregate offering price of up to \$50.0 million through Cowen as its sales agent (the "2024 ATM Program"). The offering and sale of the 2024 ATM Shares will be made pursuant to the Company's shelf registration statement on Form S-3, which was declared effective by the SEC on March 22, 2024 (the "2024 Registration Statement"). There were no shares issued under the 2024 ATM Program as of September 30, 2024. Sale of Common Stock

On August 13, 2024, the Company completed an underwritten public offering of 13,875,000 shares of its common stock, \$0.001 par value per share (the "2024 Offering Shares"), and, in lieu of shares of common stock to certain select investors, pre-funded warrants to purchase up to an aggregate of 500,000 shares of common stock at an exercise price equal to \$0.001 per share, pursuant to the 2024 Registration Statement.

The 2024 Offering Shares were sold at an offering price of \$4.00 per share. The pre-funded warrants were sold at an offering price of \$3.999 per underlying share, which was equal to the price per share of common stock being sold in this offering, minus \$0.001, which is the exercise price per share of the pre-funded warrants. The pre-funded warrants were accounted for as equity instruments. Net proceeds of the offering were \$53.5 million, after deducting underwriting discounts, commissions and offering expenses.

11. Stock-Based Compensation

Stock Options

The Company's 2017 Stock Option and Incentive Plan (the "2017 Stock Plan") became effective in November 2017, upon the closing of the Company's initial public offering and will expire in October 2027. Under the 2017 Stock Plan, the Company may grant incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units (the "RSUs") and other stock-based awards. The Company's 2014 Stock Incentive Plan (the "2014 Stock Plan") was terminated in November 2017 effective upon the completion of the Company's initial public offering and no further options will be granted under the 2014 Stock Plan. At September 30, 2024, there were 555,427 options outstanding under the 2014 Stock Plan. As of September 30, 2024, there were 8,769,977 shares of the Company's common stock authorized for issuance under the 2017 Stock Plan, including 366,823 options that have been forfeited from the 2014 Stock Plan. At September 30, 2024, there were 3,206,310 options available for issuance under the 2017 Stock Plan, 4,775,676 options outstanding and 721,766 RSUs outstanding. On February 1, 2023, the Board of Directors of the Company adopted the 2023 Employment Inducement Award Plan (the "Inducement Plan") and, subject to the adjustment provisions of the Inducement Plan, reserved 500,000 shares of the Company's common stock for issuance pursuant to equity awards granted under the Inducement Plan. At September 30, 2024, there were 385,628 options available for issuance under the Inducement Plan, and 114,372 options outstanding. Awards granted under the 2017 Stock Plan and the Inducement Plan have a term of ten years. Vesting of awards under the 2017 Stock Plan and Inducement Plan is determined by the board of directors, but is generally over one to four-year terms.

19 20 The fair value of options at date of grant was estimated using the Black-Scholes option-pricing model with the following assumptions:

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000

become due or default on contracts with third parties which would permit the holder of indebtedness in excess of a certain threshold to accelerate the maturity of such indebtedness or that could cause a material adverse change. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 3.0% per annum may apply to all obligations owed under the Credit Agreement. A On the Closing Date, we entered into a revenue participation right purchase and sale agreement (the "Revenue Purchase and Sale Agreement") with Perceptive Credit Holdings IV, LP (the "Purchaser"). Under the terms of the Revenue Purchase and Sale Agreement, in exchange for the Purchaser's payment to us of a purchase price of \$50.0 million, in the aggregate subject to certain conditions at closing (the "Purchase Price"), we have agreed to sell to the Purchaser its right to receive payment in full of a tiered single digit percentage of net sales of FUOSCIX (the "Revenue Payment") for each calendar quarter commencing on the effective date of the Revenue Purchase and Sale Agreement, subject to adjustments on June 30, 2028 and June 30, 2030 depending on the amount of Revenue Payments received by such dates. The Purchaser's right to receive the Revenue Payment terminates and we no longer have the obligation to pay Purchaser Revenue Payments once the Purchaser receives 200.0% (subject to reductions on September 30, 2027 and September 30, 2029 depending on the amount of Revenue Payments received by such dates) of the Purchase Price. We may also buy-out the Purchaser's rights to receive the Revenue Payments by paying Purchaser a tiered multiple on the Purchase Price. 24.25 The Revenue Purchase and Sale Agreement contains various representations and warranties, including with respect to organization, authorization, and certain other matters, certain covenants with respect to payment, reporting, intellectual property, in-licenses, out-licenses, and certain other actions, indemnification obligations and other provisions customary for transactions of this nature. 2024 Public Offering On August 12, 2024, we entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named in Schedule A thereto (collectively, the "Underwriters"), relating to an underwritten offering of 12,000,000 shares (the "Shares") of our common stock, \$0.0001 par value per share (the "Common Stock"), and, in lieu of Common Stock to select investors, pre-funded warrants (the "Pre-funded Warrants") to purchase 500,000 shares of Common Stock. The offering price of the Shares to the public was \$4.00 per share, and the offering price of the Pre-funded Warrants to the public was \$3.999 per underlying share, which was equal to the price per share of Common Stock being sold in the offering, minus \$0.001, which is the exercise price per share of the Pre-funded Warrants. Under the terms of the Underwriting Agreement, we also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 1,875,000 shares of Common Stock at a price of \$4.00 per share, less underwriting discounts and commissions. On August 12, 2024, the Underwriters exercised this option in full. The closing of the offering (including the sale of the Shares subject to the Underwriters' option to purchase additional shares) took place on August 13, 2024. The net proceeds from the offering were \$53.5 million, after deducting underwriting discounts, commissions and offering expenses. We do not intend to list the Pre-funded Warrants on Nasdaq or any other nationally recognized securities exchange or trading system. A We have funded our operations from inception through September 30, 2024 primarily through the sale of shares of our common stock and incurrence of debt and, prior to that, through the private placement of our preferred stock. As of September 30, 2024, we had an accumulated deficit of approximately \$347.6 million and cash and cash equivalents of \$91.5 million. We expect to continue to incur net losses for the foreseeable future as we support the commercialization efforts of FUOSCIX in the United States, including expanding our sales and marketing organization, continuing research and development efforts, engaging in scale-up manufacturing and seeking regulatory approval for new product candidates and enhancements. Our financial results may fluctuate from quarter to quarter and will depend on, among other factors, the net sales of FUOSCIX, the scope and progress of our research and development efforts and timing of certain expenses. COMPONENTS OF OUR RESULTS OF OPERATIONS Product Revenues Product revenues, net, consist of net sales of FUOSCIX. We initiated shipments of FUOSCIX to customers in the United States, which include specialty pharmacies, in February 2023. We recognize revenue for product received by our customers net of allowances for customer discounts, service fees, estimated returns and rebates. A Cost of Product Revenues Cost of product revenues include costs related to the manufacturing of FUOSCIX, including third party manufacturing costs, packaging and freight, in addition to royalty expenses. We began capitalizing inventory upon FDA approval of FUOSCIX. All costs related to inventory for FUOSCIX prior to FDA approval were expensed as incurred and therefore not included in cost of revenues. A Research and Development Expenses Research and development ("R&D") expenses consist of the cost of engineering, clinical trials, regulatory and medical affairs and quality assurance associated with developing our proprietary technology and product candidates. R&D expenses consist primarily of: employee-related expenses, including salaries, benefits, travel expense and stock-based compensation expense; cost of outside consultants who assist with technology development, regulatory affairs, clinical trials and medical affairs, and quality assurance; cost of clinical trial activities performed by third parties; cost of pre-approval pharmaceutical batch manufacturing; and 25.26 cost of facilities and supplies used for internal research and development and clinical activities. We expense R&D costs as incurred. Given the emphasis to date on our approved product FUOSCIX, our R&D expenses have not been allocated on a program-specific basis. In the future, we expect R&D expenses to increase in absolute dollars as we continue to develop new products and enhance existing products and technologies. We anticipate that our expenses will increase significantly as we: continue to advance our pipeline programs beyond FUOSCIX; continue our current research and development activity; seek to identify additional research programs and additional product candidates; initiate preclinical testing and clinical trials for any product candidates we identify and develop, maintain, expand and protect our intellectual property portfolio; and hire additional research, clinical and scientific personnel. Selling, General and Administrative Expenses Selling, general and administrative ("SG&A") expenses consist of employee-related expenses, including salaries, benefits, travel expense and stock-based compensation expense for personnel in executive, finance, commercial, field sales, human resources, facility operations and administrative functions. Other SG&A expenses include promotional activities, marketing, conferences and trade shows, professional services fees, including legal, audit and tax fees, insurance costs, general corporate expenses and allocated facilities-related expenses. We anticipate that our SG&A expenses will increase as we continue to expand our corporate and commercial infrastructure to support the commercialization activities of FUOSCIX in the United States. Results of Operations Comparison of Three Months Ended September 30, 2023 and 2024 The following table summarizes our results of operations for the three months ended September 30, 2023 and 2024 (in thousands): A A Three Months Ended September 30, A Increase A A 2023 A A 2024 A A (Decrease) A Product revenues, net A \$ 3,796 A \$ 10,026 A A \$ 6,230 A A A A A A Operating expenses A A A A A A Cost of product revenues A A 1,079 A A 3,311 A A 2,232 A Research and development A A 3,421 A A 3,541 A A 120 A Selling, general and administrative A A 14,135 A A 21,320 A A 7,185 A Total operating expenses A A 18,635 A A 28,172 A A 9,537 A A A A A A Loss from operations A A (14,839) A A (18,146) A A 3,307 A Loss on extinguishment of debt A - A (13,032) A A 13,032 A Change in fair value of term loan A - A (2,954) A A 2,954 A Change in fair value of revenue purchase and sale liability A - A (1,830) A A 1,830 A Other (expense) income A A (36) A A 1,804 A A 1,840 A Interest income A A 1,301 A A 903 A A (398) A Interest expense A A (2,060) A A (1,850) A A (210) A Net loss A \$ (15,634) A \$ (35,105) A A \$ 19,471 A A Product revenues. Product revenues were \$10.0 million for the three months ended September 30, 2024, compared to \$3.8 million for the three months ended September 30, 2023. The increase of \$6.2 million was due to an increase in demand of FUOSCIX further into commercial launch. 26.27 Cost of product revenues. Cost of product revenues were \$3.3 million for the three months ended September 30, 2024, compared to \$1.1 million for the three months ended September 30, 2023. Similar to product revenues, the increase of \$2.2 million was due to an increase in demand of FUOSCIX further into commercial launch, and related manufacturing costs. Research and development expenses. R&D expenses were \$3.5 million for the three months ended September 30, 2024, compared to \$3.4 million for the three months ended September 30, 2023. The increase of \$0.1 million was primarily attributable to an increase of \$0.2 million in clinical study costs. This was offset by a \$0.1 million decrease in pharmaceutical development, quality, regulatory and employee-related costs. Selling, general and administrative expenses. SG&A expenses were \$21.3 million for the three months ended September 30, 2024, compared to \$14.1 million for the three months ended September 30, 2023. The increase of \$7.2 million was primarily attributable to \$4.4 million in costs associated with entering into the Credit Agreement and Revenue Purchase and Sale Agreement, and a \$1.6 million increase in employee-related costs, a \$0.8 million increase in commercial costs, a \$0.3 million increase in patient support, and a \$0.2 million increase in professional service costs. The increase was partially offset by a \$0.1 million decrease in taxes and insurance. Loss on extinguishment of debt. Loss on extinguishment of debt was \$13.0 million for the three months ended September 30, 2024. The loss was related to the payoff of the Oaktree Agreement (as defined below) in August 2024. Change in fair value of term loan. The change in fair value the term loan, which is accounted for under the fair value option, was \$3.0 million for the three months ended September 30, 2024. The change in fair value was primarily due to changes in interest rates and volatility. Change in fair value of revenue purchase and sale liability. The change in fair value of the revenue purchase and sale liability, which is accounted for under the fair value option, was \$1.8 million for the three months ended September 30, 2024. The change in fair value was primarily due to changes in market yields. Other income (expense). Other income was \$1.8 million for the three months ended September 30, 2024, compared to other expense of \$36,000 for the three months ended September 30, 2023. The increase in income of \$1.8 million was primarily attributable to the fair value adjustment to the derivative liability and foreign exchange losses in the three months ended September 30, 2024. Interest income. Interest income was \$0.9 million for the three months ended September 30, 2024, compared to \$1.3 million for the three months ended September 30, 2023. The decrease of \$0.4 million was primarily attributable to lower balances on our financial instruments. Interest expense. Interest expense was \$1.9 million for the three months ended September 30, 2024 compared to \$2.1 million for the three months ended September 30, 2023. The decrease of \$0.2 million was due to lower amortization of debt costs associated with the Oaktree Agreement. A A A A A A 27.28 Comparison of Nine Months Ended September 30, 2023 and 2024 The following table summarizes our results of operations for the nine months ended September 30, 2023 and 2024 (in thousands): A A A A Nine Months Ended September 30, A A Increase A A 2023 A A 2024 A A (Decrease) A Product revenues, net A \$ 7,497 A A \$ 24,182 A A \$ 16,685 A A A A A A A A Operating expenses A A A A A A A A Cost of product revenues A A 2,038 A A 7,396 A A A 5,358 A Research and development A A 8,471 A A A 8,944 A A A 473 A Selling, general and administrative A A 37,127 A A 56,275 A A 19,148 A Total operating expenses A A 47,636 A A 72,615 A A 24,979 A A A A A A A A Loss from operations A A (40,139) A A (48,433) A A 8,294 A Loss on extinguishment of debt A - A (13,032) A A 13,032 A Change in fair value of term loan A - A (2,954) A A 2,954 A Change in fair value of revenue purchase and sale liability A - A (1,830) A A 1,830 A Other income A A 1,193 A A 3,587 A A 2,394 A Interest income A A 3,979 A A 2,444 A A (1,535) A Interest expense A A (6,031) A A (6,085) A A 54 A Net loss A \$ (40,998) A \$ (66,303) A A 25,305 A A Product revenues. Product revenues were \$24.2 million for the nine months ended September 30, 2024, compared to \$7.5 million for the nine months ended September 30, 2023. The increase of \$16.7 million was due to an increase in demand of FUOSCIX further into commercial launch. Cost of product revenues. Cost of product revenues were \$7.4 million for the nine months ended September 30, 2024, compared to \$2.0 million for the nine months ended September 30, 2023. Similar to product revenues, the increase of \$5.4 million was due to an increase in demand of FUOSCIX further into commercial launch, and related manufacturing costs. Research and development expenses. R&D expenses were \$8.9 million for the nine months ended September 30, 2024, compared to \$8.5 million for the nine months ended September 30, 2023. The increase of \$0.5 million was primarily attributable to a \$0.8 million increase in clinical study costs, a \$0.5 million increase in device development costs and a \$0.2 million increase in patent costs. The increase was partially offset by a \$0.9 million decrease in pharmaceutical development costs and a \$0.1 million decrease in shipping and storage costs. Selling, general and administrative expenses. SG&A expenses were \$56.3 million for the nine months ended September 30, 2024, compared to \$37.1 million for the nine months ended September 30, 2023. The increase of \$19.2 million was primarily attributable to a \$8.0 million increase in employee-related costs, \$4.4 million in costs associated with entering into the Credit Agreement and Revenue Purchase and Sale Agreement, a \$3.8 million increase in commercial costs, a \$2.2 million increase in product samples, a \$1.0 million increase in patient support, and a \$0.1 million increase in professional service costs. The increase was partially offset by a \$0.4 million decrease in taxes and insurance. Loss on extinguishment of debt. Loss on extinguishment of debt was \$13.0 million for the three months ended September 30, 2024. The loss was related to the payoff of the Oaktree Agreement in August of 2024. Change in fair value of term loan. The change in fair value the term loan, which is accounted for under the fair value option, was \$3.0 million for the nine months ended September 30, 2024. The change in fair value was primarily due to changes in interest rates and volatility. Change in fair value of revenue purchase and sale liability. The change in fair value of the revenue purchase and sale liability, which is accounted for under the fair value option, was \$1.8 million for the nine months ended September 30, 2024. The change in fair value was primarily due to changes in market yields. Other income. Other income was \$3.6 million for the nine months ended September 30, 2024, compared to \$1.2 million for the nine months ended September 30, 2023. The increase in income of \$2.4 million was primarily attributable to the fair value adjustment to the derivative liability in the nine months ended September 30, 2024. 28.29 Interest income. Interest income was \$2.4 million for the nine months ended September 30, 2024, compared to \$4.0 million for the nine months ended September 30, 2023. The decrease of \$1.5 million was primarily attributable to lower balances on our financial instruments. Interest expense. Interest expense was \$6.1 million for the nine months ended September 30, 2024 compared to \$6.0 million for the nine months ended September 30, 2023. The increase of \$0.1 million was due to amortization of costs associated with the Oaktree Agreement. LIQUIDITY AND CAPITAL RESOURCES Overview We have funded our operations from inception through September 30, 2024 primarily through the sale of shares of our common stock, through the private placement of our preferred stock and the incurrence of debt. As of September 30, 2024, we had received net cash proceeds of \$92.7 million from our initial public offering; \$56.7 million from sales of our preferred stock; \$81.6 million from borrowings under our previous term loan with SLR Investment Corp. and Silicon Valley Bank, our previous term loan under the Credit Agreement and Guaranty (the "Oaktree Agreement") with Oaktree Fund Administration, LLC as administrative agent, and the lenders party thereto (collectively "Oaktree"), and the Credit Agreement and Revenue Purchase and Sale Agreement with Perceptive Credit Holdings IV, LP; \$13.5 million from sales of convertible notes; \$20.2 million from our public offering of common stock in 2020; \$46.6 million from our public offering of common stock in 2022; \$53.5 million from our public offering of common stock in 2024; \$14.4 million from the sale of common stock in our 2019 at-the-market offering; and \$15.2 million from the sale of common stock in our 2021 at-the-market offering. As of September 30, 2024, we had cash and cash equivalents of \$91.5 million. Our cash and cash equivalents are maintained at a number of financial institutions in amounts that may exceed federally insured limits. Our existing cash and cash equivalents, including the available proceeds from the Credit Agreement and the Revenue Purchase and Sale Agreement, will be sufficient to meet our cash commitments for at least the next 12 months after the date that the interim condensed consolidated financial statements are issued. On March 23, 2021, we entered into an Open Market Sales Agreement (the "2021 ATM Agreement") with Cowen and Company LLC ("Cowen") to sell shares of our common stock, from time to time, with aggregate gross sales proceeds of up to \$50.0 million, through an at-the-market equity offering program under which Cowen will act as our sales agent. On March 13, 2024, we amended the 2021 ATM Agreement by issuing a the 2024 ATM Agreement. As of March 13, 2024, we had sold a total of 1,726,043 2021 ATM Shares under the 2021 ATM Program at a weighted average gross selling price of \$9.01 per share for net proceeds of \$15.2 million. On March 13, 2024, we amended and restated the 2021 ATM Agreement where we entered into an Open Market Sales Agreement with Cowen with respect to an at-the-market offering program under which we could offer and sell the 2024 ATM Shares, having an aggregate offering price of up to \$50.0 million through Cowen as its sales agent (the "2024 ATM Program"). The offering and sale of the 2024 ATM Shares will be made pursuant to the our shelf registration statement of Form S-3, which was declared effective by the SEC on March 22, 2024. There were no shares issued under the 2024 ATM Program as of June 30, 2024. Please see Note 10. Stockholders' Equity to our condensed consolidated financial statements included elsewhere in this Quarterly Report for additional information. On August 9, 2024, we entered into the Credit Agreement and Revenue Purchase and Sale Agreement. The Credit Agreement established a \$75.0 million term loan facility, consisting of (i) \$50.0 million funded immediately and (ii) \$25.0 million that we may borrow in a single borrowing on or prior to March 31, 2026. Under the Revenue Purchase and Sale Agreement, in exchange for the Purchaser's payment to us of a purchase price of \$50.0 million, in the aggregate, we have agreed to sell to the Purchaser its right to receive payment in full of a tiered single digit percentage of net sales of FUOSCIX. In connection with the Credit Agreement, we paid off all unpaid borrowings under the Oaktree Agreement on August 9, 2024, including the \$1.0 million exit fee and a prepayment premium of \$2.6 million. On August 12, 2024, we entered into the Underwriting Agreement with the Underwriters, relating to an underwritten offering of 12,000,000 shares of our Common Stock and, in lieu of Common Stock to select investors, pre-funded warrants to purchase 500,000 shares of Common Stock. Under the terms of the Underwriting Agreement, we also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 1,875,000 shares of Common Stock at a price of \$4.00 per share, less underwriting discounts and commissions. On August 12, 2024, the Underwriters exercised this option in full. The closing of the offering (including the sale of the Shares subject to the Underwriters' option to purchase additional shares) took place on August 13, 2024. The net proceeds from the offering were \$53.5 million, after deducting underwriting discounts and commissions and offering expenses. We expect to

incur substantial additional expenditures in the near future to support our ongoing activities and commercialization of FUROSCIX. We expect our costs and expenses to increase in the future as we continue U.S. commercialization of FUROSCIX, including the expansion of our direct sales force, and as we continue to make substantial expenditures on research and 29 30 development, including to increase our manufacturing capacity and for conducting clinical trials of our product candidates. Additionally, we continue to incur additional costs as a result of operating as a public company. We plan to continue to fund our operations through cash and cash equivalents on hand. Additionally, we expect to have access to funds pursuant to our at-the-market offering program with Cowen and Company, LLC, or we could otherwise seek additional funding through a combination of public or private equity offerings if we believe additional resources are needed. Our future capital requirements will depend on many factors, including without limitation: the costs and expenses of expanding our U.S. sales and marketing infrastructure; the costs and expenses related to the manufacturing of FUROSCIX and our agreements with third-party manufacturers; the degree of success we experience in commercializing FUROSCIX; the revenue generated by sales of FUROSCIX and of other product candidates that may be approved; the pricing and reimbursement of FUROSCIX and of other product candidates that may be approved; the costs, timing and outcomes of clinical trials and regulatory reviews associated with our product candidates; the emergence of competing or complementary technological developments; the extent to which FUROSCIX is adopted by the healthcare community; the number and types of future products we develop and commercialize; the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and the extent and scope of our general and administrative expenses. A Additional financing may not be available on a timely basis on terms acceptable to us, or at all. We may raise funds in equity, royalty-based or debt financings or enter into additional credit facilities in order to access funds for our capital needs. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution in their percentage ownership of our Company, and any new equity securities we issue could have rights, preferences and privileges senior to those of holders of our common stock. If we raise additional funds through royalty-based financing arrangements, we will likely agree to relinquish rights to potentially valuable future revenue streams and may agree to covenants that restrict our operations or strategic flexibility. Any debt financing obtained by us in the future would cause us to incur additional debt service expenses and could include restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and pursue business opportunities. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, we may terminate or delay the development of one or more of our products, delay clinical trials necessary to market our products, or delay establishment or expansion of sales and marketing capabilities or other activities necessary to commercialize our products. For example, the trading prices for our and other biopharmaceutical companies' securities have been highly volatile as a result of macroeconomic conditions and developments in our industry. As a result, we may face difficulties raising capital through sales of our securities and any such sales may be on unfavorable terms. Additionally, our ability to raise capital may be further impacted by global macroeconomic conditions including, for example, as a result of international political conflict and/or instability, including due to war or terrorism, supply chain issues and rising inflation and interest rates. CASH FLOWS The following table summarizes our sources and uses of cash for each of the periods presented: A A Nine Months Ended September 30, A (in thousands) A 2023 A A 2024 A Net cash (used in) provided by: A A A A Operating activities A \$ (44,086 ) A \$ (55,352 ) Investing activities A (6,498 ) A 29,311 A Financing activities A 14,383 A A 70,711 A Net (decrease) increase in cash and cash equivalents A \$ (36,201 ) A \$ 44,670 A A 30 31 Net Cash Used in Operating Activities During the nine months ended September 30, 2024, net cash used in operating activities was \$55.4 million, consisting primarily of a net loss of \$66.3 million and an increase in net operating assets of \$13.3 million. This was offset by non-cash charges of \$24.2 million. The increase in net operating assets is related to accounts receivable and inventory to support the ongoing commercial operations of FUROSCIX. The non-cash charges primarily consisted of depreciation, amortization related to our right-of-use leased assets, stock-based compensation expense, non-cash interest expense related to amortization of debt discount associated with the Oaktree Agreement, the fair value adjustments to the derivative liability, term loan and revenue purchase and sale liability, debt issuance costs, and the loss on the extinguishment of the Oaktree Agreement and accretion of premium on investments. During the nine months ended September 30, 2023, net cash used in operating activities was \$44.1 million, consisting primarily of a net loss of \$41.0 million and an increase in net operating assets of \$5.8 million. This was offset by non-cash charges of \$2.7 million. The increase in net operating assets is related to accounts receivable and inventory to support the launch of FUROSCIX. The non-cash charges primarily consisted of depreciation, amortization related to our right-of-use leased assets, stock-based compensation expense, non-cash interest expense related to amortization of debt discount associated with the Oaktree Agreement, the fair value adjustment to the derivative liability and accretion of premium on investments. Net Cash (Used in) Provided by Investing Activities During the nine months ended September 30, 2024, net cash provided by investing activities was \$29.3 million, consisting of maturities of short-term investments. During the nine months ended September 30, 2023, net cash used in investing activities was \$6.5 million, consisting primarily of purchases of short-term investments, net of maturities. Net Cash Provided by Financing Activities During the nine months ended September 30, 2024, net cash provided by financing activities was \$70.7 million due to proceeds from the Perceptive Financing, proceeds from the sale of common stock, purchases pursuant to our 2017 Employee Stock Purchase Plan and stock option exercises, offset by the payoff of the Oaktree Agreement, and related fees, and amounts paid to settle restricted stock unit tax withholding obligations. During the nine months ended September 30, 2023, net cash provided by financing activities was \$14.4 million, consisting of proceeds from the 2021 ATM Agreement, purchases pursuant to our 2017 Employee Stock Purchase Plan and stock option exercises. CRITICAL ACCOUNTING POLICIES AND ESTIMATES Management's discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. Our critical accounting policies are more fully described under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report. There have been no material changes to that information disclosed in our Annual Report during the nine months ended September 30, 2024. A Item 3. Quantitative and Qualitative Disclosures About Market Risk. We are exposed to market risks related to changes in foreign currency exchange rates and interest rates. We contract with vendors in foreign countries. As such, we have exposure to adverse changes in exchange rates of foreign currencies, principally the Swiss franc and Euro, associated with our foreign transactions. We believe this exposure to be immaterial. We currently do not hedge against this exposure to fluctuations in exchange rates. A Our exposure to market risk also relates to interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. We have elected the fair value option for certain liabilities. The fair value of the liabilities related to the Credit Agreement and the Revenue Purchase and Sale Agreement will increase as market interest rates decrease. In addition, the fair 31 32 value of the liabilities may fluctuate based upon changes in the Company's credit rating. Changes in the interest rate environment and the credit rating of the Company could have an effect on our future earnings. A We do not believe that inflation has had a material effect on our business. However, if our costs, in particular costs related to manufacture and supply, were to become subject to significant inflationary pressures, it may adversely impact our business, operating results and financial condition. Item 4. Controls and Procedures. Limitations on Effectiveness of Controls and Procedures In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. A Evaluation of Disclosure Controls and Procedures Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation of our disclosure controls and procedures as of September 30, 2024, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date were not effective at a reasonable assurance level due to the continued material weakness in our internal control over financial reporting as described below and in Item 9A, Controls and Procedures, in our Annual Report which was filed on March 13, 2024. A In light of the identified material weakness, we performed additional analysis and other procedures around the review of the calculation performed by our third-party valuation specialist. A Previously Reported Material Weakness in Internal Control over Financial Reporting As previously disclosed in Item 9A, Controls and Procedures, on Form 10-K filed March 13, 2024, as of and for the year ended December 31, 2023, we identified a deficiency resulting in a material weakness further described below. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. Beginning with the preparation of our financial statements in our Annual Report on Form 10-K, management identified a material weakness related to the controls, processes and procedures over the fair value accounting associated with its financial liabilities measured at fair value. Please see Note 9, Debt, to our condensed consolidated financial statements included elsewhere in this Quarterly Report for a description of the financial liabilities. Specifically, the calculations performed by our third-party valuation specialist during the fourth quarter of fiscal 2023 and third quarter of fiscal 2024 as it relates to fair value accounting for the liabilities included errors resulting in an overstatement in the fair values. We made adjustments necessary to properly reflect the fair value of the instruments in the financial statements, as applicable, included in our Annual Report and in this Quarterly Report. There were no changes to previously released financial results as a result of this material weakness. A Remediation Plan Management is actively working to remediate the identified material weakness and is committed to remediating the material weakness in a timely manner. Our remediation process is ongoing and includes the following steps, but is not limited to the following: (a) additional quality control processes implemented by our third-party valuation specialist, (b) detailed discussions around changes in assumptions used in the valuation and their effect on the valuation, and (c) more thorough review of sample iterations used in determining the fair value of the derivative. While the audit committee of our board of directors and senior management are closely monitoring the remediation efforts, until the remediation efforts discussed in this section, including any additional remediation efforts that our senior management identifies as necessary, are complete, tested and determined effective, we will not be able to conclude that the material weakness has been remediated. The material weakness will not be considered remediated until the controls are in place for a period of time and management concludes based on its evaluation that these controls are properly designed and operating effectively. A 32 33 Changes in Internal Control over Financial Reporting Other than the material weakness described above, there were no changes in our internal control over financial reporting identified in management's evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. A 33 34 PART II "OTHER INFORMATION" Item 1. Legal Proceedings From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. Information regarding risk factors appears in Part I, Item 1A. "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2023 (the "Annual Report"), which was filed with the SEC on March 13, 2024. There have been no material changes from the risk factors previously disclosed in our Annual Report. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds None. Item 3. Defaults Upon Senior Securities None. Item 4. Mine Safety Disclosures Not applicable. Item 5. Other Information (a) Disclosure in lieu of reporting on a Current Report on Form 8-K. A None. (b) Material changes to the procedures by which security holders may recommend nominees to the board of directors. None. (c) Insider Trading Arrangements and Policies. A During the three months ended September 30, 2024, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K. Item 6. Exhibits A 34 35 EXHIBIT INDEX Exhibit Number Description A A 3.1 A Second Amended and Restated Certificate of Incorporation of scPharmaceuticals Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's "Current Report on Form 8-K (File No. 001-38293) filed on November 21, 2017). A A A 3.2 A Amended and Restated By-laws of scPharmaceuticals Inc. (incorporated by reference to Exhibit 3.2 to the Registrant's "Current Report on Form 8-K (File No. 001-38293) filed on November 21, 2017). A A A 3.3 A Amendment No. 1 to the Amended and Restated By-laws of scPharmaceuticals Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's "Current Report on Form 8-K (File No. 001-38293) filed on June 10, 2020). A A A 3.4 A Amendment No. 2 to the Amended and Restated By-laws of scPharmaceuticals Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's "Current Report on Form 8-K (File No. 001-38293) filed on March 12, 2021). A A A 4.1 A Form of Warrant, dated October 13, 2022, issued by scPharmaceuticals Inc. to certain lenders, together with a schedule of warrant holders (incorporated by reference to Exhibit 4.1 to the Registrant's "Current Report on Form 8-K (File No. 001-38293) filed on October 14, 2022). A A A 4.2 A Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant's "Current Report on Form 8-K (File No. 001-38293) filed on November 23, 2022). A A A 4.3 A Warrant, dated August 9, 2024, issued by scPharmaceuticals, Inc. to Perceptive Credit Holdings IV, LP (incorporated by reference to Exhibit 4.1 to the Registrant's "Current Report on Form 8-K (File No. 001-38293) filed on August 12, 2024). A A A 4.4 A Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant's "Current Report on Form 8-K (File No. 001-38293) filed on August 13, 2024. A A A 10.1 A Credit Agreement and Guaranty, by and among the Company, the guarantors from time to time party thereto, the lenders from time to time party thereto and Perceptive Credit Holdings IV, LP, in its capacity as administrative agent for the Lender, dated August 9, 2024 (incorporated by reference to Exhibit 10.1 to the Registrant's "Current Report on Form 8-K (File No. 001-38293) filed on August 12, 2024). A A A 10.2 A Revenue Purchase and Sale Agreement, dated August 9, 2024 (incorporated by reference to Exhibit 10.2 to the Registrant's "Current Report on Form 8-K (File No. 001-38293) filed on August 12, 2024). A A A 31.1\* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. A A A 31.2\* Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. A A A 32.1\*\* Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. A A 101\* Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, "Financial Statements" of this Quarterly Report on Form 10-Q. A A 104\* A Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101\*). A \* Filed herewith. \*\* Furnished herewith. A 35 36 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. A A SCPharmaceuticals Inc. A A A Date: November 13, 2024 A By: A /s/ Rachael Nokes A A A Rachael Nokes A A A Chief Financial Officer (Principal Financial Officer) A 36 EX-31.1 2 scph-ex31 1.htm EX-31.1 EX-31.1 A Exhibit 31.1 CERTIFICATION I, John H. Tucker, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2024 of scPharmaceuticals Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and

disclosed in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 5. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. A Date: November 13, 2024 /s/ John H. Tucker John H. Tucker President and Chief Executive Officer (Principal Executive Officer) A A EX-31.2 3 scph-ex31 2.htm EX-31.2 EX-31.2 Exhibit 31.2 CERTIFICATION I, Rachael Nokes, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2024 of scPharmaceuticals Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. A Date: November 13, 2024 /s/ Rachael Nokes Rachael Nokes Chief Financial Officer (Principal Financial Officer) A A EX-32.1 4 scph-ex32 1.htm EX-32.1 EX-32.1 Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 A In connection with the Quarterly Report on Form 10-Q of scPharmaceuticals Inc. (the "Company") for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, John H. Tucker, President and Chief Executive Officer (Principal Executive Officer), hereby certify, pursuant to 18 U.S.C. A1350, as adopted pursuant to A906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: A 1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and A 2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. A Date: November 13, 2024 /s/ John H. Tucker John H. Tucker A A President and Chief Executive Officer A A (Principal Executive Officer) A A EX-32.2 5 scph-ex32 2.htm EX-32.2 EX-32.2 Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 A In connection with the Quarterly Report on Form 10-Q of scPharmaceuticals Inc. (the "Company") for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Rachael Nokes, Chief Financial Officer (Principal Financial Officer), hereby certify, pursuant to 18 U.S.C. A1350, as adopted pursuant to A906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: A 1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and A 2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. A Date: November 13, 2024 /s/ Rachael Nokes Rachael Nokes A A Chief Financial Officer A A (Principal Financial Officer) A EX-101.SCH 6 scph-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Commitments and Contingencies - Schedule of Maturity Analysis of Annual Undiscounted Cash Flows of Operating Lease Liabilities (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Disclosure - Financial Liabilities - Schedule of Carrying Value of Debt Balance (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Description of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Financial Liabilities link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Financial Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Net Loss per Share - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Investments - Summary of Available-for-Sale Classified Investments (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Inventory - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Inventory - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Property and Equipment - Schedule of Purchased Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Property and Equipment - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Fair Value of Financial Instruments - Summary of Assets Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Fair Value of Financial Instruments - Schedule of Changes in Fair Value of Level 3 Derivative Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Financial Liabilities - Schedule of Fair Value of Debt Balance (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Financial Liabilities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Financial Liabilities - Schedule of Carrying Value of Debt Balance (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Stock-Based Compensation - Schedule of Estimated Fair Value of Options Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Stock-Based Compensation - Summary of Information about Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Commitments and Contingencies - Schedule of Maturity Analysis of Annual Undiscounted Cash Flows of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Commitments and Contingencies - Schedule of Lease Cost and Other Information of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink (Discount) premium (Discount) premium Debt Instrument, Unamortized Discount (Premium), Net Debt Instrument, Unamortized Discount (Premium), Net, Total Statement [Line Items] Statement [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] AGGREGATE INTRINSIC VALUE Liabilities, Fair Value Disclosure [Abstract] Liabilities; Term Loan Term Loan [Member] Term loan, Debt Instrument [Axis] Debt Instrument Increase (Decrease) in Accounts Receivable Accounts receivable Plan Name [Domain] Plan Name Entity Address, Postal Zip Code Entity Address, Postal Zip Code Funded Immediately Borrowings One [Member] Borrowings one. Office Equipment [Member] Office Equipment Fair Value, Recurring and Nonrecurring [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Interest Paid, Excluding Capitalized Interest, Operating Activities Interest paid Measurement Input Derivative Liability, Measurement Input Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unrecognized compensation expense Long term additional debt discount exit fee. Long Term Additional Debt Discount Exit Fee Long term additional debt discount exit fee Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted average exercise prices, vested and exercisable ending balance Lessee operating lease liability payments due after year four. Lessee Operating Lease Liability Payments Due After Year Four Thereafter Shares, Outstanding Ending Balance, Shares Beginning Balance, Shares Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs (Level 2) [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement by Share Based Payment Award [Line Items] Long-Term Debt, Type [Domain] Long-term Debt, Type Disclosure of information about stockholders equity note. Stockholders Equity Note [Table] Stockholders Equity Note [Table] Long-Term Debt, Current Maturities Term loan, short-term Less: current portion Long-term Debt, Current Maturities, Total December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Stock Options To Purchase Common Stock Member Stock options to purchase common stock. Stock Options To Purchase Common Stock [Member] Stock Options to Purchase Common Stock Commitments and Contingencies Disclosure [Text Block] Commit

[Member] 2024 Public Offering Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Accumulated Unrealized Gains Operating Expenses [Abstract] Operating expenses: Other lease information. Other Lease Information [Abstract] Other information Aggregate offering price. Aggregate Offering Price Aggregate offering price Investments, Debt and Equity Securities [Abstract] Share-Based Payment Arrangement, Expense Total stock-based compensation expense Long-Term Debt Total RSUs outstanding RSUs outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Plan Name [Axis] Plan Name Deposits and other assets current. Deposits And Other Assets Current Deposits and other current assets Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of shares outstanding, ending balance Number of shares outstanding, beginning balance Stock option, number of shares outstanding Assets, Current [Abstract] Current assets Number of common stock shares available for issuance Common Stock, Capital Shares Reserved for Future Issuance Interest Rate Cap [Member] 2017 Employee Stock Purchase Plan Two Thousand and Seventeen Employee Stock Purchase Plan [Member] Two thousand and seventeen employee stock purchase plan. Supplier Three Supplier Three Member Supplier three. Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value AVERAGE GRANT DATE FAIR VALUE, Forfeited Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Term Loan agreement, term Property, Plant and Equipment, Net Property and equipment, net Property and equipment, Net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance December 31, 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Investment, Policy [Policy Text Block] Investments Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities Fair Value, Recurring [Member] Fair Value, Measurements, Recurring Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Summary of Assets Measured at Fair Value on Recurring Basis Common Stock, Par or Stated Value Per Share Common stock, par value Royalty Accrued Royalties, Current Unrealized gain (loss) on short term investments OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized loss on short-term investments Measurement Input Type [Domain] Accounts Receivable [Policy Text Block] Accounts Receivable Statement of Cash Flows [Abstract] Counterparty Name [Axis] Counterparty Name Debt issuance costs Adjustments To Debt Issuance Costs Adjustments to debt issuance costs. Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants to purchase of shares Equity Components [Axis] Equity Components Share-based compensation arrangement by share-based payment award options forfeited. Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Number of options forfeited Entity Address, Address Line One Entity Address, Address Line One Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Computation of Basic and Diluted Net Loss Per Share of Common Stock Employee-related Liabilities, Current Employee compensation and related costs Employee-related Liabilities, Current, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period RSUs Granted Computer Equipment [Member] Computer Equipment Valuation Approach and Technique [Axis] Property, Plant and Equipment [Line Items] Property Plant And Equipment [Line Items] Subsequent Event Type [Axis] Labor London Interbank Offered Rates LIBOR [Member] London Interbank Offered Rates LIBOR [Member] Commitments and contingencies. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share Twenty twenty one ATM agreement. Twenty Twenty One A T M Agreement [Member] 2021 ATM Agreement Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free rate Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Investments Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of restricted stock units outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance Revenue Purchase and Sale Liability Revenue Purchase and Sale Liability [Member] Revenue purchase and sale liability. Amendment Flag Amendment Flag Operating Lease, Liability, Noncurrent Lease obligation - operating, long-term Corporate Debt Securities [Member] Corporate Bonds Accrued liabilities. Accrued Liabilities Disclosure [Text Block] Accrued Expenses Debt Instrument, Name [Domain] Debt Instrument, Name Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Embedded Derivative, Fair Value of Embedded Derivative Liability Fair value of embedded derivative liability Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] SOFR Net loss Net loss Number of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of stock options, Shares Number of shares exercised Operating Costs and Expenses Total operating expenses Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Vested and exercisable, ending balance Variable Rate [Domain] Variable Rate Research and Development Expense [Member] Research and Development Customer [Domain] Debt Instrument, Interest Rate Terms Debt instrument, interest rate terms Schedule of Debt [Table Text Block] Schedule of Total Term Loan and Unamortized Debt Discount Schedule of Carrying Value of Debt Balance Equity Component [Domain] Equity Component Statistical Measurement [Domain] Statistical Measurement Other (expense) income Other income (expense) Other Nonoperating Income (Expense) Other Nonoperating Income (Expense), Total Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Term of option granted Furniture and Fixtures [Member] Office Furniture Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total United States Government Agency securities US Government Corporations and Agencies Securities [Member] United States Government Agency Securities Proceeds from Stock Options Exercised Proceeds from the exercise of vested stock options Transfer of issuance costs from other current assets to equity Transfer of issuance costs from other current assets to equity. Unamortized debt discount Unamortized debt discount Debt Instrument, Unamortized Discount, Total Allowance for excess, damaged and obsolete inventory Allowance for excess, damaged and obsolete inventory Allowance for excess, damaged and obsolete inventory. Restricted cash Restricted Cash, Current Issuance of warrants Fair value of warrants as an increase to additional paid-in capital Adjustments to Additional Paid in Capital, Warrant Issued Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock through employee stock purchase plan, Shares Number of common stock shares issued Short-Term Investments Short-term investments Short-term Investments, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, maximum Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted average exercise prices, forfeited Purchases. Purchases [Member] Purchases Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Supplier one. Supplier One Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] NUMBER OF SHARES Proceeds from revenue participation agreement, net Proceeds from Revenue Participation Agreement, Net Proceeds from revenue participation agreement, net. Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Weighted Average [Member] Weighted Average Antidilutive Securities [Axis] Antidilutive Securities Corporate Bonds Corporate Bond Securities [Member] Proceeds from sale of shares, Net Proceeds from Issuance or Sale of Equity, Total Proceeds from Issuance or Sale of Equity Proceeds from offering Number of customer. Number of Customer Amortized period for expenses incurred for research and development outside united states Amortized Period for Expenses Incurred for Research and Development Outside United States Amortized period for expenses incurred for research and development outside united states. Credit agreement. Credit Agreement [Member] Credit Agreement Entity Interactive Data Current Entity Interactive Data Current Prepayment and legal fees Payment for Debt Extinguishment or Debt Prepayment Cost Marketable Securities [Table] Marketable Securities [Table] Customer one. Customer One [Member] Customer One Document Quarterly Report Document Quarterly Report Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents and restricted cash Cash and cash equivalents at beginning of period Statistical Measurement [Axis] Statistical Measurement Operating Lease, Cost Operating lease cost Debt Instrument, Periodic Payment, Principal Scheduled repayments outstanding Assets, Fair Value Disclosure Total Lease, Cost Total lease cost Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Maturity Analysis of Annual Undiscounted Cash Flows of Operating Lease Liabilities Commercial Paper [Member] Commercial Paper Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Stock options, available for issuance Percentage of commission on gross sales proceeds. Percentage Of Commission On Gross Sales Proceeds Percentage of commission on gross sales proceeds Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value AVERAGE GRANT DATE FAIR VALUE, Granted Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Recognition period (in years) Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Statement of Income Location, Balance [Axis] Income Statement Location Assets Total assets Expected life Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Contractual life Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Table] Tranche B Loan, Tranche B Loan [Member] Tranche B Loan Entity Address, City or Town Entity Address, City or Town AOCI Attributable to Parent [Member] Other Comprehensive Income (Loss) Equity [Abstract] Assets, Fair Value Disclosure [Abstract] Assets: Schedule of Maturities of Long-Term Debt [Table Text Block] Schedule of Future Principal Payments Due Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period RSUs Forfeited RSUs Forfeited Long-term debt prepayment premium percentage after year two. Long Term Debt Prepayment Premium Percentage After Year Two Prepayment premium percentage after year two Interest Rate Floor [Member] Interest Rate Floor [Member] Prepayment premium percentage two Long Term Debt Prepayment Premium Percentage Year Two Long term debt prepayment premium percentage year two. Derivative Liability, Noncurrent Derivative liability Long-term debt prepayment premium percentage year one and two. Long Term Debt Prepayment Premium Percentage Year One And Two Prepayment premium percentage Depreciation Depreciation expense Depreciation, Total Weighted exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Number of common shares authorized for issuance Two thousand seventeen loan agreement. Two Thousand Seventeen Loan Agreement [Member] 2017 Loan Agreement Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate - operating leases Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Potential interest and penalties associated with uncertain tax positions, accruals Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total Fair Value Disclosures [Abstract] Description Of Business And Basis Of Presentation [Line Items] Description Of Business And Basis Of Presentation [Line Items] Description of business and basis of presentation. Revenue purchase and sale liability Revenue Purchase and Sale Liability Revenue purchase and sale liability. Stock Issued During Period, Value, New Issues Issuance of common stock under at-the-market offering, net of issuance costs Common shares issued Supplier Concentration Risk [Member] Supplier Concentration Risk Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Debt instrument yield protection premium amount of principal percentage year three. Debt Instrument Yield Protection Premium Amount Of Principal Percentage Year Three Yield protection premium percentage year three Liabilities, Current [Abstract] Current liabilities Lease Contractual Term [Axis] Lease Contractual Term Accounts Receivable Tranche B Warrant Tranche B Warrant [Member] Tranche B Warrant, Document Type Document Type On or Prior to December 31, 2024 Borrowings Three [Member] Borrowings three. Title of 12(b) Security Title of 12(b) Security Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Lease, Cost [Table Text Block] Schedule of Lease Cost and Other Information of Operating Lease Liabilities Statement of Stockholders' Equity [Abstract] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Beginning balance Ending balance Document Fiscal Period Focus Document Fiscal Period Focus Research and Development Expense Research and development Research and Development Expense, Total Settlement of restricted stock units for tax withholding obligations Payment, Tax Withholding, Share-Based Payment Arrangement Term loan Carrying value of term loan Long-term portion Term loan, long-term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Additional options granted Number of shares granted Long-term debt exit fee. Long Term Debt Exit Fee Exit fee Share based compensation arrangement by share based payment award options weighted average remaining contractual term. Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] WEIGHTED-AVERAGE REMAINING CONTRACTUAL TERM Taxes paid. Taxes Paid Taxes paid Asset Class [Domain] Asset Class Property, Plant and Equipment, Gross Property and equipment, gross Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Commitments And Contingencies Line Items Commitments and contingencies. Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Subsequent Event Type [Domain] Lessee, Leases [Policy Text Block] Leases Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Estimated Fair Value of Options Valuation Assumptions Change in fair value of revenue purchase and sale liability Fair value adjustment to revenue purchase and sale liability Fair Value Adjustment to Revenue Purchase and Sale Liability Fair value adjustment to revenue purchase and sale liability. Underwriting agreement. Underwriting Agreement [Member] Underwriting Agreement Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price per share Warrant, exercise price Financial Instruments [Domain] Financial Instruments Sale of Stock [Axis] Sale of Stock Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities Up to Two Draws on or Prior to September 30, 2024 Borrowings Two [Member] Borrowings two. Up to Two Draws on or Prior to March 31, 2026 Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule of RSU Activity Selling, General and Administrative Expense, Total Selling, General and Administrative Expense Selling, general and administrative Long-term debt final payment fee. Long Term Debt Final Payment Fee Final payment fee Credit Facility [Domain] Credit Facility Debt Instrument, Frequency of Periodic Payment Frequency of periodic payment Other Other Accrued Liabilities, Current Entity Address, Address Line Two Entity Address, Address Line Two Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Document Period End Date Document Period End Date Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounts Payable [Member] Accounts Payable Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities excluded from calculation of diluted net loss per share Financing costs Accrued financing related cost current. Accrued Financing Related Cost Current APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Accrued Liabilities, Current Accrued expenses Total accrued expenses Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Exercise price per warrant Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Trading Symbol Trading Symbol Variable Rate [Axis] Variable Rate Equity, Attributable to Parent Ending Balance Beginning Balance Total stockholders' equity equity AVERAGE GRANT DATE FAIR VALUE, Released Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Weighted Average Released Fair Value Share-based compensation arrangement by share-based payment award, equity instruments other than options, weighted average released fair value. Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Class of Warrant or Right, Outstanding Prefunded warrant shares Other Liabilities, Noncurrent Other liabilities Other Liabilities, Noncurrent, Total Derivative Instrument [Axis] Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) Property, Plant and Equipment [Table] Schedule Of Property Plant And Equipment [Table] Initial fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Stock-Based Compensation Expense Discount Rate Measurement Input, Discount Rate [Member] Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Change in fair value of derivative

liability Stock option and incentive plan expiration date Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date Measurement Input Type [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Equity awards granted under the inducement , Granted Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Accumulated Unrealized Losses Lease Agreement Require Standby Letter Of Credit Member Lease agreement require standby letter of credit. Lease Agreement Require Standby Letter Of Credit [Member] Lease Agreement Require Standby Letter of Credit Use of Estimates, Policy [Policy Text Block] Use of Estimates Proceeds from term loan, net Proceeds from Issuance of Long-Term Debt, Total Proceeds from Issuance of Long-Term Debt Proceeds from term loan Percentage of concentration risk Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Percentage of purchase price with related to purchaser revenue payment. Percentage Of Purchase Price With Related To Purchaser Revenue Payment Percentage of purchase price with related to purchaser revenue payment Sales returns and allowances and related costs Accrued Marketing Costs, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Security Exchange Name Security Exchange Name Counterparty Name [Domain] Counterparty Name Debt instrument yield protection premium amount of principal percentage after year three. Debt Instrument Yield Protection Premium Amount Of Principal Percentage After Year Three Yield protection premium percentage after year three Fair value adjustment to derivative liability. Fair Value Adjustment To Derivative Liability Fair value adjustment to derivative liability Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Fair Value Disclosures [Text Block] Fair Value of Financial Instruments December 31, 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant date fair value Fair market value per share of common stock Subsequent Event [Member] Subsequent Event Maximum [Member] Maximum Liabilities and Equity Total liabilities and stockholdersâ€™ equity Two thousand nineteen ATM agreement. Two Thousand Nineteen A T M Agreement [Member] 2019 ATM Agreement Loss on extinguishment of debt Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt, Total Operating Lease, Right-of-Use Asset Right-of-use lease assets - operating, net Short-term lease asset Prepaid Expense, Current Prepaid expenses Prepaid Expense, Current, Total Vested options, number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Supplemental Cash Flow Information [Abstract] Supplemental cash flow information Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Net loss per share - diluted Net loss per share, diluted Leasehold Improvements [Member] Leasehold Improvements Entity Ex Transition Period Entity Ex Transition Period Liabilities Total liabilities Payment of financing and stock issuance costs Payment of Financing and Stock Issuance Costs, Total Payment of Financing and Stock Issuance Costs Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Assets, Current Total current assets Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Purchase shares of common stock Number of shares sold Issuance of common stock under at-the-market offering, net of issuance costs, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Stock option vesting term Entity Filer Category Entity Filer Category Long term debt prepayment premium amount. Long term debt prepayment premium amount Property, Plant and Equipment [Abstract] Deposits and other assets noncurrent . Deposits And Other Assets Noncurrent Deposits and other assets Deposits and other current assets Current Fiscal Year End Date Current Fiscal Year End Date 2024 ATM Agreement Twenty twenty four ATM agreement [Member] Twenty twenty four ATM agreement. Document [Domain] Change in fair value of term loan Fair value adjustment to term loan Fair Value Adjustment to Term Loan Fair value adjustment to term loan. Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less imputed interest Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Share-based Payment Arrangement, Noncash Expense, Total Inventory in transit Accrued inventory in transit. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value, outstanding ending balance Payment of final fee. Payment Of Final Fee Payment of final fee Entity Registrant Name Entity Registrant Name Incremental stock based compensation Share Based Compensation Arrangement By Share Based Payment Incremental Stock Based Compensation Share based compensation arrangement by share based payment incremental stock based compensation. Derivative Liability Derivative Liability [Member] Derivative Liability. Cost of Revenue, Total Cost of Revenue Cost of product revenues Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Earnings Per Share [Text Block] Net Loss per Share Debt Instrument, Maturity Date Loan agreement, maturity date Debt instrument, maturity date Entity Emerging Growth Company Entity Emerging Growth Company Operating lease expiration month and year. Operating Lease Expiration Month And Year Operating lease expiration month and year Relative fair value of detachable warrants. Relative Fair Value of Detachable Warrants Relative fair value of detachable warrants Other current liabilities Other Liabilities, Current Other Liabilities, Current, Total Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding - basic Weighted-average shares used in computing net loss per share, basic Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Year ended: Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, maximum Common Stock, Shares Authorized Common stock, shares authorized Property, Plant and Equipment, Useful Life ESTIMATED USEFUL LIFE Sublease Income Sublease income Proceeds from Issuance of Common Stock Proceeds from at-the-market offering, net Concentration Risk Type [Axis] Fair Value, Inputs, Level 1 [Member] Quoted Prices in Active Markets (Level 1) [Member] Long-term debt exit fee obligation accounted as derivative liability. Long Term Debt Exit Fee Obligation Accounted As Derivative Liability Derivative liability recorded against exit fee obligation Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Debt Disclosure [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted average exercise prices, vested and expected to vest ending balance Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average exercise prices, granted Fair value of the term loan at issuance Fair value of term loan at issuance Fair value of term loan at issuance. Financial Instrument [Axis] Financial Instrument Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual term, outstanding Debt, Policy [Policy Text Block] Debt Issuance Costs General and Administrative Expense [Member] General and Administrative Schedule of Fair Value of Debt Balance Fair value of Debt Balance [Table Text Block] Fair value of debt balance. Revenue [Policy Text Block] Revenue Recognition Share-Based Payment Arrangement [Abstract] Embedded derivative liability upon issuance of Term Loan Embedded derivative liability upon issuance of Term Loan Oaktree Agreement Oaktree Agreement [Member] Oaktree agreement. Number of suppliers. Number of Suppliers Debt Securities, Available-for-Sale Fair Value Fair Value, Total Debt Securities, Available-for-sale, Total Accounting Policies [Abstract] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Information about Stock Option Activity Jefferies LLC. Jefferies L L C [Member] Jefferies Equity, Attributable to Parent [Abstract] Stockholdersâ€™ equity Statement [Table] Statement [Table] Property, Plant and Equipment [Table Text Block] Schedule of Purchased Property and Equipment Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual term, vested and expected to vest Inventory wrote off Inventory Write-down Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] WEIGHTED-AVERAGE EXERCISE PRICE Preferred Stock, Shares Authorized Preferred stock, shares authorized Revenue from Contract with Customer, Including Assessed Tax Product revenues, net Product revenues, net Securities Act File Number Entity File Number Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Share based compensation arrangement by share based payment award effective date. Share Based Compensation Arrangement By Share Based Payment Award Effective Date Stock option and incentive plan effective date Earnings Per Share [Abstract] Long-term debt increment on interest rate on default. Long Term Debt Increment On Interest Rate On Default Increase in interest rate on default Warrants and Rights Outstanding, Term Warrants exercise period Inventory Disclosure [Abstract] Supplier two. Supplier Two Lease Contractual Term [Domain] Lease Contractual Term Statement of Financial Position [Abstract] Interest Expense, Operating and Nonoperating Interest expense Interest Expense, Total Loss from operations Operating Income (Loss) Loss from operations Shares Issued, Price Per Share Selling price per share Selling price per share Debt instrument yield protection premium amount of principal percentage year one. Debt Instrument Yield Protection Premium Amount Of Principal Percentage Year One Yield protection premium percentage year one Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Letter Of Credit Member Letter of Credit [Member] Letter of Credit Entity Shell Company Entity Shell Company Document Information, Document [Axis] Accrued Professional Fees, Current Consulting and professional service fees Two thousand seventeen stock plan. Two Thousand Seventeen Stock Plan [Member] 2017 Stock Plan Debt Instrument, Interest Rate, Effective Percentage Debt instrument, effective interest rate Entity Tax Identification Number Entity Tax Identification Number Assets [Abstract] Assets Fair Value Option Fair Value of Financial Instruments, Policy [Policy Text Block] Entity Current Reporting Status Entity Current Reporting Status Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted average remaining contractual term, vested and exercisable Two thousand twenty three employment inducement award plan. Two Thousand Twenty Three Employment Inducement Award Plan [Member] 2023 Employment Inducement Award Plan Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Long-Term Debt, Type [Axis] Long-term Debt, Type Inventory Disclosure [Text Block] Inventory Initial draw amount Initial Draw Amount Initial draw amount. Document Fiscal Year Focus Document Fiscal Year Focus Preferred Stock, Value, Issued Preferred stock, \$0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Principal payments on term loan Repayments of Long-Term Debt Repayments of Long-Term Debt, Total Revenue purchase and sale agreement. Revenue Purchase and Sale Agreement [Member] Revenue Purchase and Sale Agreement City Area Code City Area Code Operating leases expiration year. Operating Leases Expiration Year Operating leases expire Liabilities, Current Total current liabilities Initial fair value adjustment Liabilities, Fair Value Adjustment Derivative Contract [Domain] Two thousand nineteen loan agreement. Two Thousand Nineteen Loan Agreement [Member] 2019 Loan Agreement Inventory, net Inventory, Net, Total Inventory, Net Inventory, Finished Goods, Gross Finished goods Tranche A Loan. Tranche A Loan [Member] Tranche A Loan Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Schedule of accounting policies. Schedule Of Accounting Policies [Line Items] Schedule Of Accounting Policies [Line Items] Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] Supplemental disclosure of non-cash activities Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Straight Line Basis Member Straight-line basis. Straight Line Basis [Member] Short-term Leases Recognized on Straight-line Basis Prepayment premium percentage one Long Term Debt Prepayment Premium Percentage Year One Long term debt prepayment premium percentage year one. Exit fee Business Exit Costs Long-term debt exit fee percentage. Long Term Debt Exit Fee Percentage Exit fee, percentage Income Tax, Policy [Policy Text Block] Income Taxes Commitments and Contingencies Disclosure [Abstract] Fair Value, by Balance Sheet Grouping [Table] Debt Securities, Available-for-Sale, Amortized Cost Cost Basis Amortized Cost, Total Operating Lease, Liability, Current Lease obligation - operating, short-term Short-term lease liability Document Information [Line Items] Debt Instrument, Interest Rate, Stated Percentage Interest rate, minimum Retained Earnings [Member] Accumulated Deficit Payments to Acquire Property, Plant, and Equipment, Total Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Purchases of property and equipment Accrued Liabilities, Current [Abstract] Document Transition Report Document Transition Report Proceeds from common stock offering, net of underwriter discounts and offering costs Proceeds from common stock offering, net Proceeds From Follow On Offering Of Stock Proceeds from follow on offering of stock. Common stock additional shares price per share. Common Stock Additional Shares Price Per Share Common stock additional shares price per share December 31, 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Valuation Approach and Technique [Domain] Antidilutive Security, Excluded EPS Calculation [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Deferred financing costs Adjustments to Additional Paid in Capital, Deferred financing costs Adjustments to additional paid in capital, deferred financing costs. Proceeds from Stock Plans Proceeds from employee stock purchase plan Weighted average exercise prices, exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Purchase price. Purchase Price Purchase price Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Minimum [Member] Minimum Common Stock [Member] Common Stock Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Aggregate intrinsic value, vested and expected to vest ending balance RSUs Released Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Released in Period Share-based compensation arrangement by share-based payment award, equity instruments other than options, released in period AVERAGE GRANT DATE FAIR VALUE, RSUs outstanding AVERAGE GRANT DATE FAIR VALUE, RSUs outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Reduction in carrying value of operating right-of-use lease assets Reduction in carrying value of operating right-of-use lease assets Operating Lease, Right-of-Use Asset, Periodic Reduction Additional Paid-in Capital [Member] Additional Paid-in Capital Common stock additional shares exercisable. Common Stock Additional Shares Exercisable Common stock additional shares exercisable Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to cash used in operating activities Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Statement of Income Location, Balance [Domain] Income Statement Location December 31, 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Fair value of warrants issued Fair value of warrants issued Fair Value of Warrants Issued Fair value of warrants issued. Paid-in-Kind Interest Non-cash interest expense Performance Shares [Member] Performance Shares Schedule of Inventory, Current [Table Text Block] Schedule of Inventory Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Maturities of short-term investments Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Increase decrease in operating lease payments. Increase Decrease In Operating Lease Payments Operating cash flows from operating leases Underwritten public offering. Underwritten Public Offering [Member] Underwritten Public Offering Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration] Supplier [Axis] Common stock, \$0.0001 par value; 150,000,000 shares authorized as of September 30, 2024; 35,968,510 and 50,040,134 shares issued and outstanding as of December 31, 2023 and September 30, 2024, respectively Common Stock, Value, Issued Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Total Common stock, \$0.0001 par value; 150,000,000 shares authorized as of June 30, 2024; 35,968,510 and 36,139,802 shares issued and outstanding as of December 31, 2023 and June 30, 2024, respectively Debt instrument yield protection premium amount of principal percentage year two. Debt Instrument Yield Protection Premium Amount Of Principal Percentage Year Two Yield protection premium percentage year two Payment of term loan final fee Payment Of Term Loan Final Fee Payment of term loan final fee. Investment Income, Interest Interest income Long-term debt amortization of final payment fee. Long Term Debt Amortization Of Final Payment Fee Amortization of final payment fee SLR Investment Corp And Silicon Valley Bank. S L R Investment Corp And Silicon Valley Bank [Member] SLR Investment Corp. and Silicon Valley Bank Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Revenue from Contract with Customer Benchmark [Member] Revenue Customer Two Customer Two [Member] Customer two. Customer Three Customer three. Operating Lease, Liability Total Operating Lease, Liability, Total Measurement Frequency [Axis] Measurement Frequency Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses Commitments and Contingencies Commitments and contingencies (Note 12) trailing 12-month net sales. Trailing of net sales Marketable Securities [Line Items] Marketable Securities [Line Items] Schedule of cash cash equivalents and restricted cash. Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block] Schedule of Cash, Cash Equivalents and Restricted Cash Weighted Average Number of Shares

Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Weighted average common shares outstanding - diluted Weighted-average shares used in computing net loss per share, diluted Significant Accounting Policies [Text Block] Significant Accounting Policies Issuance of common stock and pre-funded warrants in common stock offering, net of issuance costs, Shares Issuance Of Common Stock And Prefunded Warrants In Common Stock Offering Net Of Issuance Costs Shares Issuance of common stock and prefunded warrants in common stock offering net of issuance costs shares. Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts Receivable, after Allowance for Credit Loss, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested and expected to vest, ending balance Future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Total minimum lease payments Increase (Decrease) in Inventories, Total Increase (Decrease) in Inventories Inventory Two thousand fourteen stock plan. Two Thousand Fourteen Stock Plan [Member] 2014 Stock Plan Concentration Risk Benchmark [Domain] Accrued contract research and development expense current. Accrued Contract Research And Development Expense Current Contract research and development Amortized period for expenses incurred for research and development in united states Amortized Period for Expenses Incurred for Research and Development in United States Amortized period for expenses incurred for research and development in united states. Entity Small Business Entity Small Business Debt Instrument, Basis Spread on Variable Rate Basis spread on variable base rate Financial Liabilities Debt Disclosure [Text Block] Debt Manufacturing costs Accrued Manufacturing Costs Accrued manufacturing costs. United States Treasury securities US Treasury Securities [Member] United States Treasury Securities Investments, Fair Value Disclosure Investments Investments, Fair Value Disclosure, Total Supplier [Domain] Credit Facility [Axis] Credit Facility Vesting of restricted stock, Shares Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total Accretion (Amortization) of Discounts and Premiums, Investments Accretion of discount on investments Accretion on short-term investments At the market offering. At The Market Offering [Member] At The Market Offering Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted average exercise prices, outstanding ending balance Weighted average exercise prices, outstanding beginning balance Amortization of Debt Discount (Premium) Amortization of debt discount Schedule Of Accounting Policies [Table] Schedule of accounting policies. Schedule Of Accounting Policies [Table] Asset Class [Axis] Asset Class Proceeds from (Repayments of) Debt, Total Proceeds from (Repayments of) Debt Proceeds from (Repayments of) Debt, Total Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Change in fair value of the term loan Change in fair value of term loan Change in fair value of term loan. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Operating right-of-use asset received in exchange for lease obligations Measurement Frequency [Domain] Measurement Frequency Issuance of common stock and pre-funded warrants in common stock offering, net of issuance costs Issuance Of Common Stock And Prefunded Warrants In Common Stock Offering Net Of Issuance Costs Issuance of common stock and prefunded warrants in common stock offering net of issuance costs. Inventory, Work in Process, Gross Work-in-process Fair Value, Inputs, Level 3 [Member] Significant Unobservable Inputs (Level 3) [Member] Significant Unobservable Inputs (Level 3) [Member] Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term - operating leases Legal accounting and other costs. Legal Accounting And Other Costs [Member] Legal Accounting and Other Costs Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Liabilities, Fair Value Disclosure, Total Liabilities, Fair Value Disclosure Total Short-Term Lease, Cost Short-term lease cost XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep 30, 2024 Nov. 12, 2024 Document Information [Line Items] Á Á Document Type 10-Q Á Amendment Flag false Á Document Period End Date Sep. 30, 2024 Á Document Fiscal Year Focus 2024 Á Document Fiscal Period Focus Q3 Á Trading Symbol SCPH Á Entity Registrant Name SCPHARMACEUTICALS INC. Á Entity Central Index Key 0001604950 Á Current Fiscal Year End Date -12-31 Á Entity Filer Category Non-accelerated Filer Á Entity Current Reporting Status Yes Á Entity Small Business true Á Entity Emerging Growth Company false Á Entity Shell Company false Á Entity Interactive Data Current Yes Á Title of 12(b) Security Common stock, par value \$0.0001 per share Á Security Exchange Name NASDAQ Á Entity File Number 001-38293 Á Entity Incorporation, State or Country Code DE Á Entity Tax Identification Number 46-5184075 Á Entity Address, Address Line One 25 Mall Road Á Entity Address, Address Line Two Suite 203 Á Entity Address, City or Town Burlington Á Entity Address, State or Province MA Á Entity Address, Postal Zip Code 01803 Á City Area Code 617 Á Local Phone Number 517-0730 Á Document Quarterly Report true Á Document Transition Report false Á Entity Common Stock, Shares Outstanding Á 50,040,134 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei\_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei CityAreaCode Namespace Prefix: dei\_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei CurrentFiscalYearEndDate Namespace Prefix: dei\_ Data Type: xbrli:gMonthDayItem Type Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei DocumentFiscalPeriodFocus Namespace Prefix: dei\_ Data Type: dei:fiscalPeriodItem Type Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei DocumentFiscalYearFocus Namespace Prefix: dei\_ Data Type: xbrli:gYearItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei DocumentInformationLineItems Namespace Prefix: dei\_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei DocumentPeriodEndDate Namespace Prefix: dei\_ Data Type: xbrli:dateItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a> + Details Name: dei DocumentQuarterlyReport Namespace Prefix: dei\_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1> + Details Name: dei DocumentTransitionReport Namespace Prefix: dei\_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei DocumentType Namespace Prefix: dei\_ Data Type: dei:submissionTypeItem Type Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei EntityAddressAddressLine1 Namespace Prefix: dei\_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei EntityAddressAddressLine2 Namespace Prefix: dei\_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei EntityAddressCityOrTown Namespace Prefix: dei\_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei EntityAddressPostalZipCode Namespace Prefix: dei\_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei EntityAddressStateOrProvince Namespace Prefix: dei\_ Data Type: dei:stateOrProvinceItem Type Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityCentralIndexKey Namespace Prefix: dei\_ Data Type: dei:centralIndexKeyItem Type Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei EntityCommonStockSharesOutstanding Namespace Prefix: dei\_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei EntityCurrentReportingStatus Namespace Prefix: dei\_ Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityEmergingGrowthCompany Namespace Prefix: dei\_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei EntityFileNumber Namespace Prefix: dei\_ Data Type: dei:fileNumberItem Type Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityFilerCategory Namespace Prefix: dei\_ Data Type: dei:filerCategoryItem Type Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei EntityIncorporationStateCountryCode Namespace Prefix: dei\_ Data Type: dei:edgarStateCountryItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-T -Number 232 -Section 405> + Details Name: dei EntityInteractiveDataCurrent Namespace Prefix: dei\_ Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityRegistrantName Namespace Prefix: dei\_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityShellCompany Namespace Prefix: dei\_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntitySmallBusiness Namespace Prefix: dei\_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityTaxIdentificationNumber Namespace Prefix: dei\_ Data Type: dei:employerIdItem Type Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei LocalPhoneNumber Namespace Prefix: dei\_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b> + Details Name: dei Security12bTitle Namespace Prefix: dei\_ Data Type: dei:securityTitleItem Type Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1> + Details Name: dei SecurityExchangeName Namespace Prefix: dei\_ Data Type: dei:edgarExchangeCodeItem Type Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei TradingSymbol Namespace Prefix: dei\_ Data Type: dei:tradingSymbolItem Type Balance Type: na Period Type: duration XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets Á Á Cash and cash equivalents 91,484 \$ 46,814 Short-term investments Á 29,199 Accounts receivable, net 9,217 4,489 Inventory, net 18,107 8,840 Prepaid expenses 3,373 2,436 Deposits and other current assets 1,148 1,160 Total current assets 123,329 92,938 Property and equipment, net 51 58 Right-of-use lease assets - operating, net 1,330 1,401 Deposits and other assets 359 82 Total assets 125,069 94,479 Current liabilities Á Á Accounts payable 5,003 4,001 Accrued expenses 9,868 9,901 Lease obligation - operating, short-term 231 176 Other current liabilities 162 56 Total current liabilities 15,264 13,134 Term loan, long-term 51,099 38,811 Revenue purchase and sale liability 26,830 0 Derivative liability 0 3,857 Lease obligation - operating, long-term 1,167 1,282 Other liabilities 0 177 Total liabilities 94,360 57,261 Commitments and contingencies (Note 12) Stockholders' equity Á Á Preferred stock, \$0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding Common stock, \$0.0001 par value; 150,000,000 shares authorized as of September 30, 2024; 35,968,510 and 50,040,134 shares issued and outstanding as of December 31, 2023 and September 30, 2024, respectively 5 4 Additional paid-in capital 378,353 318,561 Accumulated deficit (347,649) (281,346) Accumulated other comprehensive income Á (1) Total stockholders' equity 30,709 37,218 Total liabilities and stockholders' equity \$ 125,069 \$ 94,479 X - DefinitionDeposits and other assets current. + ReferencesNo definition available. + Details Name: scph DepositsAndOtherAssetsCurrent Namespace Prefix: scph\_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionDeposits and other assets noncurrent. + ReferencesNo definition available. + Details Name: scph DepositsAndOtherAssetsNoncurrent Namespace Prefix: scph\_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionRevenue purchase and sale liability. + ReferencesNo definition available. + Details Name: scph RevenuePurchaseAndSaleLiability Namespace Prefix: scph\_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10) + Details Name: us-gaap AccountsPayableCurrent Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap AccountsReceivableNetCurrent Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1:

Details Name: us-gaap:AccruedLiabilitiesCusNameSpace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1:

serves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1:

Subparagraph (g) - Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap PrepaidExpenseCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap ShortTermInvestments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StockholdersEquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 10 R3.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - \$ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value \$ 0.0001 \$ 0.0001 Preferred stock, shares authorized 10,000,000 10,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value \$ 0.0001 \$ 0.0001 Common stock, shares authorized 150,000,000 150,000,000 Common stock, shares issued 50,040,134 35,968,510 Common stock, shares outstanding 50,040,134 35,968,510 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap CommonStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-13 + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-13 + Details Name: us-gaap PreferredStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap PreferredStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StatementOffFinancialPositionAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2023 Sep. 30, 2023 Income Statement [Abstract] Â Â Â Â Â Â Product revenues, net \$ 10,026 \$ 3,796 \$ 24,182 \$ 7,497 Revenue from Contract with Customer, Product and Service [Extensible Enumeration] us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember Operating expenses: Â Â Â Â Â Â Cost of product revenues \$ 3,311 \$ 1,079 \$ 7,396 \$ 2,038 Research and development 3,541 3,421 8,944 8,471 Selling, general and administrative 21,320 14,135 56,275 37,127 Total operating expenses 28,172 18,635 72,615 47,636 Loss from operations (18,146) (14,839) (48,433) (40,139) Loss on extinguishment of debt (13,032) Â (13,032) Â Change in fair value of term loan (2,954) Â (2,954) Â Change in fair value of revenue purchase and sale liability (1,830) Â (1,830) Â Other (expense) income 1,804 (36) 3,587 1,193 Interest income 903 1,301 2,444 3,979 Interest expense (1,850) (2,060) (6,085) (6,031) Net loss \$ (35,105) \$ (15,634) \$ (66,303) \$ (40,998) Net loss per share - basic \$ (0.75) \$ (0.41) \$ (1.6) \$ (1.07) Net loss per share - diluted \$ (0.75) \$ (0.41) \$ (1.6) \$ (1.07) Weighted average common shares outstanding - basic 46,558,474 38,760,895 41,516,917 38,421,676 Weighted average common shares outstanding - diluted 46,558,474 38,760,895 41,516,917 38,421,676 Other comprehensive loss: Â Â Â Â Unrealized gain (loss) on short term investments Â \$ 4 \$ 1 \$ (34) Comprehensive loss \$ (35,105) \$ (15,630) \$ (66,302) \$ (41,032) X - DefinitionFair value adjustment to revenue purchase and sale liability. + ReferencesNo definition available. + Details Name: scph\_FairValueAdjustmentToRevenuePurchaseAndSaleLiability Namespace Prefix: scph Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value adjustment to term loan. + ReferencesNo definition available. + Details Name: scph\_FairValueAdjustmentToTermLoan Namespace Prefix: scph Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-

[XBRL-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(26\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1Reference 5:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1Reference 6:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7:](#) [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap -ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap\\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1:](#) [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2:](#) [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 7:](#) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 8:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 9:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 10:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 11:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 12:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 13:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 14:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 15:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 16:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 17:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2:](#) [http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 13:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/194](#)



FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2:

S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap\_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap\_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOffForfeitures Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap\_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap\_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap\_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap\_StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap\_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap\_StockholdersEquity Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant XML 13 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD (\$) 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Cash flows from operating activities Á Á Á Á Á Á Á Net loss \$ (35,105,000) \$ (14,108,000) \$ (15,634,000) \$ (11,210,000) \$ (66,303,000) \$ (40,998,000) Á Adjustments to reconcile net loss to cash used in operating activities Á Á Á Á Á Á Á Depreciation expense 5,000 Á 6,000 Á 16,000 18,000 Á Reduction in carrying value of operating right-of-use lease assets Á Á Á Á 71,000 468,000 Á Accretion on short-term investments Á Á Á Á (120,000) (1,570,000) Á Allowance for excess, damaged and obsolete inventory Á Á Á Á 75,000 Á 0 Stock-based compensation Á Á Á Á 4,157,000 3,440,000 Á Non-cash interest expense Á Á Á Á 1,562,000 1,576,000 Á Fair value adjustment to derivative liability Á Á Á Á (3,857,000) (1,214,000) Á Fair value adjustment to term loan 2,954,000 Á Á 2,954,000 Á Fair value adjustment to revenue purchase and sale liability 1,830,000 Á Á 1,830,000 Á Debt issuance costs Á Á Á Á 4,487,000 Á Á Loss on extinguishment of debt 13,032,000 Á Á 13,032,000 Á Changes in operating assets and liabilities Á Á Á Á Á Accounts receivable Á Á Á Á (4,728,000) (4,175,000) Á Inventory Á Á Á (9,343,000) (5,893,000) Á Prepaid expenses and other assets Á Á Á (1,203,000) 867,000 Á Accounts payable, accrued expenses and other liabilities Á Á Á Á 2,018,000 3,395,000 Á Net cash used in operating activities Á Á Á Á (55,352,000) (44,086,000) Á Cash flows from investing activities Á Á Á Á Á Purchases of property and equipment Á Á Á Á (9,000) (3,000) Á Maturities of short-term investments Á Á Á Á 29,320,000 44,100,000 Á Purchases of short-term investments Á Á Á Á (50,595,000) Á Net cash (used in) provided by investing activities Á Á Á Á 29,311,000 (6,498,000) Á Cash flows from financing activities Á Á Á Á Á Proceeds from common stock offering, net of underwriter discounts and offering costs Á Á Á Á 53,547,000 Á Proceeds from term loan, net Á Á Á Á 46,772,000 Á Proceeds from revenue participation agreement, net Á Á Á Á 23,629,000 Á Proceeds from employee stock purchase plan Á Á Á Á 283,000 176,000 Á Proceeds from the exercise of vested stock options Á Á Á Á 228,000 169,000 Á Proceeds from at-the-market offering, net Á Á Á Á 14,038,000 Á Principal payments on term loan Á Á Á Á (50,000,000) Á Prepayment and legal fees Á Á Á Á (2,582,000) Á Payment of term loan final fee Á Á Á Á (1,000,000) Á Settlement of restricted stock units for tax withholding obligations Á Á Á Á (166,000) Á Net cash provided by financing activities Á Á Á Á 70,711,000 14,383,000 Á Net (decrease) increase in cash and cash equivalents Á Á Á Á 44,670,000 (36,201,000) Á Cash and cash equivalents at beginning of period Á Á Á Á 46,814,000 Á 71,243,000 46,814,000 71,243,000 Cash and cash equivalents at end of period Á Á Á Á 91,484,000 Á 35,042,000 Á 91,484,000 35,042,000 Á 46,814,000 Supplemental cash flow information Á Á Á Á Á Á Á Interest paid Á Á Á Á 4,556,000 4,455,000 Á Taxes paid Á Á Á Á 174,000 196,000 Á Supplemental disclosure of non-cash activities Á Á Á Á Á Fair value of warrants issued Á Á Á Á 1,855,000 Á Á Transfer of issuance costs from other noncurrent assets to equity Á Á Á Á 79,000 Á Operating right-of-use asset received in exchange for lease obligations Á Á Á Á 71,000 \$ 1,437,000 Á X - DefinitionAdjustments to debt issuance costs. + ReferencesNo definition available. + Details Name: scph\_AdjustmentsToDebtIssuanceCosts Namespace Prefix: scph\_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAllowance for excess, damaged and obsolete inventory. + ReferencesNo definition available. + Details Name: scph\_AllowanceForExcessDamagedAndObsoleteInventory Namespace Prefix: scph\_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionFair value adjustment to derivative liability. + ReferencesNo definition available. + Details Name: scph\_FairValueAdjustmentToDerivativeLiability Namespace Prefix: scph\_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionFair value adjustment to revenue purchase and sale liability. + ReferencesNo definition available. + Details Name: scph\_FairValueAdjustmentToRevenuePurchaseAndSaleLiability Namespace Prefix: scph\_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionFair value adjustment to term loan. + ReferencesNo definition available. + Details Name: scph\_FairValueAdjustmentToTermLoan Namespace Prefix: scph\_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionFair value of warrants issued. + ReferencesNo definition available. + Details Name: scph\_FairValueOfWarrantsIssued Namespace Prefix: scph\_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionPayment of term loan final fee. + ReferencesNo definition available. + Details Name: scph\_PaymentOfTermLoanFinalFee Namespace Prefix: scph\_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionProceeds from follow on offering of stock. + ReferencesNo definition available. + Details Name: scph\_ProceedsFromFollowOnOfferingOfStock Namespace Prefix: scph\_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionProceeds from revenue participation agreement, net. + ReferencesNo definition available. + Details Name: scph\_ProceedsFromRevenueParticipationAgreementNet Namespace Prefix: scph\_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionTaxes paid. + ReferencesNo definition available. + Details Name: scph\_TaxesPaid Namespace Prefix: scph\_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionTransfer of issuance costs from other noncurrent assets to equity. + ReferencesNo definition available. + Details Name: scph\_TransferOfIssuanceCostsFromOtherNoncurrentAssetsToEquity Namespace Prefix: scph\_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap\_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and

so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <https://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1) + Details Name: us-gaap\_Depreciation

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap\_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4> + Details Name: us-gaap\_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap\_IncreaseDecreaseInOperatingCapital

Abstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap\_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2> + Details Name: us-gaap\_InterestPaid

Net Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap\_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_NetCashProvidedByUsedInFinancingActivities

Abstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap\_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_NetCashProvidedByUsedInInvestingActivities

Abstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap\_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_NetCashProvidedByUsedInOperatingActivities

Abstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap\_OperatingLeaseRightOfUseAssetAmortizationExpense

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInterest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap\_PaidInKindInterest

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph \(g\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15) + Details Name: us-gaap\_PaymentsOfDebtExtinguishmentCosts

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15) + Details Name: us-gaap\_PaymentsRelatedToTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) + Details Name: us-gaap\_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13> + Details Name: us-gaap\_PaymentsToAcquireShortTermInvestments

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap\_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap\_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph \(a\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A) + Details Name: us-gaap\_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap\_ProceedsFromStockPlans

Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 11: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name>

Accounting Standards Codification - Section 45 - Paragraph 3 - Subparagraph (a) - Publisher FASB - URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13:

designed to enable the subcutaneous administration of therapies that have previously been limited to intravenous (âIVâ) delivery. The Companyâs headquarters and primary place of business is Burlington, Massachusetts.Basis of PresentationThe accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (âU.S. GAAPâ) for interim financial information and have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The condensed consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiary, scPharmaceuticals Securities Corporation. Certain information and disclosures normally included in financial statements in accordance with U.S. GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Companyâs audited financial statements and related notes for the year ended December 31, 2023 included in the Companyâs Annual Report on Form 10-K filed with the Securities and Exchange Commission (the âSECâ) on March 13, 2024. The Company has determined that it operates in one segment. The accompanying condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of operations and comprehensive loss and stockholdersâ equity for the three and nine months ended September 30, 2023 and 2024 and condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2024 are unaudited. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with that used to prepare the Companyâs audited annual financial statements and include, in the opinion of management, adjustments, consisting of normal recurring items, necessary for the fair statement of the condensed consolidated financial statements. The operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results expected for the full year ending December 31, 2024.Â LiquidityAs of September 30, 2024, the Company had an accumulated deficit of approximately \$347.6 million. Management expects to continue to incur operating losses for the foreseeable future. The Company has financed its operations to date from proceeds from the sale of common stock, preferred stock and the incurrence of debt.Â As of September 30, 2024, the Company had cash and cash equivalents of \$91.5 million. On October 13, 2022, the Company entered into a Credit Agreement and Guaranty (the "Oaktree Agreement") with, among others, the lenders from time to time party thereto and Oaktree Fund Administration, LLC, in its capacity as administrative agent for the lenders (Note 9). On August 9, 2024 (the "Closing Date"), the Company entered into a Credit Agreement and Guaranty (the "Credit Agreement") with the guarantors from time to time party thereto, the lenders from time to time party thereto (the "Lenders"), and Perceptive Credit Holdings IV, LP, in its capacity as administrative agent for the Lenders (in such capacity, the "Agent") (Note 9). On the Closing Date, the Company also entered into a Revenue Participation Right Purchase and Sale Agreement (the "Revenue Purchase and Sale Agreement") with Perceptive Credit Holdings IV, LP (the "Purchaser") (Note 9). The Company used the proceeds of the Credit Agreement and the Revenue Purchase and Sale Agreement to, on the Closing Date, prepay all outstanding obligations under the Oaktree Agreement, including the payment of fees and expenses associated with the Oaktree Agreement. In addition, on August 13, 2024, the Company completed an underwritten public offering of shares of its common stock (and, in lieu of such shares of common stock to selected investors, pre-funded warrants to purchase shares of its common stock) with net proceeds of \$53.5 million (Note 10). Â The Company's existing cash and cash equivalents will be sufficient to meet its cash commitments for at least the next 12 months after the date that the interim condensed consolidated financial statements are issued. Additionally, the Company expects to have access to funds pursuant to an at-the-market offering program with Cowen and Company, LLC (Note 10), or could otherwise seek additional funding through a combination of public or private equity offerings if it believes additional resources are needed. Additional financing may not be available on a timely basis on terms acceptable to the Company, or at all. X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap\_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 17 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Significant Accounting Policies 2. Significant Accounting PoliciesUse of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reported periods. Actual results could differ from those estimates.Cash and Cash Equivalents Cash and cash equivalents consists of bank deposits and money market accounts with financial institutions. Cash equivalents are carried at cost which approximates fair value due to their short-term nature and which the Company believes do not have a material exposure to credit risk. The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. The Companyâs cash and cash equivalent accounts, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts.Accounts ReceivableAccounts receivable are recorded net of any estimated expected credit losses. The Company's measurement of expected credit losses is based on relevant information about past events, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material credit loss allowance for uncollectible trade receivables.Concentration of Credit RiskFinancial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to hold a minimum rating, thereby reducing credit risk exposure.Customer and Supplier ConcentrationThe Company has a limited number of specialty pharmacy customers and distributors. As of December 31, 2023 and September 30, 2024, three customers represented 99% and two customers represented 98% of accounts receivable, respectively. For the three and nine months ended September 30, 2024, two customers represented 98% and three customers represented 99% of revenue, respectively. For the three and nine months ended September 30, 2023, two customers represented 92% and one customer represented 88% of revenue, respectively.The Company has a limited number of suppliers and contract manufacturers utilized in the production of its product. As of December 31, 2023 and September 30, 2024, one supplier represented 47% and three suppliers represented 49% of accounts payable, respectively. For the three and nine months ended September 30, 2024, two suppliers represented 45% and 49% of purchases, respectively. For the three and nine months ended September 30, 2023, one supplier represented 29% and two suppliers represented 40% of purchases, respectively.The Company depends on suppliers for raw materials, active pharmaceutical ingredients, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers may take a substantial period of time, as suppliers must be approved by the FDA. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture its products, it could have a materially adverse effect on the Company's business, financial condition and results of operations.Â InvestmentsThe Company invests excess cash balances in available-for-sale debt securities. The Company determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company reports available-for-sale investments at fair value at each balance sheet date and includes any unrealized gains and losses in accumulated other comprehensive income (loss), a component of stockholdersâ equity. Realized gains and losses are determined using the specific identification method and are included in other income. If any adjustment to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is âother than temporary,â including the intention to sell and, if so, marks the investment to market through a charge to the Companyâs consolidated statements of operations and comprehensive loss.InventoryInventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company began capitalizing inventory costs following U.S. Food and Drug Administration ("FDA") approval of FUROSCIX on October 7, 2022. Inventory is sold on a first in, first out ("FIFO") basis. The Company periodically reviews inventory for expiry and obsolescence and writes it down accordingly, if necessary. Prior to FDA approval of FUROSCIX, the Company expensed all inventory-related costs, including that used for clinical development, to research and development ("R&D") costs in the period incurred.LeasesThe Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (âROUâ) lease assets, current portion of lease obligations, and long-term lease obligations on the Companyâs balance sheets. ROU lease assets represent the Companyâs right to use an underlying asset for the lease term and lease obligations represent the Companyâs obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. As most of the Companyâs leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset excludes lease incentives. The Companyâs lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.Debt Issuance Costs Debt issuance costs have been amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheet as of December 31, 2023.Fair Value OptionAs permitted under Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 825, Financial Instruments (âASC 825â), the Company elected the fair value option to account for the Credit Agreement and the Revenue Purchase and Sale Agreement (collectively, the "Perceptive Financing"). In accordance with ASC 825, the Company records these instruments at fair value with changes in fair value recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the Perceptive Financing were expensed as incurred and were not deferred.The Company elected to account for the Perceptive Financing using the fair value option, which allows for valuing the Credit Agreement and the Revenue Purchase and Sale Agreement in their entirety versus bifurcation of the embedded derivatives.Revenue RecognitionThe Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, Revenue from Contracts with Customer (âTopic 606â), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. The Company has identified one performance obligation, the delivery of FUROSCIX to its customers. The Company has not incurred any incremental costs associated with obtaining contracts with customers. The Companyâs revenues consist solely of the sale of FUROSCIX to customers in the United States. Product Net Sales FUROSCIX was approved by the FDA on October 7, 2022. The Company launched sales of FUROSCIX in the first quarter of 2023 and its customers consist of specialty pharmacies (âSPsâ) and specialty distributors ("SDs"). The Company recognizes revenue from product sales at a point in time, typically upon receipt of product at the SPs and SDs, the date at which the rights, title, interest and risk of loss are transferred. Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration that result from (a) sales discounts, (b) rebates (c) co-pay assistance, and (d) product returns. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves for variable consideration are reflected as either as a reduction to the related account receivable or as an accrued liability, depending on how the consideration is settled. The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results vary from its estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. Sales Discounts: Sales discounts are agreed-upon discounts, from negotiated contracts, taken directly off the Companyâs sales invoices. Sales discounts are recorded as an offset to revenue based on contractual terms at the time revenue from the sale is recognized. Rebates: Allowance for rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare Part D prescription drug benefit, TRICARE program and contractual rebates with commercial payers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or statutory requirements. The allowance for rebates is based on contracted or statutory discount rates and expected utilization by benefit plan participants. The Companyâs estimates for expected utilization of rebates are based on utilization data received from the SPs since product launch. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarterâs activity, plus an accrual balance for prior quartersâ unpaid rebates. If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment. Co-Payment Assistance: The Company offers co-payment assistance to commercially insured patients meeting certain eligibility requirements. Co-payment assistance is accrued at the time of product sale to SPs based on estimated patient participation and average co-pay benefit to be paid per a claim. The Companyâs estimated amounts are compared to actual program participation and co-pay amounts paid using data provided by third-party administrators. If actual amounts differ from the original estimates the assumptions being applied are updated and adjustment for prior period accruals will be adjusted in the current period. Product Returns: Consistent with industry practice, the Company offers SPs and SDs limited product return rights for damages, shipment errors, and expiring product, provided that the return is within a specified period around the product expiration date as set forth in the applicable individual distribution agreement. The Company does not allow product returns for product that has been dispensed to a patient. As the Company receives inventory reports from the SPs and has the ability to control the amount of product that is sold to the SPs, it is able to make a reasonable estimate of future potential product returns based on this on-hand channel inventory data and sell-through data obtained from the SPs. Currently, sales to SDs are limited and there is no access to on-hand channel inventory or sell through data. As these arrangements mature, the Company will utilize any data that they can provide as part of this analysis. In arriving at its estimate, the Company also considers historical product returns, the underlying product demand, and industry data specific to the specialty pharmaceutical distribution industry. Research and Development Costs Research and development costs are expensed as incurred. Nonrefundable advance payments, if any, for goods or services used in research and development are initially recorded as an asset and then recognized as an expense as the related goods are delivered or services are performed. Research and development expenses include contract services, consulting, salaries, materials and supplies and overhead. Income TaxesThe Company accounts for income taxes in accordance with the FASB ASC 740, Income Taxes. Deferred tax assets and liabilities are recorded to reflect the impact of temporary differences between amounts of assets and liabilities for financial reporting purposes and such amounts as measured under enacted tax laws. A valuation allowance is required to offset any net deferred tax assets if, based upon the available evidence, it is more likely than not that some or all of the deferred tax asset will not be realized.The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions. The tax benefits recorded are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is âmore likely than notâ to be realized following resolution of any uncertainty related to the tax benefit, assuming that the matter in question will be raised by the tax authorities. Potential interest and penalties associated with such uncertain tax positions are recorded as a component of income tax expense. At September 30, 2024, the Company had no such accruals.As part of the Tax Cuts and Jobs Act of 2017 ("TCJA"), beginning with the Companyâs fiscal year ended December 31, 2022, the Company is required to capitalize research and development expenses, as defined under section 174 of the Internal Revenue

of 1986, as amended. For expenses that accrued prior to research and development in the United States, the amounts will be amortized over 5 years, and expenses that are incurred for research and experimentation outside the United States will be amortized over 15 years. X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147483426/235-10-50-1>Reference 2: [http://www.xbrli.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/235/tableOfContent+Details Name: us-gaap SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] X Net Loss per Share 3. Net Loss per ShareNet Loss per Share Attributable to Common StockholdersThe following table sets forth the computation of basic and diluted net loss per share of common stock (in thousands, except share and per share data): X X Three Months Ended September 30, X X Nine Months Ended September 30, X X X 2023 X 2024 X 2023 X 2024 X Net loss X (15,634) X X (35,105) X X (40,998) X X (66,303) X Weighted-average shares used in computing net loss per share X 38,760,895 X X 46,558,474 X X 38,421,676 X X 41,516,917 X Net loss per share, basic and diluted X $ (0.41) X X $ (0.75) X X $ (1.07) X X $ (1.60) X Basic and diluted weighted average shares of common stock outstanding for the three and nine months ended September 30, 2024 include the weighted average effect of outstanding pre-funded warrants for the purchase of shares of common stock for which the remaining unfunded exercise price is $0.001 per share.The CompanyX's potentially dilutive securities, which include unexercised stock options outstanding, unexercised warrants and unvested restricted stock units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect.X X Three Months Ended September 30, X X Nine Months Ended September 30, X X X 2023 X 2024 X 2023 X 2024 X Stock options to purchase common stock X 4,722,050 X X 5,445,475 X X 4,722,050 X X 5,445,475 X Warrants to purchase common stock X 516,345 X X 1,016,345 X X 516,345 X X 1,016,345 X Unvested restricted stock units X 339,556 X X 721,766 X X 339,556 X X 721,766 X Total X 5,577,951 X X 7,183,586 X X 5,577,951 X X 7,183,586 X X - ReferencesNo definition available. + Details Name: us-gaap EarningsPerShareAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrli.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 260-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrli.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-2)Reference 4: <http://www.xbrli.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-3> + Details Name: us-gaap EarningsPerShareTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Investments 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] X Investments 4. InvestmentsCash in excess of the CompanyX's immediate requirements is invested in accordance with the CompanyX's investment policy that primarily seeks to maintain adequate liquidity and preserve capital.A summary of the CompanyX's available-for-sale classified investments as of December 31, 2023 consisted of the following (in thousands): X X At December 31, 2023 X Investments - Current: X Cost Basis X Accumulated Unrealized Gains X Accumulated Unrealized Losses X Fair Value X United States Treasury securities X \$ 13,967 X X 2 X X \$ - X X \$ 13,969 X Commercial paper X \$ 9,427 X X \$ - X X (2) X X 9,425 X Corporate bonds X 3,815 X X - X X - X X 3,815 X United States Government Agency securities X 1,991 X X - X X (1) X X 1,990 X Total X \$ 29,200 X X 2 X X (3) X X \$ 29,199 X The Company did not have any investments as of September 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-10](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 940-SubTopic 320-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/940-320/tableOfContentReference 2: http://www.xbrli.org/2003/role/disclosureRef-Name Regulation S-K (SK)-Number 229-Section 1403-Paragraph b-Publisher SECReference 3: http://www.xbrli.org/2003/role/disclosureRef-Topic 320-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/320/tableOfContentReference 4: http://www.xbrli.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-10)Reference 5: [http://www.xbrli.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6B-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B](http://www.xbrli.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6B-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B)Reference 6: [http://www.xbrli.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6B-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B](http://www.xbrli.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6B-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B)Reference 7:

ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/940-820-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/940-820-50-1) + Details Name: us-gaap FairValueDisclosuresTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 24 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] A Financial Liabilities 9. Financial LiabilitiesA Perceptive FinancingA The following table presents the fair value of the Company's debt balance as of September 30, 2024 (in thousands): A A September 30, 2024 Par value of the term loan A \$ 50,000 A Initial fair value adjustment A (1,855 ) A Fair value of the term loan at issuance A 48,145 A Change in fair value of the term loan A 2,954 A Total fair value of the term loan A \$ 51,099 A A On the Closing Date, the Company entered into the Credit Agreement. The Credit Agreement establishes a \$75.0 million term loan facility, consisting of (i) \$50.0 million funded on the Closing Date ("Tranche A Loan") and (ii) subject to satisfaction of certain conditions, \$25.0 million (together with the Tranche A Loan, collectively, the "Term Loan") that the Company may borrow in a single borrowing on or prior to March 31, 2026. A Borrowings under the Term Loan bear interest at a rate per annum equal to the one-month term SOFR (subject to a 3.25% floor), plus an applicable margin of 6.75%, payable monthly in arrears. There will be no scheduled repayments of outstanding principal on the Term Loan prior to August 9, 2029 (the "Maturity Date"). The Company may voluntarily prepay the outstanding Term Loan, subject to a yield protection premium equal to (i) 5.0% of the principal amount of the Term Loan prepaid, if prepaid on or prior to the first anniversary of the Closing Date, (ii) 3.0% of the principal amount of the Term Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, (iii) 1.0% of the principal amount of the Term Loan if prepaid after the second anniversary of the Closing Date through and including the third anniversary of the Closing Date, with no prepayment premium due after the third anniversary of the Closing date through the Maturity Date. A On the Closing Date, the Company was required to issue to the Lenders of such Term Loan warrants to purchase 300,000 of shares of the Company's common stock, in the aggregate (the "Warrant"), at an exercise price of \$4.5902. Upon the completion of the sale of common stock on August 13, 2024 (Note 10), the exercise price of the warrants was adjusted to \$4.00 according to the terms of the agreement. Upon inception, the Company evaluated the warrants and determined that they met all the requirements for equity classification under ASC Topic 815 Derivatives and Hedging ("ASC 815"). This transaction was accounted for as a detachable warrant at its fair value, using the residual method, and is recorded as an increase to additional paid-in capital on the consolidated statement of stockholder's equity in the amount of \$1.6 million. The Company used the Black-Scholes option pricing model to determine the fair value of the warrants. Assumptions included the fair market value per share of common stock on the valuation date of \$4.33, the exercise price per warrant equal to \$4.00, the expected volatility of 87.5%, the risk-free interest rate of 3.83%, the contractual term of 6 years and the absence of a dividend. The Warrant is immediately exercisable, and the exercise period will expire 6 years from the date of issuance. A In addition to the Warrant, the Company will be required to issue to the Lenders warrants to purchase 200,000 of shares of the Company's common stock (the "Tranche B Warrant") upon the draw down of the second tranche of the Term Loan on or prior to March 31, 2026. These warrants were accounted for using the residual method and were recorded on a relative fair value basis, resulting in an increase to additional paid-in capital on the consolidated statement of stockholder's equity in the amount of \$0.2 million. The Company used the Black-Scholes option pricing model to determine the fair value of the warrants. Assumptions included the fair market value per share of common stock on the valuation date of \$4.33, the exercise price per warrant equal to \$4.00, the expected volatility of 82.5%, the risk-free interest rate of 3.87%, the contractual term of 7.64 years and the absence of a dividend. The Tranche B Warrant will expire 6 years from the date of issuance. A The Company's obligations under the Credit Agreement and the other Loan Documents (as defined in the Credit Agreement) will be guaranteed by any domestic subsidiaries of ours that become Guarantors (as defined in the Credit Agreement), subject to certain exceptions. The Borrowers and the Guarantors (collectively, the "Loan Parties") respective obligations under the Credit Agreement and the other Loan Documents are secured by first priority security interests in substantially all assets of the Loan Parties, subject to certain customary thresholds and exceptions. The Credit Agreement contains customary representations, warranties and affirmative and negative covenants, including financial covenants requiring the Company to (i) maintain certain levels of cash and cash equivalents in accounts subject to a control agreement in favor of the Agent of at least \$5.0 million at all times after the Closing Date and (ii) meet minimum quarterly net sales targets described in the Credit Agreement. In addition, the Credit Agreement contains customary events of default that entitle the Agent to cause the Company's indebtedness under the Credit Agreement to become immediately due and payable, and to exercise remedies against the Loan Parties and the collateral securing the Term Loan, including cash. Under the Credit Agreement, an event of default will occur if, among other things, the Company fails to make payments under the Credit Agreement (subject to specified periods), the Company or its subsidiaries breach any of the covenants under the Credit Agreement (subject to specified cure periods with respect to certain breaches), a material adverse change occurs, the Company, its subsidiaries or its respective assets become subject to certain legal proceedings, such as bankruptcy proceedings, the Company and/or its subsidiaries are unable to pay its debts as they become due or default on contracts with third parties which would permit the holder of indebtedness in excess of a certain threshold to accelerate the maturity of such indebtedness or that could cause a material adverse change. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 3.0% per annum may apply to all obligations owed under the Credit Agreement. A On the Closing Date, the Company also entered into the Revenue Purchase and Sale Agreement with the Purchaser. Under the Revenue Purchase and Sale Agreement, in exchange for the Purchaser's payment to the Company of a purchase price of up to \$50.0 million, in the aggregate, the Company has agreed to sell to the Purchaser its right to receive payment in full of a tiered single digit percentage of net sales of FUROSIX. The initial sale of the Revenue Payment under the Revenue Purchase and Sale Agreement in the amount of \$25.0 million took place on the Closing Date. The Purchaser's right to receive the Revenue Payment terminates and the Company no longer has the obligation to pay Purchaser Revenue Payments

-Paragraph 11 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-11 + Details Name: us-gaap\_DebtDisclosureTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 25 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity 9 Months Ended Sep. 30, 2024 Equity [Abstract] A Stockholders' Equity 10. Stockholdersâ€™ Equity2021 At-the-Market Issuance Sales Agreement On March 23, 2021, the Company entered into an Open Market Sale Agreement (the “2021 ATM Agreement”) with Cowen and Company, LLC (the “Cowan”) with respect to an at-the-market offering program under which the Company could offer and sell shares of its common stock (the “2021 ATM Shares”), having an aggregate offering price of up to \$50.0 million through Cowen as its sales agent. The Company agreed to pay Cowen a commission up to 3.0% of the gross sales proceeds of such 2021 ATM Shares. On March 13, 2024, the Company amended and restated the 2021 ATM Agreement and entered into a new \$50.0 million Open Market Sales Agreement with Cowen (the “2024 ATM Agreement”). As of March 13, 2024, the Company had sold a total of 1,726,043 2021 ATM Shares under the 2021 ATM Program at a weighted average gross selling price of \$9.01 per share for net proceeds of \$15.2 million. 2024 At-the-Market Issuance Sales Agreement Pursuant to the 2024 ATM Agreement, the Company could offer and sell shares of its common stock (the “2024 ATM Shares”), having an aggregate offering price of up to \$50.0 million through Cowen as its sales agent (the “2024 ATM Program”). The offering and sale of the 2024 ATM Shares will be made pursuant to the Company’s shelf registration statement on Form S-3, which was declared effective by the SEC on March 22, 2024 (the “2024 Registration Statement”). There were no shares issued under the 2024 ATM Program as of September 30, 2024. Sale of Common Stock On August 13, 2024, the Company completed an underwritten public offering of 13,875,000 shares of its common stock, \$0.0001 par value per share (the “2024 Offering Shares”), and, in lieu of shares of common stock to certain select investors, pre-funded warrants to purchase up to an aggregate of 500,000 shares of common stock at an exercise price equal to \$0.001 per share, pursuant to the 2024 Registration Statement. The 2024 Offering Shares were sold at an offering price of \$4.00 per share. The pre-funded warrants were sold at an offering price of \$3.999 per underlying share, which was equal to the price per share of common stock being sold in this offering, minus \$0.001, which is the exercise price per share of the pre-funded warrants. The pre-funded warrants were accounted for as equity instruments. Net proceeds of the offering were \$53.5 million, after deducting underwriting discounts, commissions and offering expenses. X - References No definition available. + Details Name: us-gaap\_EquityAbstract Namespace Prefix: us-gaap\_Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for equity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-50-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap\_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 26 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] A Stock-Based Compensation 11. Stock-Based Compensation Stock Options The Companyâ€™s 2017 Stock Option and Incentive Plan (the “2017 Stock Plan”) became effective in November 2017, upon the closing of the Companyâ€™s initial public offering and will expire in October 2027. Under the 2017 Stock Plan, the Company may grant incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units (the “RSUs”) and other stock-based awards. The Companyâ€™s 2014 Stock Incentive Plan (the “2014 Stock Plan”) was terminated in November 2017 effective upon the completion of the Companyâ€™s initial public offering and no further options will be granted under the 2014 Stock Plan. At September 30, 2024, there were 555,427 options outstanding under the 2014 Stock Plan. As of September 30, 2024, there were 8,769,977 shares of the Companyâ€™s common stock authorized for issuance under the 2017 Stock Plan, including 366,823 options that have been forfeited from the 2014 Stock Plan. At September 30, 2024, there were 3,206,310 options available for issuance under the 2017 Stock Plan, 4,775,676 options outstanding and 721,766 RSUs outstanding. A On February 1, 2023, the Board of Directors of the Company adopted the 2023 Employment Inducement Award Plan (the “Inducement Plan”) and, subject to the adjustment provisions of the Inducement Plan, reserved 500,000 shares of the Companyâ€™s common stock for issuance pursuant to equity awards granted under the Inducement Plan. At September 30, 2024, there were 385,628 options available for issuance under the Inducement Plan, and 114,372 options outstanding. Awards granted under the 2017 Stock Plan and the Inducement Plan have a term of ten years. Vesting of awards under the 2017 Stock Plan and Inducement Plan is determined by the board of directors, but is generally over one to four-year terms. The fair value of options at date of grant was estimated using the Black-Scholes option-pricing model with the following assumptions: A A Nine Months Ended September 30, A A 2023 A A 2024 A A Risk-free interest rate A 3.40% - 4.23% A A 3.66% - 4.59% A Expected dividend yield A 0% A A 0% A Expected life A 5.5-6.98 A years A 5.5-6.7 A years A Expected volatility A 77%-85% A A 76%-79% A Weighted-average grant date fair value A \$ 5.36 A A \$ 3.81 A A The following table summarizes information about stock option activity during the nine months ended September 30, 2024 (in thousands, except share and per share data): A A NUMBER OF SHARES A A WEIGHTED-AVERAGE EXERCISE PRICE A A WEIGHTED-AVERAGE REMAINING CONTRACTUAL TERM A A AGGREGATE INTRINSIC VALUE A Outstanding, December 31, 2023 A A 4,681,326 A A \$ 6.09 A A A A A A Granted A A 1,119,772 A A A 5.43 A A A A A Exercised A A (30,203) A A 2.85 A A A A A A Forfeited A A (325,420) A A 6.46 A A A A A A Outstanding, September 30, 2024 A A 5,445,475 A A A 5.95 A A A 6.81 A A \$ 725 A Vested and exercisable, September 30, 2024 A A 3,517,499 A A \$ 6.15 A A A 5.76 A A \$ 606 A Vested and expected to vest, September 30, 2024 A A 5,081,614 A A \$ 5.98 A A 6.66 A A \$ 709 A A 24,343 options were exercised on December 29, 2023 and the shares settled on January 2, 2024. The share issuance has been recognized on the Company’s Condensed Consolidated Statements of Stockholders’ Equity for the quarter ending March 31, 2024. The following table summarizes information about RSU activity during the nine months ended September 30, 2024: A A RSUs A A AVERAGE GRANT DATE FAIR VALUE (IN DOLLARS PER SHARE) A RSUs outstanding, December 31, 2023 A A 368,411 A A \$ 6.33 A A Granted A A 471,790 A A \$ 5.70 A A Released A A (82,818) A A 6.33 A A Forfeited A A (35,617) A A 6.24 A RSUs outstanding at September 30, 2024 A A 721,766 A A \$ 5.93 A A Unrecognized compensation expense related to unvested options as of September 30, 2024 was \$5.2 million and will be recognized over the remaining vesting periods of the underlying awards. The weighted-average period over which such compensation is expected to be recognized is 2.3 years. Unrecognized compensation expense related to unvested RSUs as of September 30, 2024 was \$2.4 million and will be recognized over the remaining vesting periods of the underlying awards. The weighted-average period over which such compensation is expected to be recognized is 3.0 years. A Employee Stock Purchase Plan In October 2017, the board of directors approved the 2017 Employee Stock Purchase Plan (the “ESPP”) which became effective in November 2017, upon the closing of the Company’s IPO. As part of the ESPP, eligible employees may acquire an ownership interest in the Company by purchasing common stock, at a discount, through payroll deductions. Eligible employees who elected to participate were able to participate in the ESPP beginning September 1, 2021. During the nine months ended September 30, 2024, 85,393 shares were issued under the ESPP. As of September 30, 2024, there were 1,377,173 shares of common stock available for issuance under the ESPP. The Company recorded stock-based compensation expense in the following expense categories of its accompanying condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2023 and 2024 (in thousands): A A Three Months Ended September 30, A A Nine Months Ended September 30, A A 2023 A A 2024 A A 2023 A A 2024 A Research and development A \$ 370 A A \$ 385 A A \$ 1,075 A A \$ 1,160 A General and administrative A 911 A A 842 A A 2,365 A A 2,997 A Total A \$ 1,281 A A \$ 1,227 A A \$ 3,440 A A 4,157 A X - Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap\_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap\_Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration XML 27 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] A Commitments and Contingencies 12. Commitments and Contingencies Operating Leases The Company leases office facilities and equipment under long-term, non-cancelable operating lease agreements. The leases expire at various dates through 2029 and do not include renewal options. Certain leases provide for increases in future minimum annual rental payments as defined in the lease agreements. The leases generally also include real estate taxes and common area maintenance charges in the annual rental payments. Short-term leases are leases having a term of twelve months or less. The Company recognizes short-term leases on a straight-line basis and does not record a related lease asset or liability for such leases. The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of September 30, 2024 (in thousands): A Year ended: A A December 31, 2024 A \$ 96 A December 31, 2025 A \$ 381 A December 31, 2026 A \$ 376 A December 31, 2027 A \$ 358 A December 31, 2028 A \$ 367 A Thereafter A \$ 249 A Total minimum lease payments A 1,827 A Less imputed interest A (429) A Total A \$ 1,398 A A A Nine Months Ended September 30, A A 2023 A A 2024 A Lease cost: A A A A Operating lease cost A \$ 497 A A \$ 261 A Short-term lease cost A 28 A A 35 A Total lease cost A \$ 525 A A \$ 296 A Other information A A A A Cash paid for amounts included in the measurement of lease liabilities A \$ 489 A A \$ 258 A Operating cash flows from operating leases A \$ 8 A A \$ 10 A Weighted-average remaining lease term - operating leases A 5.54 years A A 4.84 years A Weighted-average discount rate - operating leases A 11.6 % A A 12.1 % Research and Development Agreements As part of the Companyâ€™s research and development efforts, the Company enters into research and development agreements with certain companies. These agreements contain varying terms and provisions which include fees and milestones to be paid by the Company. Some of these agreements also contain provisions which require the Company to make payments for exclusivity in the development of products in the area of loop diuretics. X - References No definition available. + Details Name: us-gaap\_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap\_Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for commitments and contingencies. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap\_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 28 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] A Use of Estimates Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reported periods. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and Cash Equivalents Cash and cash equivalents consists of bank deposits and money market accounts with financial institutions. Cash equivalents are carried at cost which approximates fair value due to their short-term nature and which the Company believes do not have a material exposure to credit risk. The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. The Companyâ€™s cash and cash equivalent accounts, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. Accounts Receivable Accounts Receivable Accounts receivable are recorded net of any estimated expected credit losses. The Company’s measurement of expected credit losses is based on relevant information about past events, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material credit loss allowance for uncollectible trade receivables. Concentration of Credit Risk Concentration of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to hold a minimum rating,

thereby reducing credit risk exposureThe Company has a limited number of specialty pharmacy customers and distributors. As of December 31, 2023 and September 30, 2024, three customers represented 99% and two customers represented 98% of accounts receivable, respectively. For the three and nine months ended September 30, 2024, two customers represented 98% and three customers represented 99% of revenue, respectively. For the three and nine months ended September 30, 2023, two customers represented 92% and one customer represented 88% of revenue, respectively.The Company has a limited number of suppliers and contract manufacturers utilized in the production of its product. As of December 31, 2023 and September 30, 2024, one supplier represented 47% and three suppliers represented 49% of accounts payable, respectively. For the three and nine months ended September 30, 2024, two suppliers represented 45% and 49% of purchases, respectively. For the three and nine months ended September 30, 2023, one supplier represented 29% and two suppliers represented 40% of purchases, respectively.The Company depends on suppliers for raw materials, active pharmaceutical ingredients, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers may take a substantial period of time, as suppliers must be approved by the FDA. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture its products, it could have a materially adverse effect on the Company's business, financial condition and results of operations. Investments InvestmentsThe Company invests excess cash balances in available-for-sale debt securities. The Company determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company reports available-for-sale investments at fair value at each balance sheet date and includes any unrealized gains and losses in accumulated other comprehensive income (loss), a component of stockholders' equity. Realized gains and losses are determined using the specific identification method and are included in other income. If any adjustment to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is "other than temporary," including the intention to sell and, if so, marks the investment to market through a charge to the Company's consolidated statements of operations and comprehensive loss. Inventory InventoryInventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company began capitalizing inventory costs following U.S. Food and Drug Administration ("FDA") approval of FUROSCIX on October 7, 2022. Inventory is sold on a first in, first out ("FIFO") basis. The Company periodically reviews inventory for expiry and obsolescence and writes it down accordingly, if necessary. Prior to FDA approval of FUROSCIX, the Company expensed all inventory-related costs, including that used for clinical development, to research and development ("R&D") costs in the period incurred. Leases LeasesThe Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use ("ROU") lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets. ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Debt Issuance Costs Debt Issuance Costs Debt issuance costs have been amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheet as of December 31, 2023. Fair Value Option Fair Value OptionAs permitted under Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 825, Financial Instruments ("ASC 825"), the Company elected the fair value option to account for the Credit Agreement and the Revenue Purchase and Sale Agreement (collectively, the "Perceptive Financing"). In accordance with ASC 825, the Company records these instruments at fair value with changes in fair value recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the Perceptive Financing were expensed as incurred and were not deferred. The Company elected to account for the Perceptive Financing using the fair value option, which allows for valuing the Credit Agreement and the Revenue Purchase and Sale Agreement in their entirety versus bifurcation of the embedded derivatives. Revenue Recognition Revenue RecognitionThe Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, Revenue from Contracts with Customers ("ASC Topic 606"), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. The Company has identified one performance obligation, the delivery of FUROSCIX to its customers. The Company has not incurred any incremental costs associated with obtaining contracts with customers. The Company's revenues consist solely of the sale of FUROSCIX to customers in the United States. Product Net Sales FUROSCIX was approved by the FDA on October 7, 2022. The Company launched sales of FUROSCIX in the first quarter of 2023 and its customers consist of specialty pharmacies ("SPs") and specialty distributors ("SDs"). The Company recognizes revenue from product sales at a point in time, typically upon receipt of product at the SPs and SDs, the date at which the rights, title, interest and risk of loss are transferred. Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration that result from (a) sales discounts, (b) rebates (c) co-pay assistance, and (d) product returns. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves for variable consideration are reflected as either a reduction to the related account receivable or as an accrued liability, depending on how the consideration is settled. The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results vary from its estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. Sales Discounts: Sales discounts are agreed-upon discounts, from negotiated contracts, taken directly off the Company's sales invoices. Sales discounts are recorded as an offset to revenue based on contractual terms at the time revenue from the sale is recognized. Rebates: Allowance for rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare Part D prescription drug benefit, TRICARE program and contractual rebates with commercial payers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or statutory requirements. The allowance for rebates is based on contracted or statutory discount rates and expected utilization by benefit plan participants. The Company's estimates for expected utilization of rebates are based on utilization data received from the SPs since product launch. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter's activity, plus an accrual balance for prior quarters' unpaid rebates. If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment. Co-Payment Assistance: The Company offers co-payment assistance to commercially insured patients meeting certain eligibility requirements. Co-payment assistance is accrued at the time of product sale to SPs based on estimated patient participation and average co-pay benefit to be paid per a claim. The Company's estimated amounts are compared to actual program participation and co-pay amounts paid using data provided by third-party administrators. If actual amounts differ from the original estimates the assumptions being applied are updated and adjustment for prior period accruals will be adjusted in the current period. Product Returns: Consistent with industry practice, the Company offers SPs and SDs limited product return rights for damages, shipment errors, and expiring product, provided that the return is within a specified period around the product expiration date as set forth in the applicable individual distribution agreement. The Company does not allow product returns for product that has been dispensed to a patient. As the Company receives inventory reports from the SPs and has the ability to control the amount of product that is sold to the SPs, it is able to make a reasonable estimate of future potential product returns based on this on-hand channel inventory data and sell-through data obtained from the SPs. Currently, sales to SDs are limited and there is no access to on-hand channel inventory or sell through data. As these arrangements mature, the Company will utilize any data that they can provide as part of this analysis. In arriving at its estimate, the Company also considers historical product returns, the underlying product demand, and industry data specific to the specialty pharmaceutical distribution industry. Research and Development Costs Research and Development Costs Research and development costs are expensed as incurred. Nonrefundable advance payments, if any, for goods or services used in research and development are initially recorded as an asset and then recognized as an expense as the related goods are delivered or services are performed. Research and development expenses include contract services, consulting, salaries, materials and supplies and overhead. Income Taxes Income TaxesThe Company accounts for income taxes in accordance with the FASB ASC 740, Income Taxes. Deferred tax assets and liabilities are recorded to reflect the impact of temporary differences between amounts of assets and liabilities for financial reporting purposes and such amounts as measured under enacted tax laws. A valuation allowance is required to offset any net deferred tax assets if, based upon the available evidence, it is more likely than not that some or all of the deferred tax asset will not be realized. The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions. The tax benefits recorded are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is "more likely than not" to be realized following resolution of any uncertainty related to the tax benefit, assuming that the matter in question will be raised by the tax authorities. Potential interest and penalties associated with such uncertain tax positions are recorded as a component of income tax expense. At September 30, 2024, the Company had no such accruals. As part of the Tax Cuts and Jobs Act of 2017 ("TCJA"), beginning with the Company's fiscal year ended December 31, 2022, the Company is required to capitalize research and development expenses, as defined under section 174 of the Internal Revenue Code of 1986, as amended. For expenses that are incurred for research and development in the United States, the amounts will be amortized over 5 years, and expenses that are incurred for research and experimentation outside the United States will be amortized over 15 years. X - ReferencesNo definition available. + Details Name: us-gaap\_AccountingPoliciesAbstract Namespace Prefix: us-gaap\_ Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1:

1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 944> -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2>: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946> -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 3>: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946> -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 4>: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946> -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5>: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946> -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 6>: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946> -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/214747721/946-320-S99-12Reference 7>: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946> -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477271/946-320-S99-19> + Details Name: us-gaap\_InvestmentPolicyTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842> -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-1> + Details Name: us-gaap\_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 730> -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483044/730-10-05-1> + Details Name: us-gaap\_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946> -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2>: <http://www.xbrl.org/2003/role/exampleRef-Topic 235> -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 3>: [http://www.xbrl.org/2003/role/exampleRef-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(e\)-SubTopic 10-Topic 235](http://www.xbrl.org/2003/role/exampleRef-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (e)-SubTopic 10-Topic 235) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483426/235-10-50-4> + Details Name: us-gaap\_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for accounts receivable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 310> -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481962/310-10-50-6Reference 2>: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 310> -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 3>: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 310> -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 4>: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 310> -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481569/310-20-50-1Reference 5>: <http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 310> -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481962/310-10-50-15Reference 6>: <http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 310> -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481962/310-10-50-11B> + Details Name: us-gaap\_TradeAndOtherAccountsReceivablePolicy Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 275> -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2>: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 275> -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3>: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)-SubTopic 10-Topic 275](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)-SubTopic 10-Topic 275) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4>: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(c\)-SubTopic 10-Topic 275](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (c)-SubTopic 10-Topic 275) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 5>: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 12-SubTopic 10-Topic 275> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 6>: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 275> -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-8> + Details Name: us-gaap\_UseOfEstimates Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Á Computation of Basic and Diluted Net Loss Per Share of Common Stock The following table sets forth the computation of basic and diluted net loss per share of common stock (in thousands, except share and per share data): Á Á Three Months Ended September 30, Á Á Nine Months Ended September 30, Á Á 2023 Á Á 2024 Á Á 2023 Á Á 2024 Á Net loss Á \$ (15,634 ) Á \$ (35,105 ) Á \$ (40,998 ) Á \$ (66,303 ) Weighted-average shares used in computing net loss per share Á Á 38,760,895 Á Á 46,558,474 Á Á 38,421,676 Á Á 41,516,917 Á Net loss per share, basic and diluted Á \$ (0.41 ) Á \$ (0.75 ) Á \$ (1.07 ) Á \$ (1.60 ) Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share The Companyâ€™s potentially dilutive securities, which include unexercised stock options outstanding, unexercised warrants and unvested restricted stock units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect. Á Á Three Months Ended September 30, Á Á Nine Months Ended September 30, Á Á 2023 Á Á 2024 Á 2023 Á 2024 Á Stock options to purchase common stock Á 4,722,050 Á 5,445,475 Á 4,722,050 Á 5,445,475 Á Warrants to purchase common stock Á 516,345 Á 1,016,345 Á 516,345 Á 1,016,345 Á Unvested restricted stock units Á 339,556 Á 721,766 Á 339,556 Á 721,766 Á Total Á 5,577,951 Á 7,183,586 Á X - ReferencesNo definition available. + Details Name: us-gaap\_EarningsPerShareAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 260> -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1> + Details Name: us-gaap\_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 260> -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1> + Details Name: us-gaap\_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Investments (Tables) 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] Á Summary of Available-for-Sale Classified Investments A summary of the Companyâ€™s available-for-sale classified investments as of December 31, 2023 consisted of the following (in thousands): Á Á At December 31, 2023 Á Investments - Current: Á Cost Basis Á Á Accumulated Unrealized Gains Á Á Accumulated Unrealized Losses Á Á Fair Value Á United States Treasury securities Á \$ 13,967 Á Á 2 Á Á \$ - Á Á \$ 13,969 Á Commercial paper Á \$ 9,427 Á Á \$ - Á (2) Á Á 9,425 Á Corporate bonds Á 3,815 Á Á - Á - Á Á 3,815 Á United States Government Agency securities Á 1,991 Á Á - Á - Á (1) Á Á 1,990 Á Total Á \$ 29,200 Á Á 2 Á Á \$ (3) Á Á 29,199 Á The Company did not have any investments as of September 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap\_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of unrealized gains and losses on investments. + Details Name: us-gaap\_UnrealizedGainLossOnInvestmentsTableTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Inventory (Tables) 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Á Schedule of Inventory The Company's inventory balance consists of the following (in thousands): Á Á Á December 31, 2023 Á September 30, 2024 Á Raw materials Á \$ 4,256 Á Á \$ 6,874 Á Work-in-process Á 4,188 Á Á 10,363 Á Finished goods Á 396 Á Á 870 Á Á 8,840 Á Á 18,107 Á X - ReferencesNo definition available. + Details Name: us-gaap\_InventoryDisclosureAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210> -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2>: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210> -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3>: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210> -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4>: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210> -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483489/210-10-50-1> + Details Name: us-gaap\_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment (Tables) 9 Months Ended Sep. 30, 2024 Property, Plant and Equipment [Abstract] Á Schedule of Purchased Property and Equipment Purchased property and equipment consist of the following (dollars in thousands): Á Á Á ESTIMATEDUSEFUL LIFE Á December 31, 2023 Á Á September 30, 2024 Á Office equipment Á 5Á years Á \$ 31 Á Á 31 Á Office furniture Á 7Á years Á Á 64 Á Á 73 Á Computer equipment Á 3Á years Á Á 15 Á Á 15 Á Leasehold improvements Á Life of lease Á Á 9 Á Á 9 Á Á 119 Á Á 128 Á Less: Accumulated depreciation Á Á (61) Á Á (77) Á Property and equipment, net Á Á \$ 58 Á Á \$ 51 Á X - ReferencesNo definition available. + Details Name: us-gaap\_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-SubTopic 10-Topic 360> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap\_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses (Tables) 9 Months Ended Sep. 30, 2024 Accrued Liabilities, Current [Abstract] Á Schedule of Accrued Expenses Accrued expenses consist of the following (in thousands): Á Á Á December 31, 2023 Á Á September 30, 2024 Á Employee compensation and related costs Á \$ 4,375 Á Á \$ 3,891 Á Manufacturing costs Á 434 Á Á 2,260 Á Sales returns and allowances and related costs Á 1,418 Á Á 1,477 Á Contract research and development Á 1,202 Á Á 1,240 Á Consulting and professional service fees Á 945 Á Á 658 Á Royalty Á 249 Á Á 259 Á Inventory in transit Á 150 Á Á Á Á 0 Á Other Á 128 Á Á 83 Á Total accrued expenses Á \$ 8,901 Á Á \$ 9,868 Á X - ReferencesNo definition available. + Details Name: us-gaap\_AccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap\_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Á Summary of Assets Measured at Fair Value on Recurring Basis The following tables summarize the Companyâ€™s assets that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands): Á Á Á As of December 31, 2023 Á Á Á TOTAL Á Á Quoted Pricesin ActiveMarkets(Level 1) Á Á SignificantOtherObservableInputs(Level 2) Á Á SignificantUnobservableInputs(Level 3) Á Assets: Á Á Á Á Á Á Á Cash equivalents Á 44,202 Á Á 44,202 Á Á \$ Á Á \$ Á Total cash equivalents Á 44,202 Á Á 44,202 Á Á \$ Á Á \$ Á Á \$ Á Á \$ Á 44,202 Á Á 44,202 Á Á \$ Á Á \$ Á Á \$ Á Á \$ Á United States Treasury securities Á 13,969 Á Á 13,969 Á Á - Á Á \$ Á Commercial paper Á 9,425 Á Á 9,425 Á Á \$ Á Á \$ Á 9,425 Á Á 9,425 Á Á \$ Á Á \$ Á Corporate bonds Á 3,815 Á Á 3,815 Á Á \$ Á Á \$ Á United States Government Agency securities Á 1,990 Á Á 1,990 Á Á \$ Á Á \$ Á Investments Á 29,199 Á Á 13,969 Á Á 15,230 Á Á \$ Á Á \$ Á Á \$ Á Total Á \$ 73,401 Á Á \$ 58,171 Á Á \$ 15,230 Á Á \$ Á Liabilities: Á Á Á Á Á Á Á Derivative liability Á \$ 3,857 Á Á \$ Á Á \$ 3,857 Á Á \$ Á Á \$ Á Total Á \$ 3,857 Á Á \$ Á Á \$ Á Á \$ Á As of September 30, 2024 Á Á Á TOTAL Á Á Quoted Pricesin ActiveMarkets(Level 1) Á Á SignificantOtherObservableInputs(Level 2) Á Á SignificantUnobservableInputs(Level 3) Á Assets: Á Á Á Á Á Á Á Cash equivalents Á 90,346 Á Á 90,346 Á Á \$ Á Á \$ Á Á \$ Á Á \$ Á Total Á \$ 90,346 Á Á \$ 90,346 Á Á \$ Á Á \$ Á Liabilities: Á Á Á Á Á Á Á Term loan Á 51,099 Á Á \$ Á Á \$ Á Revenue purchase and sale liability Á 26,830 Á Á \$ Á Á \$ Á 26,830 Á Á \$ Á Á \$ Á Total Á \$ 77,929 Á Á \$ Á Á \$ Á 77,929 Á Á \$ Á Schedule of Changes in Fair Value of Level 3 Derivative Liabilities Changes in the fair value of the Company's Level 3 liabilities for the nine months ended September 30, 2024 are as follows (in thousands): Á Á Á Derivative Liability Á Á Term Loan Á Á Revenue purchase and sale liability Á At December 31, 2023 Á \$ 3,857 Á Á \$ Á Á \$ Á Initial fair value Á Á \$ Á Á 48,145 Á Á 25,000 Á Change in fair value Á (3,857 ) Á Á 2,954 Á Á 1,830 Á At September 30, 2024 Á \$ Á \$ 51,099 Á Á 26,830 Á Á X - ReferencesNo definition available. + Details Name: us-gaap\_FairValueDisclosuresAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the

availability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration XML 35 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities (Tables) 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] A Schedule of Fair Value of Debt Balance The following table presents the fair value of the Company's debt balance as of September 30, 2024 (in thousands):A A September 30, 2024 Par value of the term loan A \$ 50,000 A Initial fair value adjustment A A (1,855 ) Fair value of the term loan at issuance A A 48,145 A Change in fair value of the term loan A A 2,954 A Total fair value of the term loan A A \$ 51,099 A Schedule of Carrying Value of Debt Balance The following table presents the carrying value of the Company's debt balance as of December 31, 2023 (in thousands):A A December 31, 2023 Face value A \$ 50,000 A Discount A A (11,189 ) Total A A 38,811 A Less: current portion A A æ~ A Long-term portion A A 38,811 A X - DefinitionFair value of debt balance. + ReferencesNo definition available. + Details Name: scph FairValueOfDebtBalanceTableTextBlock Namespace Prefix: scph Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap DebtDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration XML 36 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] A Schedule of Estimated Fair Value of Options Valuation Assumptions The fair value of options at date of grant was estimated using the Black-Scholes option-pricing model with the following assumptions: A A Nine Months EndedSeptember 30, A A 2023 A A 2024 A Risk-free interest rate A 3.40% - 4.23% A A 3.66% - 4.59% A Expected dividend yield A 0% A A 0% A Expected life A 5.5-6.98A years A A 5.5-6.7A years A Expected volatility A 77%-85% A A 76%-79% A Weighted-average grant date fair value A \$ 5.36 A A \$ 3.81 A Summary of Information about Stock Option Activity The following table summarizes information about stock option activity during the nine months ended September 30, 2024 (in thousands, except share and per share data): A A NUMBER OFSHARES A A WEIGHTED-AVERAGEEXERCISEPRICE A A WEIGHTED-AVERAGEGERMAININGCONTRACTUALTERM A A AGGREGATEINTRINSICVALUE A A Outstanding, December 31, 2023 A A 4,681,326 A A \$ 6.09 A A A A A A Granted A A 1,119,772 A A 5,434 A A A A A Exercised A A (30,203) A A 2.85 A A A A A A Forfeited A A (325,420) A A 6.46 A A A A A A Outstanding, September 30, 2024 A A 5,445,475 A A 5,95 A A A A 6.81 A A A 725 A A Vested and exercisable, September 30, 2024 A A 3,517,499 A A \$ 6.15 A A A 5.76 A A A 606 A A Vested and expected to vest, September 30, 2024 A A 5,081,614 A A 5.98 A A A 6.66 A A A 709 A A Schedule of RSU Activity The following table summarizes information about RSU activity during the nine months ended September 30, 2024:A A RSUs A A AVERAGE GRANTDATE FAIRVALUE (IN DOLLARS PER SHARE) A A RSUs outstanding, December 31, 2023 A A 368,411 A A \$ 6.33 A A Granted A A 471,790 A A \$ 5.70 A Released A A (82,818 ) A A 6.33 A A Forfeited A A (35,617 ) A A 6.24 A A RSUs outstanding at September 30, 2024 A A 721,766 A A \$ 5.93 A Summary of Stock-Based Compensation Expense The Company recorded stock-based compensation expense in the following expense categories of its accompanying condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2023 and 2024 (in thousands):A A Three Months EndedSeptember 30, A A Nine Months EndedSeptember 30, A A 2023 A A 2024 A A 2023 A A 2024 A Research and development A \$ 370 A A \$ 385 A A \$ 1,075 A A \$ 1,160 A General and administrative A A 911 A A A 842 A A A 2,365 A A A 2,997 A Total A A \$ 1,281 A A \$ 1,227 A A \$ 3,440 A A \$ 4,157 A X - ReferencesNo definition available. + Details Name: us-gaap DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock units. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration XML 37 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Tables) 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] A Schedule of Maturity Analysis of Annual Undiscounted Cash Flows of Operating Lease Liabilities The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of September 30, 2024 (in thousands):A Year ended: A A December 31, 2024 A \$ 96 A December 31, 2025 A A 381 A December 31, 2026 A A 376 A December 31, 2027 A A 358 A December 31, 2028 A A 367 A Thereafter A A 249 A Total minimum lease payments A A 1,827 A Less imputed interest A A (429 ) Total A A \$ 1,398 A Schedule of Lease Cost and Other Information of Operating Lease Liabilities A A Nine Months EndedSeptember 30, A A 2023 A A 2024 A Lease cost: A A A A Operating lease cost A A 497 A A 261 A Short-term lease cost A A 28 A A 35 A Total lease cost A A \$ 525 A A \$ 296 A Other information A A A A A A Cash paid for amounts included in the measurement of lease liabilities A A 489 A A 258 A Operating cash flows from operating leases A A \$ 8 A A \$ 10 A Weighted-average remaining lease term - operating leases A 5.5A years A A 4.8A years A Weighted-average discount rate - operating leases A 11.6 % A A 12.1 % X - ReferencesNo definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap LeaseCostTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration XML 38 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Basis of Presentation - Additional Information (Details) - USD (\$) \$ / shares in Units, in Thousands 3 Months Ended Aug. 09, 2024 Jun. 30, 2023 Mar. 3

2023 Significant Accounting Policies - Additional Information (Details) 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 USD (\$) Supplier Customer Sep. 30, 2023 Supplier Customer Sep. 30, 2024 USD (\$) Supplier Customer Sep. 30, 2023 Supplier Customer Sep. 30, 2023 Supplier Customer Dec. 31, 2023 Customer Supplier Schedule Of Accounting Policies [Line Items] A A A A Potential interest and penalties associated with uncertain tax positions, accruals | \$ 0 A \$ 0 A A Amortized period for expenses incurred for research and development in united states A A 5 years A A Amortized period for expenses incurred for research and development outside united states A A 15 years A A Accounts Receivable A A A A Schedule Of Accounting Policies [Line Items] A A A A Number of Customer | Customer A A 2 A 3 Revenue A A A A Schedule Of Accounting Policies [Line Items] A A A A Number of Customer | Customer 2 2 3 1 A Accounts Payable A A A A Schedule Of Accounting Policies [Line Items] A A A A Number of Suppliers | Supplier A A 3 A 1 Purchases A A A A Schedule Of Accounting Policies [Line Items] A A A A Number of Suppliers | Supplier 2 1 2 2 A Customer Concentration Risk | Accounts Receivable | Customer Three A A A A Schedule Of Accounting Policies [Line Items] A A A A Percentage of concentration risk A A A A 99.00% Customer Concentration Risk | Accounts Receivable | Customer Two A A A A A Schedule Of Accounting Policies [Line Items] A A A A Percentage of concentration risk 98.00% 92.00% 99.00% A A Customer Concentration Risk | Revenue | Customer Two A A A A A Schedule Of Accounting Policies [Line Items] A A A A Percentage of concentration risk A A A A 88.00% Supplier Concentration Risk | Accounts Payable | Supplier One A A A A A Schedule Of Accounting Policies [Line Items] A A A A Percentage of concentration risk A A A A 47.00% Supplier Concentration Risk | Accounts Payable | Supplier Three A A A A A Schedule Of Accounting Policies [Line Items] A A A A Percentage of concentration risk A A A A 49.00% A A Supplier Concentration Risk | Purchases | Supplier One A A A A A Schedule Of Accounting Policies [Line Items] A A A A Percentage of concentration risk 29.00% A A A Supplier Concentration Risk | Purchases | Supplier Two A A A A A Schedule Of Accounting Policies [Line Items] A A A A Percentage of concentration risk 45.00% A 49.00% 40.00% A X - DefinitionAmortized period for expenses incurred for research and development in united states. + ReferencesNo definition available. + Details Name: scph\_AmortizedPeriodForExpensesIncurredForResearchAndDevelopmentInUnitedStates Namespace Prefix: scph\_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionAmortized period for expenses incurred for research and development outside united states. + ReferencesNo definition available. + Details Name: scph\_AmortizedPeriodForExpensesIncurredForResearchAndDevelopmentOutsideUnitedStates Namespace Prefix: scph\_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionNumber of customer. + ReferencesNo definition available. + Details Name: scph\_NumberOfCustomer Namespace Prefix: scph\_Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - DefinitionNumber of suppliers. + ReferencesNo definition available. + Details Name: scph\_NumberOfSuppliers Namespace Prefix: scph\_Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - DefinitionSchedule of accounting policies. + ReferencesNo definition available. + Details Name: scph\_ScheduleOfAccountingPoliciesLineItems Namespace Prefix: scph\_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1:



valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(8\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterials Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant XML 45 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Inventory - Additional Information (Details) - USD ($) 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Á Á Allowance for excess, damaged and obsolete inventory $ 75,000 $ 0 X - DefinitionAllowance for excess, damaged and obsolete inventory. + ReferencesNo definition available. + Details Name: scph_AallowanceForExcessDamagedAndObsoleteInventory Namespace Prefix: scph_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 46 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment - Schedule of Purchased Property and Equipment (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property Plant And Equipment [Line Items] Á Á Property and equipment, gross $ 128 $ 119 Less: Accumulated depreciation (77) (61) Property and equipment, net $ 51 58 Office Equipment Á Á Property Plant And Equipment [Line Items] Á Á ESTIMATED USEFUL LIFE 5 years Á Á Property and equipment, gross $ 31 31 Office Furniture Á Á Property Plant And Equipment [Line Items] Á Á ESTIMATED USEFUL LIFE 7 years Á Á Property and equipment, gross $ 73 64 Computer Equipment Á Á Property Plant And Equipment [Line Items] Á Á ESTIMATED USEFUL LIFE 3 years Á Á Property and equipment, gross $ 15 15 Leasehold Improvements Á Á Property Plant And Equipment [Line Items] Á Á Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration] us-gaap:UsefulLifeTermOfLeaseMember Á Property and equipment, gross $ 9 $ 9 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(14\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(13\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A)Reference 3: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: instant X - DefinitionIndicates description of term of useful life for property, plant, and equipment when not stated as numeric value. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3 + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment - Additional Information (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Property, Plant and Equipment [Abstract] Á Á Á Depreciation expense $ 5,000 $ 6,000 $ 16,000 $ 18,000 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant XML 49 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments - Summary of Assets Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Liabilities: Á Á Derivative liability $ 0 $ 3,857 Term loan 51,099 38,811 Revenue purchase and sale liability 26,830 0 Fair Value, Measurements, Recurring Á Á Assets: Á Á Cash equivalents 90,346 44,202 Investments Á 29,199 Total Á 73,401 Liabilities: Á Á Derivative liability Á 3,857 Term loan 51,099 Á Revenue purchase and sale liability 26,830 Á Total Á 77,929 Á Fair Value, Measurements, Recurring | Commercial Paper Á Á Assets: Á Á Investments Á 9,425 Fair Value, Measurements, Recurring | United States Treasury securities Á Á Assets: Á Á Investments Á 13,969 Fair Value, Measurements, Recurring | United States Government Agency securities Á Á Assets: Á Á Investments Á 1,990 Fair Value, Measurements, Recurring | Corporate Bonds Á Á Assets: Á Á Investments Á 3,815 Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level 1) [Member] Á Á Assets: Á Á Cash equivalents 90,346 44,202 Investments Á 13,969 Total Á 58,171 Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level 1) [Member] | United States Treasury securities Á Á Assets: Á Á Investments Á 13,969 Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) [Member] | Commercial Paper Á Á Assets: Á Á Investments Á 9,425 Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) [Member] | United States Government Agency securities Á Á Assets: Á Á Investments Á 1,990 Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) [Member] | Corporate Bonds Á Á Assets: Á Á Investments Á 3,815 Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) [Member] Á Á Liabilities: Á Á Derivative liability Á 3,857 Term loan 51,099 Á Revenue purchase and sale liability 26,830 Á Total Á 77,929 Á 3,857 X - DefinitionRevenue purchase and sale liability. + ReferencesNo definition available. + Details Name: scph_RevenuePurchaseAndSaleLiability Namespace Prefix: scph_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3:

highly liquid investments that are both convertible to known amounts of cash and near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 - Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap DerivativeLiabilitiesNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap InvestmentsFairValueDisclosure Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap LiabilitiesFairValueDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap LongTermDebtNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap FairValueByMeasurementFrequencyAxis=us-gaap FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByAssetClassAxis=us-gaap FairValueByAssetClassAxis=us-gaap CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByAssetClassAxis=us-gaap USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByAssetClassAxis=us-gaap USGovernmentCorporationsAndAgenciesSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByAssetClassAxis=us-gaap CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis=us-gaap FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis=us-gaap FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis=us-gaap FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments - Schedule of Changes in Fair Value of Level 3 Derivative Liabilities (Details) - Significant Unobservable Inputs (Level 3) [Member] \$ in Thousands 9 Months Ended Sep. 30, 2024 USD (\$) Term Loan A Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] A Initial fair value \$ 48,145 Change in fair value \$ 2,954 Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other Nonoperating Income (Expense) Ending balance \$ 51,099 Revenue Purchase and Sale Liability A Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] A Initial fair value 25,000 Change in fair value \$ 1,830 Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other Nonoperating Income (Expense) Ending balance \$ 26,830 Derivative Liability A Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] A Beginning balance 3,857 Change in fair value \$ (3,857) Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other Nonoperating Income (Expense) X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 - Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 - Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 - Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 - Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList Namespace Prefix: us-gaap Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis=us-gaap FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap LongtermDebtTypeAxis=schp TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap RevenuePurchaseAndSaleLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DerivativeInstrumentRiskAxis=schp DerivativeLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments - Additional Information (Details) Sep. 30, 2024 Discounted Cash Flow | Discount Rate A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A Measurement input 0.205 X - DefinitionValue of input used to measure derivative liability

xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap LongTermDebtTypeAxis=scpsh TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Liabilities - Additional Information (Details) - USD (\$) 3 Months Ended 9 Months Ended Aug. 09, 2024 Oct. 13, 2022 Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Fair value of warrants as an increase to additional paid-in capital Á Á \$ 1,744,000 Á Á \$ 1,744,000 Á Á Á Á Cash and cash equivalents Á Á \$ 91,484,000 Á Á \$ 91,484,000 Á Á \$ 46,814,000 Proceeds from term loan Á Á Á Á Á Á \$ 46,772,000 Á Á Exercise price per share Á Á \$ 0.001 Á Á \$ 0.001 Á Á Á Fair market value per share of common stock Á Á Á Á Á Á \$ 3.81 Á Á \$ 5.36 Á Á Minimum Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Contractual life Á Á Á Á Á Á Á Á 5 years 6 months 5 years 6 months Á Maximum Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Contractual life Á Á Á Á Á Á Á Á 6 years 8 months 12 days 6 years 11 months 23 days Á Common Stock Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Purchase shares of common stock Á Á Á Á Á Á Á Á 33,333 1,511,157 Á Á Á Term Loan Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Fair value of debt Á 48,100,000 Á \$ 51,100,000 Á Á \$ 51,100,000 Á Á Credit Agreement Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Loan and security agreement, amount \$ 75,000,000 Á Á Á Á Á Á Á Á Loan agreement, maturity date Aug. 09, 2029 Á Á Á Á Á Á Á Á Scheduled repayments outstanding \$ 0 Á Á Á Á Á Á Á Á Yield protection premium percentage year one 5.00% Á Á Á Á Á Á Á Á Yield protection premium percentage year two 3.00% Á Á Á Á Á Á Á Á Yield protection premium percentage year three 1.00% Á Á Á Á Á Á Á Á Yield protection premium percentage after year three 0.00% Á Á Á Á Á Á Á Á Cash and cash equivalents \$ 5,000,000 Á Á Á Á Á Á Á Á Exercise price per share Á 4.5902 Á Á Á Á Á Á Á Á Increase in interest rate on default 3.00% Á Á Á Á Á Á Á Á Credit Agreement | Common Stock Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Warrants to purchase of shares 300,000 Á Á Á Á Á Á Á Á Fair market value per share of common stock \$ 4.33 Á Á Á Á Á Á Á Á Credit Agreement | Warrants Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Warrants exercise period 6 years Á Á Á Á Á Á Á Á Fair value of warrants as an increase to additional paid-in capital Á 200,000 Á Á Á Á Á Á Á Á Risk-free rate 3.87% Á Á Á Á Á Á Á Á Warrants exercise period 6 years Á Á Á Á Á Á Á Á Fair value of warrants as an increase to additional paid-in capital Á 200,000 Á Á Á Á Á Á Á Á Risk-free rate 3.87% Á Á Á Á Á Á Á Á Contractual life 7 years 7 months 20 days Á Á Á Á Á Á Á Á Fair market value per share of common stock Á 4.33 Á Á Á Á Á Á Á Á Exercise price per warrant Á 4 Á Á Á Á Á Á Á Á Expected volatility 82.50% Á Á Á Á Á Á Á Á Credit Agreement | SOFR Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Basis spread on variable base rate 6.75% Á Á Á Á Á Á Á Á Frequency of periodic payment monthly Á Á Á Á Á Á Á Á Credit Agreement | SOFR | Interest Rate Floor [Member] Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Basis spread on variable base rate 3.25% Á Á Á Á Á Á Á Á Credit Agreement | Borrowings One [Member] Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Loan and security agreement, amount \$ 50,000,000 Á Á Á Á Á Á Á Á Credit Agreement | Borrowings Two [Member] Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Loan and security agreement, amount 25,000,000 Á Á Á Á Á Á Á Á Revenue Purchase and Sale Agreement Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Purchase price 50,000,000 Á Á Á Á Á Á Á Á Initial draw amount \$ 25,000,000 Á Á Á Á Á Á Á Á Percentage of purchase price with related to purchaser revenue payment 200.00% Á Á Á Á Á Á Á Á Fair value of debt Á 25,000,000 Á 26,800,000 Á Á 26,800,000 Á Á Oaktree Agreement [Member] Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Loan and security agreement, amount Á Á Á Á Á Á Á Á \$ 50,000,000 Loan agreement, maturity date Á Oct. 13, 2027 Á Á Á Á Á Á Á Á Exit fee 1,000,000 Á Á Á Á Á Á Á Á Embedded derivative liability upon issuance of Term Loan Á \$ 8,900,000 Á Á Á Á Á Á Á Á Amortization of debt discount Á Á 276,000 \$ 521,000 Á Á 1,500,000 Á 1,500,000 Á Á Exit fee Á \$ 20,000 \$ 38,000 Á Á \$ 107,000 Á 108,000 Á Á Prepayment premium percentage one Á 0.02 Á Á Á Á Á Á Á Á Long term debt prepayment premium amount \$ 2,600,000 Á Á Á Á Á Á Á Á Oaktree Agreement [Member] | Maximum Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Loan and security agreement, amount Á \$ 100,000,000 Á Á Á Á Á Á Á Á Oaktree Agreement [Member] | Warrants Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Exercise price per share Á \$ 5.4 Á Á Á Á Á Á Á Á Relative fair value of detachable warrants Á 2,000,000 Á Á Á Á Á Á Á Á Risk-free rate Á 4.11% Á Á Á Á Á Á Á Á Contractual life Á 7 years Á Á Á Á Á Á Á Á Fair market value per share of common stock Á \$ 5.5 Á Á Á Á Á Á Á Á Exercise price per warrant Á \$ 5.4 Á Á Á Á Á Á Á Á Expected volatility Á 77.00% Á Á Á Á Á Á Á Á Oaktree Agreement [Member] | Warrants | Maximum Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Purchase shares of common stock Á 516,345 Á Á Á Á Á Á Á Á Oaktree Agreement [Member] | Borrowings One [Member] Á Á Á Á Á Á Á Á Debt Instrument [Line Items] Á Á Á Á Á Á Á Á Loan and security agreement, amount Á \$ 50,000,000 Á Á Á Á Á Á Á Á X - DefinitionDebt instrument yield protection premium amount of principal percentage after year three. + ReferencesNo definition available. + Details Name: scpsh\_DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageAfterYearThree Namespace Prefix: scpsh\_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDebt instrument yield protection premium amount of principal percentage year one. + ReferencesNo definition available. + Details Name: scpsh\_DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageYearOne Namespace Prefix: scpsh\_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDebt instrument yield protection premium amount of principal percentage year three. + ReferencesNo definition available. + Details Name: scpsh\_DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageYearThree Namespace Prefix: scpsh\_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDebt instrument yield protection premium amount of principal percentage year two. + ReferencesNo definition available. + Details Name: scpsh\_DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageYearTwo Namespace Prefix: scpsh\_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionEmbedded derivative liability upon issuance of Term Loan + ReferencesNo definition available. + Details Name: scpsh\_EmbeddedDerivativeLiabilityUponIssuanceOfTermLoan Namespace Prefix: scpsh\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInitial draw amount. + ReferencesNo definition available. + Details Name: scpsh\_InitialDrawAmount Namespace Prefix: scpsh\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLong-term debt exit fee. + ReferencesNo definition available. + Details Name: scpsh\_LongTermDebtExitFee Namespace Prefix: scpsh\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLong-term debt increment on interest rate on default. + ReferencesNo definition available. + Details Name: scpsh\_LongTermDebtIncrementOnInterestRateOnDefault Namespace Prefix: scpsh\_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLong term debt prepayment premium amount. + ReferencesNo definition available. + Details Name: scpsh\_LongTermDebtPrepaymentPremiumAmount Namespace Prefix: scpsh\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLong term debt prepayment premium percentage year one. + ReferencesNo definition available. + Details Name: scpsh\_LongTermDebtPrepaymentPremiumPercentageYearOne Namespace Prefix: scpsh\_Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionPercentage of purchase price with related to purchaser revenue payment. + ReferencesNo definition available. + Details Name: scpsh\_PercentageOfPurchasePriceWithRelatedToPurchaserRevenuePayment Namespace Prefix: scpsh\_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPurchase price. + ReferencesNo definition available. + Details Name: scpsh\_PurchasePrice Namespace Prefix: scpsh\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRelative fair value of detachable warrants. + ReferencesNo definition available. + Details Name: scpsh\_RelativeFairValueOfDetachableWarrants Namespace Prefix: scpsh\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. + ReferencesReference 1:

Accounting -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap DebtInstrumentLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap DebtInstrumentMaturityDate Namespace Prefix: us-gaap Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAmount of the required periodic payments applied to principal. + ReferencesReference 1: http://asc.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap DebtInstrumentPeriodicPaymentPrincipal Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 2: http://asc.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-1 + Details Name: us-gaap ProceedsFromIssuanceOfLongTermDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award. + ReferencesNo definition available. + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl



unit options. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap\_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriod1 Namespace Prefix: us-gaap\_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionDate the equity-based award expires, in YYYY-MM-DD format. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate Namespace Prefix: us-gaap\_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details</a> Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNet number of non-option equity instruments granted to participants. + ReferencesReference 1: <a href=) Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details> Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap\_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap\_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details) Name: us-gaap\_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details) Name: us-gaap\_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap\_AwardTypeAxis=us-gaap\_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_PlanNameAxis=scph\_TwoThousandSeventeenStockPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_RangeAxis=srt\_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_PlanNameAxis=scph\_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_PlanNameAxis=scph\_TwoThousandTwentyThreeEmploymentInducementAwardPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 57 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Schedule of Estimated Fair Value of Options Valuation Assumptions (Details) - \$ / shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Á Risk-free interest rate, minimum 3.66% 3.40% Risk-free interest rate, maximum 4.59% 4.23% Expected dividend yield 0.00% 0.00% Expected volatility, minimum 76.00% 77.00% Expected volatility, maximum 79.00% 85.00% Weighted-average grant date fair value \$ 3.81 \$ 5.36 Minimum Á Á Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Á Expected life 5 years 6 months 5 years 6 months Maximum Á Á Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Á Expected life 6 years 8 months 12 days 6 years 11 months 23 days X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap\_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Namespace Prefix: us-gaap\_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Namespace Prefix: us-gaap\_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe maximum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Namespace Prefix: us-

gaap\_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe minimum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap\_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap\_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt\_RangeAxis=srt\_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML \$5 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Summary of Information about Stock Option Activity (Details) \$ / shares in Units, \$ in Thousands 9 Months Ended Dec. 29, 2023 Shares Sep. 30, 2024 USD (\$) \$ / shares shares NUMBER OF SHARES A A Number of shares outstanding, beginning balance | shares A 4,681,326 Number of shares granted | shares A 1,119,772 Number of shares exercised | shares (24,343) (30,203) Number of shares forfeited | shares A (325,420) Number of shares outstanding, ending balance | shares A 5,445,475 Vested and exercisable, ending balance | shares A 3,517,499 Vested and expected to vest, ending balance | shares A 5,081,614 WEIGHTED-AVERAGE EXERCISE PRICE A A Weighted average exercise prices, outstanding beginning balance | \$ / shares A 6.09 Weighted average exercise prices, granted | \$ / shares A 5.43 Weighted average exercise prices, exercised | \$ / shares A 2.85 Weighted average exercise prices, forfeited | \$ / shares A 6.46 Weighted average exercise prices, outstanding ending balance | \$ / shares A 5.95 Weighted average exercise prices, vested and exercisable ending balance | \$ / shares A 6.15 Weighted average exercise prices, vested and expected to vest ending balance | \$ / shares A 5.98 WEIGHTED-AVERAGE REMAINING CONTRACTUAL TERM A A Weighted average remaining contractual term, outstanding A 6 years 9 months 21 days Weighted average remaining contractual term, vested and exercisable A 5 years 9 months 3 days Weighted average remaining contractual term, vested and expected to vest A 6 years 7 months 28 days AGGREGATE INTRINSIC VALUE A A Aggregate intrinsic value, outstanding ending balance | \$ A 725 Aggregate intrinsic value, vested and exercisable ending balance | \$ A 606 Aggregate intrinsic value, vested and expected to vest ending balance | \$ A 709 X - DefinitionShare based compensation arrangement by share based payment award options weighted average remaining contractual term. + ReferencesNo definition available. + Details Name: scph\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract Namespace Prefix: scph\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1:

Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableValue1 Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap\_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -SubParagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap\_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap\_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-599-1 + Details Name: us-gaap\_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration XML 59 R52.htm IDEA: XBRL DOCUMENT V3.24.3 Stock-Based Compensation - Schedule of RSU Activity (Details) - Restricted Stock Units (RSUs) 9 Months Ended Sep. 30, 2024 \$ / shares shares Share Based Compensation Arrangement By Share Based Payment Award [Line Items] A RSUs outstanding | shares 368,411 RSUs Granted | shares 471,790 RSUs Released | shares (82,818) RSUs Forfeited | shares (35,617) RSUs outstanding | shares 721,766 AVERAGE GRANT DATE FAIR VALUE, RSUs outstanding | \$ / shares \$ 6.33 AVERAGE GRANT DATE FAIR VALUE, Granted | \$ / shares 5.7 AVERAGE GRANT DATE FAIR VALUE, Released | \$ / shares 6.33 AVERAGE GRANT DATE FAIR VALUE, Forfeited | \$ / shares 6.24 AVERAGE GRANT DATE FAIR VALUE, RSUs outstanding | \$ / shares 5.93 X - DefinitionShare-based compensation arrangement by share-based payment award, equity instruments other than options, released in period + ReferencesNo definition available. + Details Name: scph\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod Namespace Prefix: scph\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionShare-based compensation arrangement by share-based payment award, equity instruments other than options, weighted average released fair value. + ReferencesNo definition available. + Details Name: scph\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageReleasedFairValue Namespace Prefix: scph\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap\_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionNumber of equity instruments other than options outstanding, including both vested and non-vested instruments. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardNoOptionEquityInstrumentsOutstandingNumber Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap\_AwardTypeAxis=us-gaap\_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R53.htm IDEA: XBRL DOCUMENT V3.24.3 Stock-Based Compensation - Summary of Stock Based Compensation Expense (Details) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2023 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] A A A Total stock-based compensation expense \$ 1,227 \$ 1,281 \$ 4,157 \$ 3,440 Research and Development A A A Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] A A A Total stock-based compensation expense 385 370 1,160 1,075 General and Administrative A A A Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] A A A Total stock-based compensation expense \$ 842 \$ 911 \$ 2,997 \$ 2,365 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-599-1Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionLine items represent

Financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap IncomeStatementLocationAxis=us-gaap ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: instant X - Details Name: us-gaap IncomeStatementLocationAxis=us-gaap GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Details) - USD (\$) 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Commitments And Contingencies [Line Items] A - Operating leases expire 2029 A - Short-term lease asset \$ 1,330,000 + 1,401,000 Short-term lease liability 231,000 \$ 176,000 Short-term Leases Recognized on Straight-line Basis A - Commitments And Contingencies [Line Items] A - Short-term lease asset 0 A - Short-term lease liability 0 A X - DefinitionCommitments and contingencies. + ReferencesNo definition available. + Details Name: scph CommitmentsAndContingenciesLineItems Namespace Prefix: scph Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionOperating leases expiration year. + ReferencesNo definition available. + Details Name: scph OperatingLeasesExpirationYear Namespace Prefix: scph Data Type: xbrli:yearItem Type Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Details Name: us-gaap LeaseContractualTermAxis=scph StraightLineBasisMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Schedule of Maturity Analysis of Annual Undiscounted Cash Flows of Operating Lease Liabilities (Details) \$ in Thousands Sep. 30, 2024 USD (\$) Year ended: A December 31, 2024 \$ 96 December 31, 2025 381 December 31, 2026 376 December 31, 2027 358 December 31, 2028 367 Thereafter 249 Total minimum lease payments 1,827 Less imputed interest (429) Total \$ 1,398 X - DefinitionLessee operating lease liability payments due after year four. + ReferencesNo definition available. + Details Name: scph LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour Namespace Prefix: scph Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityUndiscountedEx

[illegible]



[illegible]



[illegible]

UNCONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 995444 -- Disclosure -- Pay vs Performance Disclosure Sheet  
http://xbrl.sec.gov/ced/role/PyvDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995444 -- Disclosure -- Insider Trading Arrangements Sheet  
http://xbrl.sec.gov/ced/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995444 -- Disclosure -- Description of Business and Basis of Presentation Sheet  
http://xbrl.sec.gov/20240930/taxonomy/role/Role\_DisclosureDescriptionOfBusinessAndBasisOfPresentation Description of Business and Basis of Presentation Notes 9 false false R10.htm 995465 -- Disclosure -- Significant Accounting Policies Sheet http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 10 false false R11.htm 995475 -- Disclosure -- Net Loss per Share Sheet http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureNetLossPerShare Net Loss per Share Notes 11 false false R12.htm 995485 -- Disclosure -- Investments Sheet http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureInvestments Investments Notes 12 false false R13.htm 995495 -- Disclosure -- Inventory Sheet http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureInventory Inventory Notes 13 false false R14.htm 995505 -- Disclosure -- Property and Equipment Sheet http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosurePropertyAndEquipment Property and Equipment Notes 14 false false R15.htm 995515 -- Disclosure -- Accrued Expenses Sheet http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureAccruedExpenses Accrued Expenses Notes 15 false false R16.htm 995525 -- Disclosure -- Fair Value of Financial Instruments Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 16 false false R17.htm 995535 -- Disclosure -- Financial Liabilities Sheet http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFinancialLiabilities Financial Liabilities Notes 17 false false R18.htm 995545 -- Disclosure -- Stockholders' Equity Sheet http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquity Stockholders' Equity Notes 18 false false R19.htm 995555 -- Disclosure -- Stock Based Compensation Sheet http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensation Stock Based Compensation Notes 19 false false R20.htm 995565 -- Disclosure -- Commitments and Contingencies Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 995575 -- Disclosure -- Significant Accounting Policies (Policies) Sheet http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPolicies Policies (Policies) Notes 21 false false R22.htm 995595 -- Disclosure -- Net Loss per Share (Tables) Sheet http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureNetLossPerShareTables Net Loss per Share (Tables) Notes 22 false false R23.htm 995605 -- Disclosure -- Investments (Tables) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureInvestmentsTables Investments (Tables) Notes 23 false false R24.htm 995615 -- Disclosure -- Inventory (Tables) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureInventoryTables Inventory (Tables) Notes 24 false false R25.htm 995625 -- Disclosure -- Property and Equipment (Tables) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Notes 25 false false R26.htm 995635 -- Disclosure -- Accrued Expenses (Tables) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureAccruedExpensesTables Accrued Expenses (Tables) Notes 26 false false R27.htm 995645 -- Disclosure -- Fair Value of Financial Instruments (Tables) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Notes 27 false false R28.htm 995655 -- Disclosure -- Financial Liabilities (Tables) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFinancialLiabilitiesTables Financial Liabilities (Tables) Notes 28 false false R29.htm 995665 -- Disclosure -- Stock Based Compensation (Tables) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationTables Stock Based Compensation (Tables) Notes 29 false false R30.htm 995675 -- Disclosure -- Commitments and Contingencies (Tables) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Notes 30 false false R31.htm 995685 -- Disclosure -- Description of Business and Basis of Presentation -- Additional Information (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails Description of Business and Basis of Presentation -- Additional Information (Details) Details 31 false false R32.htm 995695 -- Disclosure -- Significant Accounting Policies -- Additional Information (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails Significant Accounting Policies -- Additional Information (Details) Details 32 false false R33.htm 995705 -- Disclosure -- Net Loss per Share -- Computation of Basic and Diluted Net Loss Per Share of Common Stock (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails Net Loss per Share -- Computation of Basic and Diluted Net Loss Per Share of Common Stock (Details) Details 33 false false R34.htm 995715 -- Disclosure -- Net Loss per Share -- Additional Information (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureNetLossPerShareAdditionalInformationDetails Net Loss per Share -- Additional Information (Details) Details 34 false false R35.htm 995725 -- Disclosure -- Net Loss per Share -- Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails Net Loss per Share -- Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details) Details 35 false false R36.htm 995735 -- Disclosure -- Investments -- Summary of Available for Sale Classified Investments (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureInvestmentsSummaryOfAvailableForSaleClassifiedInvestmentsDetails Investments -- Summary of Available for Sale Classified Investments (Details) Details 36 false false R37.htm 995745 -- Disclosure -- Inventory -- Schedule of Inventory (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureInventoryScheduleOfInventoryDetails Inventory -- Schedule of Inventory (Details) Details 37 false false R38.htm 995755 -- Disclosure -- Inventory -- Additional Information (Details) Sheet http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureInventoryAdditionalInformationDetails Inventory -- Additional Information (Details) Details 38 false false R39.htm 995765 -- Disclosure -- Property and Equipment -- Schedule of Purchased Property and Equipment (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosurePropertyAndEquipmentScheduleOfPurchasedPropertyAndEquipmentDetails Property and Equipment -- Schedule of Purchased Property and Equipment (Details) Details 39 false false R40.htm 995775 -- Disclosure -- Property and Equipment -- Additional Information (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosurePropertyAndEquipmentAdditionalInformationDetails Property and Equipment -- Additional Information (Details) Details 40 false false R41.htm 995785 -- Disclosure -- Accrued Expenses -- Schedule of Accrued Expenses (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails Accrued Expenses -- Schedule of Accrued Expenses (Details) Details 41 false false R42.htm 995795 -- Disclosure -- Fair Value of Financial Instruments -- Summary of Assets Measured at Fair Value on Recurring Basis (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails Fair Value of Financial Instruments -- Summary of Assets Measured at Fair Value on Recurring Basis (Details) Details 42 false false R43.htm 995805 -- Disclosure -- Fair Value of Financial Instruments -- Schedule of Changes in Fair Value of Level 3 Derivative Liabilities (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFairValueOfFinancialInstrumentsScheduleOfChangesInFairValueOfLevel3DerivativeLiabilitiesDetails Fair Value of Financial Instruments -- Schedule of Changes in Fair Value of Level 3 Derivative Liabilities (Details) Details 43 false false R44.htm 995815 -- Disclosure -- Fair Value of Financial Instruments -- Additional Information (Details) Sheet http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails Fair Value of Financial Instruments -- Additional Information (Details) Details 44 false false R45.htm 995825 -- Disclosure -- Financial Liabilities -- Schedule of Fair Value of Debt Balance (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFinancialLiabilitiesScheduleOfFairValueOfDebtBalanceDetails Financial Liabilities -- Schedule of Fair Value of Debt Balance (Details) Details 45 false false R46.htm 995835 -- Disclosure -- Financial Liabilities -- Additional Information (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFinancialLiabilitiesAdditionalInformationDetails Financial Liabilities -- Additional Information (Details) Details 46 false false R47.htm 995845 -- Disclosure -- Financial Liabilities -- Schedule of Carrying Value of Debt Balance (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFinancialLiabilitiesScheduleOfCarryingValueOfDebtBalanceDetails Financial Liabilities -- Schedule of Carrying Value of Debt Balance (Details) Details 47 false false R48.htm 995855 -- Disclosure -- Stockholders' Equity -- Additional Information (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquityAdditionalInformationDetails Stockholders' Equity -- Additional Information (Details) Details 48 false false R49.htm 995865 -- Disclosure -- Stock Based Compensation -- Additional Information (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails Stock Based Compensation -- Additional Information (Details) Details 49 false false R50.htm 995875 -- Disclosure -- Stock Based Compensation -- Schedule of Estimated Fair Value of Options Valuation Assumptions (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails Stock Based Compensation -- Schedule of Estimated Fair Value of Options Valuation Assumptions (Details) Details 50 false false R51.htm 995885 -- Disclosure -- Stock Based Compensation -- Summary of Information about Stock Option Activity (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails Stock Based Compensation -- Summary of Information about Stock Option Activity (Details) Details 51 false false R52.htm 995895 -- Disclosure -- Stock Based Compensation -- Schedule of RSU Activity (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfRSUActivityDetails Stock Based Compensation -- Schedule of RSU Activity (Details) Details 52 false false R53.htm 995905 -- Disclosure -- Stock Based Compensation -- Summary of Stock Based Compensation Expense (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails Stock Based Compensation -- Summary of Stock Based Compensation Expense (Details) Details 53 false false R54.htm 995915 -- Disclosure -- Commitments and Contingencies -- Additional Information (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies -- Additional Information (Details) Details 54 false false R55.htm 995925 -- Disclosure -- Commitments and Contingencies -- Schedule of Maturity Analysis of Annual Undiscounted Cash Flows of Operating Lease Liabilities (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLiabilitiesDetails Commitments and Contingencies -- Schedule of Maturity Analysis of Annual Undiscounted Cash Flows of Operating Lease Liabilities (Details) Details 55 false false R56.htm 995935 -- Disclosure -- Commitments and Contingencies -- Schedule of Lease Cost and Other Information of Operating Lease Liabilities (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostAndOtherInformationOfOperatingLeaseLiabilitiesDetails Commitments and Contingencies -- Schedule of Lease Cost and Other Information of Operating Lease Liabilities (Details) Details 56 false false R57.htm 995945 -- Disclosure -- Commitments and Contingencies -- Schedule of Lease Cost and Other Information of Operating Lease Liabilities (Details) Sheet  
http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostAndOtherInformationOfOperatingLeaseLiabilitiesDetails Commitments and Contingencies -- Schedule of Lease Cost and Other Information of Operating Lease Liabilities (Details) Details 57 false false R58.htm 995955 -- Disclosure -- Commitments and Contingencies -- Schedule of Lease Cost and Other Information of Operating Lease Liabilities (Details) Sheet  
http://www.sepharmaceuticals.com/2024093

```

"us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U United States Of America Dollars Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "uniqueAnchor": { "contextRef": "C bf67b39-590a-4494-497d-ce94a3ebbc378", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U United States Of America Dollars Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "longName": "100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C 467e98a-4a94-497f-8632-1d30d4446964", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C 467e98a-4a94-497f-8632-1d30d4446964", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html", "1", "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "longName": "100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C 7fef1bf8-e1bf-4765-bdb4-5986cf329cb82", "name": "us-gaap:StockholdersEquity", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C e8a8bf44-464d-40a1-b8cf-ea8496e53fcd", "name": "us-gaap:ProfitLoss", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "unique": true } }, "R6": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "longName": "100070 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C 467e98a-4a94-497f-8632-1d30d4446964", "name": "us-gaap:ProfitLoss", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C eed71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/eed/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C 467e98a-4a94-497f-8632-1d30d4446964", "name": "us-gaap:NetIncomeLoss", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/eed/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C 467e98a-4a94-497f-8632-1d30d4446964", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "unique": true } }, "R9": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureDescriptionOfBusinessAndBasisOfPresentation", "longName": "995455 - Disclosure - Description of Business and Basis of Presentation", "shortName": "Description of Business and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C eed71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C eed71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPolicies", "longName": "995465 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C eed71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C eed71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureNetLossPerShare", "longName": "995475 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C eed71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C eed71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureInvestments", "longName": "995485 - Disclosure - Investments", "shortName": "Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C eed71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C eed71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureInventory", "longName": "995495 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C eed71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C eed71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html", "1", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.se
```

"uniqueAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentTables", "longName": "995625-Disclosure-Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureAccruedExpensesTables", "longName": "995635-Disclosure-Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "seph:AccruedLiabilitiesDisclosureTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "seph:AccruedLiabilitiesDisclosureTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureFairValueOfFinancialInstrumentsTables", "longName": "995645-Disclosure-Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:ScheduleOffairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "ix:continuation", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:ScheduleOffairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "ix:continuation", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesTables", "longName": "995655-Disclosure-Financial Liabilities (Tables)", "shortName": "Financial Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "seph:FairValueOfDebtBalanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "us-gaap:DebtDisclosureTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "seph:FairValueOfDebtBalanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "us-gaap:DebtDisclosureTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationTables", "longName": "995665-Disclosure-Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "ix:continuation", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "ix:continuation", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesTables", "longName": "995675-Disclosure-Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "longName": "995685-Disclosure-Description of Business and Basis of Presentation-Additional Information (Details)", "shortName": "Description of Business and Basis of Presentation-Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C-bf6e7b39-590a-4ff9-942d-ce94aebbc378", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "U-USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "995695-Disclosure-Significant Accounting Policies-Additional Information (Details)", "shortName": "Significant Accounting Policies-Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C-bf6e7b39-590a-4ff9-942d-ce94aebbc378", "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "unitRef": "U-USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "p", "ix:continuation", "div": "ix:continuation", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "seph:AmortizedPeriodForExpensesIncurredForResearchAndDevelopmentInUnitedStates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "ix:continuation", "div": "ix:continuation", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "unique": true } }, "R33": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails", "longName": "995705-Disclosure-Net Loss per Share-Computation of Basic and Diluted Net Loss Per Share of Common Stock (Details)", "shortName": "Net Loss per Share-Computation of Basic and Diluted Net Loss Per Share of Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C-46c7e98a-4a94-497f-8632-1d30d4446964", "name": "us-gaap:NetIncomeLoss", "unitRef": "U-USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails", "longName": "995715-Disclosure-Net Loss per Share-Additional Information (Details)", "shortName": "Net Loss per Share-Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C-bf6e7b39-590a-4ff9-942d-ce94aebbc378", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "unitRef": "U-UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true }, "uniqueAnchor": null }, "R35": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails", "longName": "995725-Disclosure-Net Loss per Share-Schedule of Antidilutive Securities Excluded From Computation of Net Loss Per Share (Details)", "shortName": "Net Loss per Share-Schedule of Antidilutive Securities Excluded From Computation of Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C-46c7e98a-4a94-497f-8632-1d30d4446964", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U-shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-46c7e98a-4a94-497f-8632-1d30d4446964", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U-shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureInvestmentsSummaryOfAvailableForSaleClassifiedInvestmentsDetails", "longName": "995735-Disclosure-Investments-Summary of Available for Sale Classified Investments (Details)", "shortName": "Investments-Summary of Available for Sale Classified Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C-fab0ba73-e437-474b-a0ef-ddf4a4844fd", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U-USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-fab0ba73-e437-474b-a0ef-ddf4a4844fd", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U-USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetails", "longName": "995745-Disclosure-Inventory-Schedule of Inventory (Details)", "shortName": "Inventory-Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C-bf6e7b39-590a-4ff9-942d-ce94aebbc378", "name": "us-gaap:InventoryNet", "unitRef": "U-USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:InventoryRawMaterials", "unitRef": "U-USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "unique": true } }, "R38": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureInventoryAdditionalInformationDetails", "longName": "995755-Disclosure-Inventory-Additional Information (Details)", "shortName": "Inventory-Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "seph:AllowanceForExcessDamagedAndObsoleteInventory", "unitRef": "U-USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span": "p", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true }, "uniqueAnchor": null }, "R39": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentScheduleOfPurchasedPropertyAndEquipmentDetails", "longName": "995765-Disclosure-Property and Equipment-Schedule of Purchased Property and Equipment (Details)", "shortName": "Property and Equipment-Schedule of Purchased Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C-bf6e7b39-590a-4ff9-942d-ce94aebbc378", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U-USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-bf6e7b39-590a-4ff9-942d-ce94aebbc378", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U-USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails", "longName": "995795-Disclosure-Fair Value of Financial Instruments-Summary of Assets Measured at Fair Value on Recurring Basis (Details)", "shortName": "Fair Value of Financial Instruments-Summary of Assets Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C-bf6e7b39-590a-4ff9-942d-ce94aebbc378", "name": "us-gaap:DerivativeLiabilitiesNoncurrent", "unitRef": "U-USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-bf6e7b39-590a-4ff9-942d-ce94aebbc378", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U-USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails", "longName": "995795-Disclosure-Fair Value of Financial Instruments-Summary of Assets Measured at Fair Value on Recurring Basis (Details)", "shortName": "Fair Value of Financial Instruments-Summary of Assets Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C-bf6e7b39-590a-4ff9-942d-ce94aebbc378", "name": "us-gaap:DerivativeLiabilitiesNoncurrent", "unitRef": "U-USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOffairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "ix:continuation", "div", "body", "html", "reportCount": 1, "baseRef": "seph-20240930.htm", "unique": true } }, "R43": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangesInFairValueOfLevel3DerivativeLiabilitiesDetails", "longName": "995805-Disclosure-Fair Value of Financial Instruments-Schedule of Changes in Fair Value of Level 3 Derivative Liabilities (Details)", "shortName": "Fair Value of Financial Instruments-

Module of Changes in Fair Value of Level 3 Derivative Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C-f339c9ff1-08f7-42b8-a223-66e7ec2ea6dd", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "unitRef": "U\_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-f339c9ff1-08f7-42b8-a223-66e7ec2ea6dd", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "unitRef": "U\_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "longName": "095815 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)", "shortName": "Fair Value of Financial Instruments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C-b37790da-4744-4674-9127-fd2d23e82dc9", "name": "us-gaap:DerivativeLiabilityMeasurementInput", "unitRef": "U\_pure", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:FairValueOfDebtBalanceTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-b37790da-4744-4674-9127-fd2d23e82dc9", "name": "us-gaap:DerivativeLiabilityMeasurementInput", "unitRef": "U\_pure", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:FairValueOfDebtBalanceTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOffFairValueOfDebtBalanceDetails", "longName": "095825 - Disclosure - Financial Liabilities - Schedule of Fair Value of Debt Balance (Details)", "shortName": "Financial Liabilities - Schedule of Fair Value of Debt Balance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C-ba0b8dda-082d-4e7f-bf22-87be794cb5be", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U\_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtInstrumentCarryingAmountTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-ba0b8dda-082d-4e7f-bf22-87be794cb5be", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U\_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtInstrumentCarryingAmountTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "longName": "095835 - Disclosure - Financial Liabilities - Additional Information (Details)", "shortName": "Financial Liabilities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C-46e7c98a-9a44-497f-8632-1d30d4446964", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "unitRef": "U\_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "unitRef": "U\_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNetTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-d8e4f409-08ce-4f0b-b7d9-10ebc24a8f15", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "U\_USD", "xsiNil": "false", "lang": "null", "decimals": "5", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtInstrumentFairValueTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfCarryingValueOfDebtBalanceDetails", "longName": "095845 - Disclosure - Financial Liabilities - Schedule of Carrying Value of Debt Balance (Details)", "shortName": "Financial Liabilities - Schedule of Carrying Value of Debt Balance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C-bf6e7b39-590a-4ff9-942d-ce94aebbc378", "name": "us-gaap:LongTermDebtNoncurrent", "unitRef": "U\_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "unitRef": "U\_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNetTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-adc73d23-daba-4d8b-9847-726e1938d139", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "unitRef": "U\_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNetTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetails", "longName": "095855 - Disclosure - Stockholders' Equity - Additional Information (Details)", "shortName": "Stockholders' Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C-ce1ec39a8-bb90-4ed1-b93a-0991b223766d1", "name": "seph:AggregateOfferingPrice", "unitRef": "U\_USD", "xsiNil": "false", "lang": "null", "decimals": "5", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-9ad966f8-84d7-4143-ac7d-975f0261b89b", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U\_shares", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:StockIssuedDuringPeriodSharesNewIssuesTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationAdditionalInformationDetails", "longName": "095865 - Disclosure - Stock Based Compensation - Additional Information (Details)", "shortName": "Stock Based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U\_shares", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-bf6e7b39-590a-4ff9-942d-ce94aebbc378", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "U\_USD", "xsiNil": "false", "lang": "null", "decimals": "5", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptionsTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails", "longName": "095875 - Disclosure - Stock Based Compensation - Schedule of Estimated Fair Value of Options Valuation Assumptions (Details)", "shortName": "Stock Based Compensation - Schedule of Estimated Fair Value of Options Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "U\_pure", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimumTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "seph-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-cded71fa-b45d-488f-b09d-e1964e627ffc", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "U\_pure", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Payable [Member] ", "terseLabel": "Accounts Payable", "documentation": "Obligations incurred and payable to vendors for goods and services received." } } }, "auth\_ref": { "r55" } }, "us\_gaap\_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth\_ref": { "r631" } }, "us\_gaap\_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth\_ref": { "r822" } } }, "us\_gaap\_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "terseLabel": "Accretion of discount on investments", "negatedLabel": "Accretion on short-term investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth\_ref": { "r84" } } }, "scph\_AccruedContractResearchAndDevelopmentExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AccruedContractResearchAndDevelopmentExpenseCurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "lang": { "en-us": { "role": { "documentation": "Accrued contract research and development expense current", "label": "Accrued Contract Research And Development Expense Current", "terseLabel": "Contract research and development" } } }, "auth\_ref": { "1" } } }, "scph\_AccruedFinancingRelatedCostCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AccruedFinancingRelatedCostCurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Financing costs", "documentation": "Accrued financing related cost current", "label": "Accrued Financing Related Cost Current" } } }, "auth\_ref": { "1" } } }, "scph\_AccruedInventoryInTransit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AccruedInventoryInTransit", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "lang": { "en-us": { "role": { "label": "Inventory in transit", "documentation": "Accrued inventory in transit" } } }, "auth\_ref": { "1" } } }, "us\_gaap\_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth\_ref": { "r56" } } }, "us\_gaap\_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth\_ref": { "1" } } }, "scph\_AccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AccruedLiabilitiesDisclosureTextBlock", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureAccruedExpenses": { "lang": { "en-us": { "role": { "documentation": "Accrued liabilities", "label": "Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "auth\_ref": { "1" } } }, "scph\_AccruedManufacturingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AccruedManufacturingCosts", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Manufacturing costs", "label": "Accrued Manufacturing Costs", "documentation": "Accrued manufacturing costs." } } }, "auth\_ref": { "1" } } }, "us\_gaap\_AccruedMarketingCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedMarketingCostsCurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Sales returns and allowances and related costs", "label": "Accrued Marketing Costs, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth\_ref": { "1" } } }, "us\_gaap\_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Consulting and professional service fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth\_ref": { "r56" } } }, "us\_gaap\_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Royalty", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth\_ref": { "r56", "r641" } } }, "us\_gaap\_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosurePropertyAndEquipmentScheduleOfPurchasedPropertyAndEquipmentDetails": { "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth\_ref": { "r32", "r139", "r531" } } }, "us\_gaap\_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth\_ref": { "r17", "r18", "r73", "r144", "r528", "r549", "r550" } } }, "us\_gaap\_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Other Comprehensive Income (Loss)", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth\_ref": { "r1", "r9", "r18", "r416", "r419", "r478", "r545", "r546", "r804", "r805", "r806", "r812", "r813", "r814", "r815" } } }, "ecd\_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth\_ref": { "r738" } } }, "us\_gaap\_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "lang": { "en-us": { "role": { "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of non-cash activities" } } }, "auth\_ref": { "1" } } }, "us\_gaap\_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "lang": { "en-us": { "role": { "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid in capital", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "documentation": "Value received from shareholders in common stock related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid in capital." } } }, "auth\_ref": { "r65" } } }, "us\_gaap\_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquityAdditionalInformationDetails": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "lang": { "en-us": { "role": { "label": "Additional Paid in Capital [Member]", "terseLabel": "Additional Paid in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth\_ref": { "r562", "r812", "r813", "r814", "r815", "r874", "r941" } } }, "ecd\_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth\_ref": { "r751" } } }, "ecd\_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation" } } }, "auth\_ref": { "r751" } } }, "ecd\_AdjToNonPeeNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth\_ref": { "r751" } } }, "ecd\_AdjToPeeCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeeCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment to PEO Compensation, Footnote" } } }, "auth\_ref": { "r751" } } }, "scph\_AdjustmentsToAdditionalPaidInCapitalDeferredFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalDeferredFinancingCosts", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Deferred financing costs", "label": "Adjustments to Additional Paid in Capital, Deferred financing costs", "documentation": "Adjustments to additional paid in capital, deferred financing costs." } } }, "auth\_ref": { "1" } } }, "us\_gaap\_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "documentation": "Amount of increase to additional paid in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth\_ref": { "r41", "r42", "r352" } } }, "us\_gaap\_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFinancialLiabilitiesAdditionalInformationDetails": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "lang": { "en-us": { "role": { "verboseLabel": "Issuance of warrants", "terseLabel": "Fair value of warrants as an increase to additional paid in capital", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth\_ref": { "r10", "r34", "r97" } } }, "scph\_AdjustmentsToDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AdjustmentsToDebtIssuanceCosts", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs", "label": "Adjustments To Debt Issuance Costs", "documentation": "Adjustments to debt issuance costs." } } }, "auth\_ref": { "1" } } }, "us\_gaap\_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities"

```

"auth-ref": [ ] }, "seph AggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AggregateOfferingPrice", "crdr": "debit", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ] }, "lang": { "en-us": { "role": { "documentation": "Aggregate offering price." }, "label": "Aggregate Offering Price", "terseLabel": "Aggregate offering price" } } }, "auth-ref": [ ] }, "ecd AggtChngPnsnValnSmmryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValnSmmryCompstnTblForApblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } } }, "auth-ref": [ "r784" ] }, "ecd AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } } }, "auth-ref": [ "r710", "r720", "r730", "r762" ] }, "ecd AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } } }, "auth-ref": [ "r713", "r723", "r733", "r765" ] }, "ecd AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } } }, "auth-ref": [ "r785" ] }, "ecd AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } } }, "auth-ref": [ "r751" ] }, "ecd AllExcutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExcutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } } }, "auth-ref": [ "r758" ] }, "ecd AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ] }, "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } } }, "auth-ref": [ "r714", "r724", "r734", "r758", "r766", "r770", "r778" ] }, "ecd AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ] }, "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } } }, "auth-ref": [ "r776" ] }, "us gaap AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ] }, "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } } }, "auth-ref": [ "r382", "r387" ] }, "seph AllowanceForExcessDamagedAndObsoleteInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AllowanceForExcessDamagedAndObsoleteInventory", "crdr": "debit", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureInventoryAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited" ] }, "lang": { "en-us": { "role": { "terseLabel": "Allowance for excess, damaged and obsolete inventory", "label": "Allowance for excess, damaged and obsolete inventory", "documentation": "Allowance for excess, damaged and obsolete inventory." } } } }, "auth-ref": [ ] }, "dei AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ] }, "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } } }, "auth-ref": [ ] }, "us-gaap AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" ] }, "lang": { "en-us": { "role": { "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } } }, "auth-ref": [ "r5", "r77", "r316", "r894" ] }, "seph AmortizedPeriodForExpensesIncurredForResearchAndDevelopmentInUnitedStates": { "xbrltype": "durationItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AmortizedPeriodForExpensesIncurredForResearchAndDevelopmentInUnitedStates", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Amortized period for expenses incurred for research and development in united states", "label": "Amortized Period for Expenses Incurred for Research and Development in United States", "documentation": "Amortized period for expenses incurred for research and development in united states." } } } }, "auth-ref": [ ] }, "seph AmortizedPeriodForExpensesIncurredForResearchAndDevelopmentOutsideUnitedStates": { "xbrltype": "durationItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "AmortizedPeriodForExpensesIncurredForResearchAndDevelopmentOutsideUnitedStates", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Amortized period for expenses incurred for research and development outside united states", "label": "Amortized Period for Expenses Incurred for Research and Development Outside United States", "documentation": "Amortized period for expenses incurred for research and development outside united states." } } } }, "auth-ref": [ ] }, "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails" ] }, "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities", "documentation": "Information by type of antidilutive security." } } } }, "auth-ref": [ "r25" ] }, "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails" ] }, "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive securities excluded from calculation of diluted net loss per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } } }, "auth-ref": [ "r198" ] }, "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails" ] }, "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities", "documentation": "Information by type of antidilutive security." } } } }, "auth-ref": [ "r25" ] }, "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails" ] }, "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concept included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth-ref": [ ] }, "us-gaap AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails" ] }, "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } } }, "auth-ref": [ "r25" ] }, "us-gaap ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ] }, "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue generating activity or operations." } } } }, "auth-ref": [ "r407" ] }, "us-gaap Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS Unaud
```

{}}, "ced AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth\_ref": { "r769" } }, "ced AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth\_ref": { "r769" } }, "ced AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth\_ref": { "r769" } }, "ced AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth\_ref": { "r769" } }, "ced AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth\_ref": { "r769" } }, "ced AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth\_ref": { "r769" } }, "us gaap AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfRSUsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth\_ref": { "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381" } }, "ced AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth\_ref": { "r772" } }, "ced AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth\_ref": { "r771" } }, "ced AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth\_ref": { "r770" } }, "ced AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth\_ref": { "r770" } }, "scph BorrowingsOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "BorrowingsOneMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Funded Immediately", "label": "Borrowings One [Member]", "documentation": "Borrowings one." } } }, "auth\_ref": { "scph BorrowingsThreeMember" }, "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "BorrowingsThreeMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "On or Prior to December 31, 2024", "label": "Borrowings Three [Member]", "documentation": "Borrowings three." } } }, "auth\_ref": { "scph BorrowingsTwoMember" }, "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "BorrowingsTwoMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Up to Two Draws on or Prior to September 30, 2024", "label": "Borrowings Two [Member]", "documentation": "Borrowings two.", "verboseLabel": "Up to Two Draws on or Prior to March 31, 2026" } } }, "auth\_ref": { "us-gaap-BusinessDescriptionAndBasisOfPresentationTextBlock" }, "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureDescriptionOfBusinessAndBasisOfPresentation" }, "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Description of Business and Basis of Presentation", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth\_ref": { "r53", "r85", "r86" } }, "us-gaap-BusinessExitCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessExitCosts1", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Exit fee", "label": "Business Exit Costs", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth\_ref": { "r5" } }, "us-gaap-CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" }, "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth\_ref": { "r23", "r137", "r638" } }, "us-gaap-CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFairValueOffFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" }, "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth\_ref": { "r876", "r877" } }, "us-gaap-CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth\_ref": { "r24" } }, "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWSUnaudited" }, "lang": { "en-us": { "role": { "label": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "totalLabel": "Cash, cash equivalents and restricted cash", "periodStartLabel": "Cash and cash equivalents at beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth\_ref": { "r23", "r82", "r168" } }, "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWSUnaudited" }, "lang": { "en-us": { "role": { "label": "Net (decrease) increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth\_ref": { "r0", "r82" } }, "scph-CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostAndOtherInformationOfOperatingLeaseLiabilitiesDetails" }, "lang": { "en-us": { "role": { "documentation": "Cash paid for amounts included in measurement of lease liabilities", "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "auth\_ref": { "scph-ChangeInFairValueOfTermLoan" }, "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "ChangeInFairValueOfTermLoan", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfFairValueOfDebtBalanceDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of the term loan", "label": "Change in fair value of term loan", "documentation": "Change in fair value of term loan" } } }, "auth\_ref": { "ced-ChangedPeerGroupFnTextBlock" }, "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth\_ref": { "r749" } }, "ced-ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth\_ref": { "r746" } }, "ced-ChngInFrValOfOutsgndAndUnvstdEqtyAwrdsGrntdInPrYrYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsgndAndUnvstdEqtyAwrdsGrntdInPrYrYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years that are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years that are Outstanding and Unvested" } } }, "auth\_ref": { "r744" } }, "dei-CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DocumentDocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth\_ref": { "us-gaap-ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" }, "xbrltype": "porShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquityAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price per share", "verboseLabel": "Warrant, exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth\_ref": { "r339" } }, "us-gaap-ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants to purchase of shares", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth\_ref": { "r339" } }, "us-gaap-ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Prefunded warrant shares", "documentation": "Number of warrants or rights outstanding." } } }, "auth\_ref": { "ced-CoSelectedMeasureAmt": "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth\_ref": { "r750" } }, "ced-CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth\_ref": {

"r750"}], "us-gaap-CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureFairValueOffFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureInvestmentsSummaryOfAvailableForSaleClassifiedInvestmentsDetails", "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short term funds." } } }, "auth\_ref": { "r93", "r284", "r695", "r696", "r697", "r698"} }, "us-gaap-CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 12)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth\_ref": { "r61", "r109", "r525", "r574"} }, "us-gaap-CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth\_ref": { } }, "us-gaap-CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureCommitmentsAndContingencies", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth\_ref": { "r91", "r277", "r278", "r632", "r833", "r838"} }, "seph-CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "CommitmentsAndContingenciesLineItems", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "verboseLabel": "Commitments And Contingencies Line Items", "documentation": "Commitments and contingencies", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "auth\_ref": { } }, "seph-CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "CommitmentsAndContingenciesTable", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "auth\_ref": { } }, "seph-CommonStockAdditionalSharesExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "CommonStockAdditionalSharesExercisable", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureCommonStockAdditionalSharesExercisable", "lang": { "en-us": { "role": { "documentation": "Common stock additional shares exercisable", "label": "Common Stock Additional Shares Exercisable", "terseLabel": "Common stock additional shares exercisable" } } }, "auth\_ref": { } }, "seph-CommonStockAdditionalSharesPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "CommonStockAdditionalSharesPricePerShare", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureStockholdersEquityAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Common stock additional shares price per share", "label": "Common Stock Additional Shares Price Per Share", "terseLabel": "Common stock additional shares price per share" } } }, "auth\_ref": { } }, "us-gaap-CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureStockBasedCompensationAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Number of common stock shares available for issuance", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth\_ref": { "r64"} }, "us-gaap-CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth\_ref": { "r691", "r692", "r693", "r695", "r696", "r697", "r698", "r812", "r813", "r815", "r874", "r940", "r941"} }, "us-gaap-CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth\_ref": { "r64"} }, "us-gaap-CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth\_ref": { "r64", "r575"} }, "us-gaap-CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "lang": { "en-us": { "role": { "label": "Common Stock, Shares Issued", "terseLabel": "Common stock, shares issued", "totalLabel": "Common Stock, Shares Issued, Total", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth\_ref": { "r64"} }, "us-gaap-CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "lang": { "en-us": { "role": { "label": "Common Stock, Shares Outstanding", "terseLabel": "Common stock, shares outstanding", "periodStartLabel": "Common Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Common Stock, Shares Outstanding, Ending Balance", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth\_ref": { "r10", "r64", "r575", "r593", "r941", "r942"} }, "us-gaap-CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "verboseLabel": "Common stock, \$0.0001 par value; 150,000,000 shares authorized as of September 30, 2024; 35,968,510 and 50,040,134 shares issued and outstanding as of December 31, 2023 and September 30, 2024, respectively", "label": "Common Stock, Value Issued", "periodStartLabel": "Common Stock, Value Issued, Beginning Balance", "periodEndLabel": "Common Stock, Value Issued, Ending Balance", "totalLabel": "Common Stock, Value Issued, Total", "terseLabel": "Common stock, \$0.0001 par value; 150,000,000 shares authorized as of June 30, 2024; 35,968,510 and 36,139,802 shares issued and outstanding as of December 31, 2023 and June 30, 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth\_ref": { "r64", "r527", "r685"} }, "ecd-CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth\_ref": { "r755"} }, "ecd-CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth\_ref": { "r754"} }, "ecd-CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth\_ref": { "r756"} }, "ecd-CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth\_ref": { "r753"} }, "us-gaap-CompensatingBalanceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensatingBalanceAmount", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Compensating Balance Amount", "terseLabel": "Unrestricted cash", "documentation": "The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability." } } }, "auth\_ref": { "r137"} }, "us-gaap-ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth\_ref": { "r19", "r153", "r155", "r160", "r518", "r537", "r538"} }, "us-gaap-ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosurePropertyAndEquipmentScheduleOfPurchasedPropertyAndEquipmentDetails", "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth\_ref": { } }, "us-gaap-ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth\_ref": { "r26", "r27", "r48", "r49", "r215", "r631"} }, "us-gaap-ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth\_ref": { "r26", "r27", "r48", "r49", "r215", "r552", "r631"} }, "us-gaap-ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employee, supplier, lender." } } }, "auth\_ref": { "r26", "r27", "r48", "r49", "r215", "r631"} }, "us-gaap-ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureSignificantAccountingPolicies", "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth\_ref": { "r52", "r125"} }, "us-gaap-ConcentrationRiskPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Percentage of concentration risk", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the 'benchmark' (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth\_ref": { "r26", "r27", "r48", "r49", "r215"} }, "us-gaap-ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employee, supplier, lender) of the concentration." } } }, "auth\_ref": { "r26", "r27", "r48", "r49", "r215", "r631"} }, "us-gaap-CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateBondSecuritiesMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureInvestmentsSummaryOfAvailableForSaleClassifiedInvestmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Corporate Bonds", "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."} } }, "auth\_ref": { } }, "us-gaap-CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role- DisclosureFairValueOffFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails", "lang": { "en-

us": { "role": { "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Bonds", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } }, "auth\_ref": { "r663": "r665", "r673": "r686", "r690": "r937" } }, "us\_gaap\_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Cost of Revenue, Total", "label": "Cost of Revenue", "terseLabel": "Cost of product revenues", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } }, "auth\_ref": { "r74": "r172", "r250": "r285", "r286": "r287", "r288": "r289", "r290": "r291", "r292": "r293", "r452": "r651", "r841" } }, "srt-CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } }, "auth\_ref": { "r173": "r174", "r298": "r327", "r479": "r497", "r522": "r642", "r644" } }, "dei\_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } }, "auth\_ref": { } }, "seph\_CowenAndCompanyLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "CowenAndCompanyLLCMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Cowen and Company, LLC", "label": "Cowen And Company L L C [Member]", "terseLabel": "Cowen" } }, "auth\_ref": { } }, "seph\_CreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "CreditAgreementMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Credit agreement", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement" } }, "auth\_ref": { } }, "us\_gaap\_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } }, "auth\_ref": { "r284": "r839" } }, "us\_gaap\_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } }, "auth\_ref": { "r284": "r839", "r840" } }, "dei\_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayTimeType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format MM-DD." } }, "auth\_ref": { } }, "us\_gaap\_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Customer Concentration Risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } }, "auth\_ref": { "r87": "r215" } }, "seph\_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "CustomerOneMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Customer one", "label": "Customer One [Member]", "terseLabel": "Customer One" } }, "auth\_ref": { } }, "seph\_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "CustomerThreeMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Customer Three", "documentation": "Customer three." } }, "auth\_ref": { } }, "seph\_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "CustomerTwoMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "verboseLabel": "Customer Two", "label": "Customer Two [Member]", "documentation": "Customer two." } }, "auth\_ref": { } }, "us\_gaap\_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "documentation": "Debt instrument", "label": "Debt Disclosure [Text Block]", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilities", "lang": { "en-us": { "role": { "verboseLabel": "Financial Liabilities", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } }, "auth\_ref": { "r92": "r170", "r270", "r271", "r272", "r273", "r274", "r283", "r284", "r294", "r300", "r301", "r302", "r303", "r304", "r305", "r310", "r317", "r318", "r320", "r461" } }, "us\_gaap\_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } }, "auth\_ref": { "r15": "r55", "r56", "r107", "r108", "r175", "r295", "r296", "r297", "r298", "r299", "r301", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r655", "r656", "r657", "r658", "r659", "r683", "r810", "r834", "r835", "r836", "r893", "r895" } }, "us\_gaap\_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Debt Instrument Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable base rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } }, "auth\_ref": { } }, "us\_gaap\_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfCarryingValueOfDebtBalanceDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfFairValueOfDebtBalanceDetails", "lang": { "en-us": { "role": { "verboseLabel": "Par value of the term loan", "totalLabel": "Total minimum principal payments", "terseLabel": "Face value", "label": "Loan and security agreement, amount", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt, and other types of debt." } }, "auth\_ref": { "r15": "r15", "r108", "r321" } }, "us\_gaap\_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfFairValueOfDebtBalanceDetails", "lang": { "en-us": { "role": { "totalLabel": "Total fair value of the term loan", "terseLabel": "Fair value of debt", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } }, "auth\_ref": { "r308", "r451", "r656", "r657", "r877", "r878", "r879", "r880", "r887" } }, "us\_gaap\_DebtInstrumentFrequencyOfPeriodicPayment": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Frequency of periodic payment", "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)." } }, "auth\_ref": { "r15": "r51" } }, "us\_gaap\_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt instrument, effective interest rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } }, "auth\_ref": { "r58", "r323", "r461", "r462", "r683" } }, "us\_gaap\_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate, minimum", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } }, "auth\_ref": { "r58", "r296" } }, "us\_gaap\_DebtInstrumentInterestRateTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateTerms", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate Terms", "terseLabel": "Debt instrument, interest rate terms", "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets." } }, "auth\_ref": { "r58" } }, "us\_gaap\_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfCarryingValueOfDebtBalanceDetails", "lang": { "en-us": { "role": { "label": "Debt Instrument Line Items", "terseLabel": "Debt Instrument Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, "auth\_ref": { "r175", "r295", "r296", "r297", "r298", "r299", "r301", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r319", "r655", "r656", "r657", "r658", "r659", "r683", "r810", "r893", "r895" } }, "us\_gaap\_DebtInstrumentMaturityDate": { "xbrltype": "dateTimeType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Debt Instrument Maturity Date", "terseLabel": "Loan agreement, maturity date", "verboseLabel": "Debt instrument, maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } }, "auth\_ref": { "r142", "r655", "r879", "r880" } }, "us\_gaap\_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } }, "auth\_ref": { "r15", "r175", "r295", "r296", "r297", "r298", "r299", "r301", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r655", "r656", "r657", "r658", "r659", "r683", "r810", "r834", "r835", "r836", "r893", "r895" } }, "us\_gaap\_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Debt Instrument Periodic Payment, Principal", "terseLabel": "Scheduled repayments outstanding", "documentation": "Amount of the required periodic payments applied to principal." } }, "auth\_ref": { "r15" } }, "us\_gaap\_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfCarryingValueOfDebtBalanceDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } }, "auth\_ref": { "r15", "r37", "r38", "r50", "r95", "r96", "r175", "r295", "r296", "r297", "r298", "r299", "r301", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r319", "r655", "r656", "r657", "r658", "r659", "r683", "r810", "r893", "r895" } }, "us\_gaap\_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Debt Instrument Term", "terseLabel": "Loan agreement, term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDnHnMnS format, for example, P1Y5M13D, represents the reported fact of one year, five months, and thirteen days." } }, "auth\_ref": { } }, "us\_gaap\_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Unamortized debt discount", "negatedTerseLabel": "Unamortized debt discount", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Less, discount", "totalLabel": "Debt Instrument, Unamortized Discount, Total", "documentation": "Amount after accumulated amortization of debt discount." } }, "auth\_ref": { "r844", "r892", "r893", "r895" } }, "us\_gaap\_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfCarryingValueOfDebtBalanceDetails", "lang": { "en-us": { "role": { "negatedLabel": "Discount premium", "terseLabel": "Discount premium", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "totalLabel": "Debt Instrument, Unamortized Discount (Premium), Net, Total", "documentation": "Amount, after accumulated amortization, of debt discount (premium)." } }, "auth\_ref": { "r844", "r892", "r893", "r895" } },

"seph\_DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageAfterYearThree": { "xbrltype": "percentItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageAfterYearThree", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Debt instrument yield protection premium amount of principal percentage after year three." }, "label": "Debt Instrument Yield Protection Premium Amount Of Principal Percentage After Year Three", "terseLabel": "Yield protection premium percentage after year three" } } }, "auth\_ref": { "r1": "seph\_DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageYearOne", "xbrltype": "percentItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageYearOne", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Debt instrument yield protection premium amount of principal percentage year one." }, "label": "Debt Instrument Yield Protection Premium Amount Of Principal Percentage Year One", "terseLabel": "Yield protection premium percentage year one" } } }, "auth\_ref": { "r1": "seph\_DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageYearThree", "xbrltype": "percentItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageYearThree", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Debt instrument yield protection premium amount of principal percentage year three." }, "label": "Debt Instrument Yield Protection Premium Amount Of Principal Percentage Year Three", "terseLabel": "Yield protection premium percentage year three" } } }, "auth\_ref": { "r1": "seph\_DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageYearTwo", "xbrltype": "percentItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "DebtInstrumentYieldProtectionPremiumAmountOfPrincipalPercentageYearTwo", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Debt instrument yield protection premium amount of principal percentage year two." }, "label": "Debt Instrument Yield Protection Premium Amount Of Principal Percentage Year Two", "terseLabel": "Yield protection premium percentage year two" } } }, "auth\_ref": { "r1": "us\_gaap\_DebtPolicyTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtPolicyTextBlock", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Debt Policy [Policy Text Block]", "terseLabel": "Debt Issuance Costs", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth\_ref": { "r7": "seph\_DepositsAndOtherAssetsCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "DepositsAndOtherAssetsCurrent", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "lang": { "en-us": { "role": { "documentation": "Deposits and other assets current." }, "label": "Deposits And Other Assets Current", "terseLabel": "Deposits and other current assets" } } }, "auth\_ref": { "r1": "seph\_DepositsAndOtherAssetsNoncurrent", "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "DepositsAndOtherAssetsNoncurrent", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "lang": { "en-us": { "role": { "documentation": "Deposits and other assets noncurrent." }, "label": "Deposits And Other Assets Noncurrent", "terseLabel": "Deposits and other assets", "verboseLabel": "Deposits and other current assets" } } }, "auth\_ref": { "r1": "us\_gaap\_Depreciation", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosurePropertyAndEquipmentAdditionalInformationDetails": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWSUnaudited": { "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation expense", "totalLabel": "Depreciation Total", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth\_ref": { "r5": "us\_gaap\_DerivativeContractTypeDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOffLevel3DerivativeLiabilitiesDetails": { "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth\_ref": { "r564": "r566", "r580": "r581", "r582": "r583", "r584": "r585", "r586": "r588", "r589", "r590", "r591", "r601", "r602", "r603", "r604", "r607", "r608", "r609", "r610", "r624", "r625", "r626", "r627", "r691", "r693", "r881", "r882", "r883", "r884", "r885", "r886", "r888", "r889" } } }, "us\_gaap\_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOffLevel3DerivativeLiabilitiesDetails": { "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth\_ref": { "r43": "r44", "r45": "r105", "r564", "r566", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r588", "r589", "r590", "r591", "r601", "r602", "r603", "r604", "r607", "r608", "r609", "r610", "r624", "r625", "r626", "r627", "r644", "r691", "r693", "r881", "r882", "r883", "r884", "r885", "r886", "r888", "r889" } } }, "us\_gaap\_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFairValueOffinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "lang": { "en-us": { "role": { "label": "Derivative Liability Noncurrent", "terseLabel": "Derivative liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth\_ref": { "r140": "us\_gaap\_DerivativeLiabilityMeasurementInput", "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityMeasurementInput", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Measurement input", "label": "Derivative Liability Measurement Input", "documentation": "Value of input used to measure derivative liability." } } }, "auth\_ref": { "r429": "r430", "r431" } } }, "seph\_DerivativeLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "DerivativeLiabilityMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOffLevel3DerivativeLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability", "label": "Derivative Liability [Member]", "documentation": "Derivative Liability." } } }, "auth\_ref": { "r1": "seph\_DescriptionOfBusinessAndBasisOfPresentationLineItems", "xbrltype": "stringItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "DescriptionOfBusinessAndBasisOfPresentationLineItems", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Description Of Business And Basis Of Presentation [Line Items]", "label": "Description Of Business And Basis Of Presentation [Line Items]", "documentation": "Description of business and basis of presentation." } } }, "auth\_ref": { "r1": "us\_gaap\_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensation": { "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement [Text Block]", "terseLabel": "Stock Based Compensation", "documentation": "The entire disclosure for share based payment arrangement." } } }, "auth\_ref": { "r351": "r355", "r383", "r384", "r386", "r667" } } }, "us\_gaap\_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement [Abstract]" } } }, "auth\_ref": { "r1": "dei\_DocumentDomain", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDomain", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth\_ref": { "r1": "dei\_DocumentFiscalPeriodFocus", "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY\_Q1\_Q2 and Q3\_1st, 2nd and 3rd quarter 10 Q or 10 QT statements have value Q1\_Q2 and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth\_ref": { "r1": "dei\_DocumentFiscalYearFocus", "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "verboseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth\_ref": { "r1": "dei\_DocumentInformationDocumentAxis", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationDocumentAxis", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth\_ref": { "r1": "dei\_DocumentInformationLineItems", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": { "r1": "dei\_DocumentInformationTable", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth\_ref": { "r1": "dei\_DocumentPeriodEndDate", "xbrltype": "dateTimeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A, the filing date; for all other submission types, the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth\_ref": { "r1": "dei\_DocumentQuarterlyReport", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth\_ref": { "r705": "dei\_DocumentTransitionReport", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth\_ref": { "r737": "dei\_DocumentType", "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth\_ref": { "r1": "eed\_DvdsdOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInThlCompForCvrdYrMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/eed/2024", "localname": "DvdsdOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInThlCompForCvrdYrMember", "presentation": { "http://xbrl.sec.gov/eed/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid On Equity Awards Not Otherwise Reflected In Total Compensation For Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid On Equity Awards Not Otherwise Reflected In Total Compensation For Covered Year" } } }, "auth\_ref": { "r748": "us\_gaap\_EarningsPerShareAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth\_ref": { "r1": "us\_gaap\_EarningsPerShareBasic", "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Basic, Total", "label": "Earnings Per Share, Basic", "verboseLabel": "Net loss per share - basic", "terseLabel": "Net loss per share, basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth\_ref": { "r161": "r181", "r182", "r183", "r184", "r185", "r186", "r193", "r195", "r196", "r197", "r201", "r403", "r406", "r424", "r425", "r519", "r539", "r648" } } }, "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Diluted, Total", "label": "Earnings Per Share, Diluted", "verboseLabel": "Net loss per share - diluted", "terseLabel": "Net loss per share, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth\_ref": { "r161": "r181", "r182", "r183", "r184", "r185", "r186", "r193", "r195", "r196", "r197", "r201", "r403", "r406", "r424", "r425", "r519", "r539", "r648" } } }, "us\_gaap\_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureNetLossPerShare": { "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth\_ref": { "r190": "r198", "r199", "r200" } } }, "us\_gaap\_EmbeddedDerivativeFairValueOffEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeFairValueOffEmbeddedDerivativeLiability", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Embedded Derivative, Fair





"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crd": "credit", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsScheduleOfChangesInFairValueOffLevel3DerivativeLiabilitiesDetails", "lang": { "en-us": { "role": { "label": "Fair Value Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth ref": { "r432", "r442" } }, "us-gaap FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsScheduleOfChangesInFairValueOffLevel3DerivativeLiabilitiesDetails", "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "terselabel": "Fair Value Hierarchy and NAV", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth ref": { "r308", "r344", "r345", "r346", "r347", "r348", "r349", "r426", "r428", "r429", "r430", "r431", "r440", "r441", "r443", "r484", "r485", "r486", "r656", "r657", "r663", "r664", "r665", "r673", "r676" } } }, "us-gaap FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureFairValueOffFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails", "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terselabel": "Fair Value, Measurements, Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth ref": { "r673", "r677", "r678", "r679", "r680", "r690" } } }, "seph FairValueOfDebtBalanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "FairValueOfDebtBalanceTableTextBlock", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesTables", "lang": { "en-us": { "role": { "terselabel": "Schedule of Fair Value of Debt Balance", "label": "Fair value of Debt Balance [Table Text Block]", "documentation": "Fair value of debt balance." } } }, "auth ref": { "r673", "r677", "r678", "r679", "r680", "r690" } } }, "us-gaap FairValueOffFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOffFinancialInstrumentsPolicy", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "verboseLabel": "Fair Value Option", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth ref": { "r80" } } }, "seph FairValueOfTermLoanAtIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "FairValueOfTermLoanAtIssuance", "crd": "credit", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfFairValueOfDebtBalanceDetails", "lang": { "en-us": { "role": { "role": { "terselabel": "Fair value of the term loan at issuance", "label": "Fair value of term loan at issuance", "documentation": "Fair value of term loan at issuance." } } }, "auth ref": { "r673", "r677", "r678", "r679", "r680", "r690" } } } }, "seph FairValueOfWarrantsIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "FairValueOfWarrantsIssued", "crd": "credit", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "lang": { "en-us": { "role": { "negatedLabel": "Fair value of warrants issued", "terselabel": "Fair value of warrants issued", "label": "Fair Value of Warrants Issued", "documentation": "Fair value of warrants issued." } } }, "auth ref": { "r673", "r677", "r678", "r679", "r680", "r690" } } } }, "us-gaap FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsScheduleOfChangesInFairValueOffLevel3DerivativeLiabilitiesDetails", "lang": { "en-us": { "role": { "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)." } } }, "auth ref": { "r433", "r442" } } }, "us-gaap FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "terselabel": "Financial Instrument", "documentation": "Information by type of financial instrument." } } }, "auth ref": { "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r253", "r254", "r255", "r256", "r257", "r259", "r260", "r261", "r319", "r337", "r421", "r448", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r536", "r654", "r673", "r674", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r686", "r687", "r692", "r703", "r704", "r705", "r706", "r707", "r708", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900" } } } }, "ecd ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [{" "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terselabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth ref": { "r714", "r724", "r734", "r766" } } } }, "ecd ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [{" "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terselabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth ref": { "r714", "r724", "r734", "r766" } } } }, "ecd ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [{" "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terselabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth ref": { "r714", "r724", "r734", "r766" } } } }, "ecd ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [{" "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terselabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth ref": { "r714", "r724", "r734", "r766" } } } }, "ecd ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [{" "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terselabel": "Name" } } }, "auth ref": { "r714", "r724", "r734", "r766" } } } }, "ecd FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCndsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCndsDrngCvrdYrMember", "presentation": [{" "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terselabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth ref": { "r747" } } }, "us-gaap FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentScheduleOfPurchasedPropertyAndEquipmentDetails", "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "terselabel": "Office Furniture", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth ref": { "r673", "r677", "r678", "r679", "r680", "r690" } } } }, "monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crd": "credit", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "lang": { "en-us": { "role": { "terselabel": "Loss on extinguishment of debt", "negatedLabel": "Loss on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth ref": { "r5", "r35", "r36" } } }, "us-gaap GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terselabel": "General and Administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth ref": { "r76" } } } }, "us-gaap IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terselabel": "Income Statement Location Axis", "documentation": "Income Statement Location Axis", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "terselabel": "Income Statement Location", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth ref": { "r269", "r275", "r276", "r433", "r437", "r442", "r542", "r544", "r598", "r635", "r675", "r911" } } }, "us-gaap IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "terselabel": "Income Statement Location", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth ref": { "r275", "r276", "r433", "r437", "r442", "r542", "r544", "r598", "r635", "r675", "r911" } } } }, "us-gaap IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terselabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth ref": { "r156", "r391", "r392", "r394", "r395", "r396", "r397", "r557" } } }, "us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crd": "debit", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terselabel": "Accounts payable, accrued expenses and other liabilities", "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth ref": { "r4" } } }, "us-gaap IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crd": "credit", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth ref": { "r4" } } } }, "us-gaap IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crd": "credit", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Inventories, Total", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth ref": { "r4" } } } }, "us-gaap IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "lang": { "en-us": { "role": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terselabel": "Changes in operating assets and liabilities" } } }, "auth ref": { "r4" } } } } }, "seph IncreaseDecreaseInOperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "IncreaseDecreaseInOperatingLeasePayments", "crd": "credit", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostAndOtherInformationOfOperatingLeaseLiabilitiesDetails", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease payments", "label": "Increase Decrease In Operating Lease Payments", "verboseLabel": "Operating cash flows from operating leases" } } }, "auth ref": { "r4" } } } }, "us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crd": "credit", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth ref": { "r4" } } } }, "ecd IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [{" "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terselabel": "Individual", "documentation": "Individual Award Timing Disclosure" } } }, "auth ref": { "r714", "r724", "r734", "r758", "r766", "r770", "r778" } } } }, "seph InitialDrawAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "InitialDrawAmount", "crd": "debit", "presentation": [{" "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "terselabel": "Initial draw amount", "label": "Initial Draw Amount", "documentation": "Initial draw amount." } } }, "auth ref": { "r4" } } } } }, "ecd InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arr Line Items", "terselabel": "Insider Trading Arr Line Items", "documentation": "Insider Trading Arr Line Items" } } }, "auth ref": { "r4" } } } } }

```
"InterestTradingArrangements[LineItems]":{"terselabel":"","label":"","insiderTradingPoliciesProcLineItems":"","lang":"","en-us":{"role":{"label":"Insider Trading Policies and Procedures [Line Items]"},"terseLabel":"","insiderTradingPoliciesAndProcedures":"","auth_ref":{"r706":"","r782"}}},"ced InsiderTrdPoliciesProcAdoptedFlag":{"xbrltype":"","booleanItemType":"","nsuri":"","http://xbrl.sec.gov/ced/2024","localname":"","insiderTrdPoliciesProcAdoptedFlag","presentation":{"http://xbrl.sec.gov/ced/ro/InsiderTradingPoliciesProc"},"lang":"","en-us":{"role":{"label":"Insider Trading Policies and Procedures Adopted [Flag]"},"terseLabel":"","insiderTradingPoliciesAndProceduresAdopted":"","auth_ref":{"r706":"","r782"}}},"ced InsiderTrdPoliciesProcNotAdoptedTextBlock":{"xbrltype":"","textBlockItemType":"","nsuri":"","http://xbrl.sec.gov/ced/2024","localname":"","insiderTrdPoliciesProcNotAdoptedTextBlock","presentation":{"http://xbrl.sec.gov/ced/ro/InsiderTradingPoliciesProc"},"lang":"","en-us":{"role":{"label":"Insider Trading Policies and Procedures Not Adopted [Text Block]"},"terseLabel":"","insiderTradingPoliciesAndProceduresNotAdopted":"","auth_ref":{"r706":"","r782"}}},"us-gaap InterestExpense":{"xbrltype":"","monetaryItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InterestExpense","crdr":"","debit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"},"lang":"","en-us":{"role":{"label":"Interest Expense, Operating and Nonoperating","negatedLabel":"","InterestExpense","totalLabel":"","InterestExpenseTotal","documentation":"","Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."}}},"auth_ref":{"r202":"","r204":"","r208":"","r209":"","r212":"","r460":"","r651":"","r652"},"us-gaap InterestPaidNet":{"xbrltype":"","monetaryItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InterestPaidNet","crdr":"","credit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited"},"lang":"","en-us":{"role":{"label":"Interest Paid, Excluding Capitalized Interest, Operating Activities"},"terseLabel":"","InterestPaid","documentation":"","Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."}}},"auth_ref":{"r163":"","r166":"","r167"},"us-gaap InterestRateCapMember":{"xbrltype":"","domainItemtype":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InterestRateCapMember","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"},"lang":"","en-us":{"role":{"label":"Interest Rate Cap [Member]"},"terseLabel":"","InterestRateCapMember","documentation":"","Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest rate level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount."}}},"auth_ref":{"r637"},"us-gaap InterestRateFloorMember":{"xbrltype":"","domainItemtype":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InterestRateFloorMember","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"},"lang":"","en-us":{"role":{"label":"Interest Rate Floor [Member]"},"terseLabel":"","InterestRateFloorMember","documentation":"","Contracts in which the floor writer, in return for a premium, agrees to limit the risk associated with a decline in interest rates based on a notional amount. If rates fall below an agreed rate, the floor holder will receive cash payments from the floor writer equal to the difference between the market rate and an agreed rate multiplied by the notional principal amount."}}},"auth_ref":{"r637"},"us-gaap InventoryDisclosureAbstract":{"xbrltype":"","stringItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InventoryDisclosureAbstract","lang":"","en-us":{"role":{"label":"Inventory Disclosure [Abstract]"},"auth_ref":{"us-gaap InventoryDisclosureTextBlock":{"xbrltype":"","textBlockItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InventoryDisclosureTextBlock","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureInventory"},"lang":"","en-us":{"role":{"label":"Inventory Disclosure [Text Block]"},"terseLabel":"","Inventory","documentation":"","The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."}}},"auth_ref":{"r262"},"us-gaap InventoryFinishedGoods":{"xbrltype":"","monetaryItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InventoryFinishedGoods","crdr":"","debit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetails"},"lang":"","en-us":{"role":{"label":"Inventory, Finished Goods, Gross"},"terseLabel":"","InventoryFinishedGoods","documentation":"","Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."}}},"auth_ref":{"r800"},"us-gaap InventoryNet":{"xbrltype":"","monetaryItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InventoryNet","crdr":"","debit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetails"},"lang":"","en-us":{"role":{"label":"Inventory, Net Total"},"label":"","InventoryNet","documentation":"","Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."}}},"auth_ref":{"r146":"","r639":"","r685"},"us-gaap InventoryPolicyTextBlock":{"xbrltype":"","textBlockItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InventoryPolicyTextBlock","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesPolicies"},"lang":"","en-us":{"role":{"label":"Inventory, Policy [Policy Text Block]"},"terseLabel":"","Inventory","documentation":"","Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."}}},"auth_ref":{"r122":"","r136":"","r145":"","r262":"","r263":"","r265":"","r514":"","r645"},"us-gaap InventoryRawMaterials":{"xbrltype":"","monetaryItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InventoryRawMaterials","crdr":"","debit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetails"},"lang":"","en-us":{"role":{"label":"Inventory, Raw Materials, Gross"},"terseLabel":"","Raw materials","documentation":"","Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."}}},"auth_ref":{"r802"},"us-gaap InventoryWorkInProcess":{"xbrltype":"","monetaryItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InventoryWorkInProcess","crdr":"","debit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetails"},"lang":"","en-us":{"role":{"label":"Inventory, Work In Process, Gross"},"terseLabel":"","Work in process","documentation":"","Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."}}},"auth_ref":{"r801"},"us-gaap InventoryWriteDown":{"xbrltype":"","monetaryItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InventoryWriteDown","crdr":"","debit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureInventoryAdditionalInformationDetails"},"lang":"","en-us":{"role":{"label":"Inventory write off"},"label":"","Inventory Write down","documentation":"","Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."}}},"auth_ref":{"r264"},"us-gaap InvestmentIncomeInterest":{"xbrltype":"","monetaryItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InvestmentIncomeInterest","crdr":"","credit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONS AND COMPREHENSIVE LOSS Unaudited"},"lang":"","en-us":{"role":{"label":"Investment Income, Interest"},"terseLabel":"","Investment income","documentation":"","Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."}}},"auth_ref":{"r202":"","r207":"","r212":"","r651":"","r807"},"us-gaap InvestmentPolicyTextBlock":{"xbrltype":"","textBlockItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InvestmentPolicyTextBlock","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesPolicies"},"lang":"","en-us":{"role":{"label":"Investment, Policy [Policy Text Block]"},"terseLabel":"","Investments","documentation":"","Disclosure of accounting policy for investment in financial asset."}}},"auth_ref":{"r540":"","r553":"","r554":"","r555":"","r556":"","r610":"","r620"},"us-gaap InvestmentsClassifiedByContractualMaturityDateTableTextBlock":{"xbrltype":"","textBlockItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InvestmentsClassifiedByContractualMaturityDateTableTextBlock","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureInvestmentsTables"},"lang":"","en-us":{"role":{"label":"Investments Classified by Contractual Maturity Date [Table Text Block]"},"terseLabel":"","Summary of Amortized Cost and Fair Value of Available for Sale Investments by Contract Maturity","documentation":"","Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."}}},"auth_ref":{"us-gaap InvestmentsDebtAndEquitySecuritiesAbstract":{"xbrltype":"","stringItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InvestmentsDebtAndEquitySecuritiesAbstract","lang":"","en-us":{"role":{"label":"Investments, Debt and Equity Securities [Abstract]"},"auth_ref":{"us-gaap InvestmentsFairValueDisclosure":{"xbrltype":"","monetaryItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InvestmentsFairValueDisclosure","crdr":"","debit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureFairValueOffinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"},"lang":"","en-us":{"role":{"label":"Investments, Fair Value Disclosure"},"terseLabel":"","Investments","totalLabel":"","Investments,Fair Value Disclosure, Total","documentation":"","Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."}}},"auth_ref":{"r876":"","r877":"","r887"},"us-gaap InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock":{"xbrltype":"","textBlockItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureInvestments"},"lang":"","en-us":{"role":{"label":"Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]"},"terseLabel":"","Investments","documentation":"","The entire disclosure for investments in certain debt and equity securities."}}},"auth_ref":{"r114":"","r131":"","r217":"","r218":"","r449":"","r450":"","r907"},"scph IssuanceOfCommonStockAndPrefundedWarrantsInCommonStockOfferingNetOfIssuanceCosts":{"xbrltype":"","monetaryItemType":"","nsuri":"","http://www.sepharmaceuticals.com/20240930","localname":"","IssuanceOfCommonStockAndPrefundedWarrantsInCommonStockOfferingNetOfIssuanceCosts","crdr":"","credit","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF STOCKHOLDERSEQUITYUnaudited"},"lang":"","en-us":{"role":{"verboseLabel":"","Issuance of common stock and pre-funded warrants in common stock offering, net of issuance costs","label":"","Issuance Of Common Stock And Prefunded Warrants In Common Stock Offering Net Of Issuance Costs","documentation":"","Issuance of common stock and prefunded warrants in common stock offering net of issuance costs."}}},"auth_ref":{"scph IssuanceOfCommonStockAndPrefundedWarrantsInCommonStockOfferingNetOfIssuanceCostsShares":{"xbrltype":"","sharesItemType":"","nsuri":"","http://www.sepharmaceuticals.com/20240930","localname":"","IssuanceOfCommonStockAndPrefundedWarrantsInCommonStockOfferingNetOfIssuanceCostsShares","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF STOCKHOLDERSEQUITYUnaudited"},"lang":"","en-us":{"role":{"verboseLabel":"","Issuance of common stock and pre-funded warrants in common stock offering, net of issuance costs, Shares","label":"","Issuance Of Common Stock And Prefunded Warrants In Common Stock Offering Net Of Issuance Costs Shares","documentation":"","Issuance of common stock and prefunded warrants in common stock offering net of issuance costs shares."}}},"auth_ref":{"scph JefferiesLLCMember":{"xbrltype":"","domainItemtype":"","nsuri":"","http://www.sepharmaceuticals.com/20240930","localname":"","JefferiesLLCMember","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetails"},"lang":"","en-us":{"role":{"label":"Jefferies LLC Member"},"terseLabel":"","Jefferies"},"auth_ref":{"scph LeaseAgreementRequireStandbyLetterOfCreditMember":{"xbrltype":"","domainItemtype":"","nsuri":"","http://www.sepharmaceuticals.com/20240930","localname":"","LeaseAgreementRequireStandbyLetterOfCreditMember","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"},"lang":"","en-us":{"role":{"verboseLabel":"","Lease Agreement Require Standby Letter Of Credit Member","documentation":"","Lease agreement require standby letter of credit,"label":"","Lease Agreement Require Standby Letter Of Credit [Member]"},"terseLabel":"","Lease Agreement Require Standby Letter Of Credit"},"auth_ref":{"us-gaap LeaseContractualTermAxis":{"xbrltype":"","stringItemType":"","nsuri":"","http://fasb.org/us-gaap/2024","localname":"","LeaseContractualTermAxis","presentation":{"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"},"lang":"","en-us":{"role":{"label":"Lease Contractual Term [Axis]"},"terseLabel":"","Lease Contractual Term","documentation":"","Information by contractual term of lease arrangement."}}},"auth_ref":{"r477":"","r791"},"us-ga
```

1. "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturity Analysis of Annual Undiscounted Cash Flows of Operating Lease Liabilities", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth\_ref": { "r897" } }, "us gaap\_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLia1. "lang": { "en-us": { "role": { "terseLabel": "Future minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth\_ref": { "r475" } }, "seph\_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLia1. "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after year four." "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "auth\_ref": { } }, "us gaap\_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLia1. "lang": { "en-us": { "role": { "terseLabel": "December 31, 2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth\_ref": { "r475" } }, "us gaap\_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLia1. "lang": { "en-us": { "role": { "terseLabel": "December 31, 2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth\_ref": { "r475" } }, "us gaap\_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLia1. "lang": { "en-us": { "role": { "terseLabel": "December 31, 2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth\_ref": { "r475" } }, "us gaap\_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLia1. "lang": { "en-us": { "role": { "terseLabel": "December 31, 2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth\_ref": { "r475" } }, "us gaap\_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLia1. "lang": { "en-us": { "role": { "terseLabel": "December 31, 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth\_ref": { "r897" } }, "us gaap\_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLia1. "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth\_ref": { "r475" } }, "us gaap\_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LetterOfCreditMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "verboseLabel": "Letter Of Credit Member", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth\_ref": { } }, "us gaap\_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" } }, "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth\_ref": { "r15", "r55", "r56", "r57", "r59", "r60", "r61", "r62", "r172", "r250", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r410", "r413", "r414", "r452", "r573", "r649", "r701", "r841", "r898", "r899" } }, "us gaap\_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" } }, "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' 2019 equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth\_ref": { "r69", "r110", "r530", "r685", "r81", "r831", "r891" } }, "us gaap\_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" } }, "lang": { "en-us": { "role": { "label": "Liabilities Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth\_ref": { "r57", "r135", "r172", "r250", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r410", "r413", "r414", "r452", "r685", "r841", "r898", "r899" } }, "us gaap\_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" } }, "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities" } } }, "auth\_ref": { } }, "us gaap\_LiabilitiesFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LiabilitiesFairValueAdjustment", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfFairValueOfDebtBalanceDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Initial fair value adjustment", "label": "Liabilities, Fair Value Adjustment", "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties." } } }, "auth\_ref": { } }, "us gaap\_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" } }, "lang": { "en-us": { "role": { "totalLabel": "Liabilities, Fair Value Disclosure, Total", "label": "Liabilities, Fair Value Disclosure", "terseLabel": "Total", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth\_ref": { "r428", "r876" } }, "us gaap\_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" } }, "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities" } } }, "auth\_ref": { } }, "dei\_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DocumentDocumentAndEntityInformation" } }, "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth\_ref": { } }, "seph\_LondonInterbankOfferedRatesLiborMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LondonInterbankOfferedRatesLiborMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Libor", "label": "London Interbank Offered Rates LIBOR [Member]", "documentation": "London Interbank Offered Rates LIBOR [Member]" } } }, "auth\_ref": { } }, "seph\_LongTermAdditionalDebtDiscountExitFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermAdditionalDebtDiscountExitFee", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "documentation": "Long term additional debt discount exit fee", "label": "Long Term Additional Debt Discount Exit Fee", "terseLabel": "Long term additional debt discount exit fee" } } }, "auth\_ref": { } }, "us gaap\_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfCarryingValueOfDebtBalanceDetails" } }, "lang": { "en-us": { "role": { "label": "Long Term Debt", "totalLabel": "Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth\_ref": { "r15", "r108", "r307", "r322", "r656", "r657", "r683", "r909" } }, "seph\_LongTermDebtAmortizationOfFinalPaymentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtAmortizationOfFinalPaymentFee", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "documentation": "Long-term debt amortization of final payment fee", "label": "Long Term Debt Amortization Of Final Payment Fee", "terseLabel": "Amortization of final payment fee" } } }, "auth\_ref": { } }, "us gaap\_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfCarryingValueOfDebtBalanceDetails" } }, "lang": { "en-us": { "role": { "label": "Long Term Debt, Current Maturities", "terseLabel": "Term loan, short-term", "negatedLabel": "Less: current portion", "totalLabel": "Long-term Debt, Current Maturities, Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth\_ref": { "r141" } }, "seph\_LongTermDebtExitFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtExitFee", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "documentation": "Long-term debt exit fee", "label": "Long Term Debt Exit Fee", "terseLabel": "Exit fee" } } }, "auth\_ref": { } }, "seph\_LongTermDebtExitFeeObligationAccountedAsDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtExitFeeObligationAccountedAsDerivativeLiability", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "documentation": "Long-term debt exit fee obligation accounted as derivative liability", "label": "Long Term Debt Exit Fee Obligation Accounted As Derivative Liability", "terseLabel": "Derivative liability recorded against exit fee obligation" } } }, "auth\_ref": { } }, "seph\_LongTermDebtExitFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "documentation": "Long-term debt exit fee percentage", "label": "Long Term Debt Exit Fee Percentage", "terseLabel": "Exit fee, percentage" } } }, "auth\_ref": { } }, "seph\_LongTermDebtFinalPaymentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtFinalPaymentFee", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "documentation": "Long-term debt final payment fee", "label": "Long Term Debt Final Payment Fee", "terseLabel": "Final payment fee" } } }, "auth\_ref": { } }, "seph\_LongTermDebtIncrementOnInterestRateOnDefault": { "xbrltype": "percentItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtIncrementOnInterestRateOnDefault", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "documentation": "Long-term debt increment on interest rate on default", "label": "Long Term Debt Increment On Interest Rate On Default", "terseLabel": "Increase in interest rate on default" } } }, "auth\_ref": { } }, "us gaap\_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfCarryingValueOfDebtBalanceDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" } }, "lang": { "en-us": { "role": { "label": "Term loan", "totalLabel": "Carrying value of term loan", "verboseLabel": "Long-term portion", "terseLabel": "Term loan, long-term", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth\_ref": { "r143" } }, "seph\_LongTermDebtPrepaymentPremiumAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtPrepaymentPremiumAmount", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "documentation": "Long-term debt

```


```

"paymentPremiumAmount": "label", "LongTermDebtPrepaymentPremiumPercentageAmount": "}}", "authRef": "[]", "scphLongTermDebtPrepaymentPremiumPercentageAfterYearTwo": { "xbrlytpe": "percentItemTpe", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtPrepaymentPremiumPercentageAfterYearTwo", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": "}}", "lang": { "en-us": { "role": { "documentation": "Long-term debt prepayment premium percentage after year two", "label": "Long Term Debt Prepayment Premium Percentage Year Two", "terseLabel": "Prepayment premium percentage after year two" } } }, "authRef": "[]", "scphLongTermDebtPrepaymentPremiumPercentageYearOne": { "xbrlytpe": "pureItemTpe", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtPrepaymentPremiumPercentageYearOne", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": "}}", "lang": { "en-us": { "role": { "terseLabel": "Prepayment premium percentage one", "label": "Long Term Debt Prepayment Premium Percentage Year One", "documentation": "Long-term debt prepayment premium percentage year one" } } }, "authRef": "[]", "scphLongTermDebtPrepaymentPremiumPercentageYearOneAndTwo": { "xbrlytpe": "percentItemTpe", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtPrepaymentPremiumPercentageYearOneAndTwo", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": "}}", "lang": { "en-us": { "role": { "documentation": "Long-term debt prepayment premium percentage year one and two", "label": "Long Term Debt Prepayment Premium Percentage Year One And Two", "terseLabel": "Prepayment premium percentage" } } }, "authRef": "[]", "scphLongTermDebtPrepaymentPremiumPercentageYearTwo": { "xbrlytpe": "pureItemTpe", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "LongTermDebtPrepaymentPremiumPercentageYearTwo", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": "}}", "lang": { "en-us": { "role": { "terseLabel": "Prepayment premium percentage two", "label": "Long Term Debt Prepayment Premium Percentage Year Two", "documentation": "Long-term debt prepayment premium percentage year two" } } }, "authRef": "[]", "usGaapLongTermDebtTypeAxis": { "xbrlytpe": "stringItemTpe", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTypeAxis", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOfLevel3DerivativeLiabilitiesDetails": "}}", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": "}}", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfCarryingValueOfDebtBalanceDetails": "}}", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfFairValueOfDebtBalanceDetails": "}}", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails": "}}", "lang": { "en-us": { "role": { "label": "Long-Term Debt Type", "terseLabel": "Long-term Debt Type", "documentation": "Information by type of long-term debt" } } }, "authRef": { "r15", "r834", "r835", "r836" } }, "us-gaapLongTermDebtTypeDomain": { "xbrlytpe": "domainItemTpe", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTypeDomain", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfChangesInFairValueOfLevel3DerivativeLiabilitiesDetails": "}}", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": "}}", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfCarryingValueOfDebtBalanceDetails": "}}", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfFairValueOfDebtBalanceDetails": "}}", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails": "}}", "lang": { "en-us": { "role": { "label": "Long-Term Debt Type", "terseLabel": "Long-term Debt Type", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "authRef": { "r15", "r834", "r835", "r836" } }, "srtMajorCustomersAxis": { "xbrlytpe": "stringItemTpe", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails": "}}", "lang": { "en-us": { "role": { "label": "Customer [Axis]", "authRef": { "r215", "r662", "r687", "r689", "r845", "r910", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r938", "r939" } } }, "us-gaapMarketableSecuritiesLineItems": { "xbrlytpe": "stringItemTpe", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesLineItems", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureInvestmentsSummaryOfAvailableForSaleClassifiedInvestmentsDetails": "}}", "lang": { "en-us": { "role": { "label": "Marketable Securities [Line Items]", "terseLabel": "Marketable Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "authRef": "[]", "us-gaapMarketableSecuritiesTable": { "xbrlytpe": "stringItemTpe", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTable", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureInvestmentsSummaryOfAvailableForSaleClassifiedInvestmentsDetails": "}}", "lang": { "en-us": { "role": { "label": "Marketable Securities [Table]", "terseLabel": "Marketable Securities [Table]", "documentation": "Disclosure of information about investment in marketable security." } } }, "authRef": "[]", "srtMaximumMember": { "xbrlytpe": "domainItemTpe", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": "}}", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails": "}}", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails": "}}", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails": "}}", "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum", "authRef": { "r279", "r280", "r281", "r282", "r350", "r388", "r431", "r513", "r541", "r543", "r551", "r565", "r666", "r618", "r621", "r622", "r623", "r628", "r633", "r634", "r653", "r660", "r666", "r676", "r677", "r681", "r682", "r688", "r843", "r900", "r901", "r902", "r903", "r904", "r905" } } }, "ecdMeasureAxis": { "xbrlytpe": "stringItemTpe", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": "}}", "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure", "authRef": { "r750" } } }, "ecdMeasureName": { "xbrlytpe": "normalizedStringItemTpe", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": "}}", "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name", "authRef": { "r750" } } }, "us-gaapMeasurementInputDiscountRateMember": { "xbrlytpe": "domainItemTpe", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputDiscountRateMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsAdditionalInformationDetails": "}}", "lang": { "en-us": { "role": { "terseLabel": "Discount Rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows" } } }, "authRef": { "r878", "r879", "r880" } }, "us-gaapMeasurementInputTypeAxis": { "xbrlytpe": "stringItemTpe", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsAdditionalInformationDetails": "}}", "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "authRef": { "r429", "r430", "r431", "r676" } }, "us-gaapMeasurementInputTypeDomain": { "xbrlytpe": "domainItemTpe", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsAdditionalInformationDetails": "}}", "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "authRef": { "r429", "r430", "r431", "r676" } }, "srtMinimumMember": { "xbrlytpe": "domainItemTpe", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": "}}", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails": "}}", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails": "}}", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails": "}}", "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum", "authRef": { "r279", "r280", "r281", "r282", "r350", "r388", "r431", "r513", "r541", "r543", "r551", "r565", "r566", "r618", "r621", "r622", "r623", "r628", "r633", "r634", "r653", "r660", "r666", "r676", "r677", "r681", "r688", "r843", "r900", "r901", "r902", "r903", "r904", "r905" } } }, "ecdMnpiDiscTimedForCompValFlag": { "xbrlytpe": "booleanItemTpe", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": "}}", "lang": { "en-us": { "role": { "label": "Mnpi Disclosure Timed for Compensation Value [Flag]", "terseLabel": "Mnpi Disclosure Timed for Compensation Value", "authRef": { "r769" } } }, "ecdMtrTermsOfFrdArrTextBlock": { "xbrlytpe": "textBlockItemTpe", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrTermsOfFrdArrTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": "}}", "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block
```


```

"label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth\_ref": { "r758" } }, "ecd\_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth\_ref": { "r777" } }, "ecd\_NonRule10b51ArrTrmmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth\_ref": { "r777" } } }, "scph\_NumberOfCustomer": { "xbrltype": "integerItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "NumberOfCustomer", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Number of customer.", "label": "Number of Customer" } } }, "auth\_ref": { } }, "scph\_NumberOfSuppliers": { "xbrltype": "integerItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "NumberOfSuppliers", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Number of suppliers.", "label": "Number of Suppliers" } } }, "auth\_ref": { } }, "scph\_OaktreeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "OaktreeAgreementMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Oaktree Agreement", "label": "Oaktree Agreement [Member]", "documentation": "Oaktree agreement." } } }, "auth\_ref": { } }, "us\_gaap\_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosurePropertyAndEquipmentScheduleOfPurchasedPropertyAndEquipmentDetails", "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "terseLabel": "Office Equipment", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth\_ref": { } }, "us\_gaap\_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth\_ref": { } }, "us\_gaap\_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "auth\_ref": { } }, "us\_gaap\_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "terseLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth\_ref": { "r117", "r650", "r817", "r818", "r819", "r820", "r821" } }, "us\_gaap\_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostAndOtherInformationOfOperatingLeaseLiabilitiesDetails", "lang": { "en-us": { "role": { "label": "Operating Lease Cost", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right of use asset, calculated by amortization of remaining right of use asset and accretion of lease liability." } } }, "auth\_ref": { "r469", "r684" } }, "scph\_OperatingLeaseExpirationMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "OperatingLeaseExpirationMonthAndYear", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Operating lease expiration month and year.", "label": "Operating Lease Expiration Month And Year", "terseLabel": "Operating lease expiration month and year" } } }, "auth\_ref": { } }, "us\_gaap\_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLiabilities", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Year ended." } } }, "auth\_ref": { } }, "us\_gaap\_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsOfOperatingLeaseLiabilities", "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Total", "totalLabel": "Operating Lease, Liability, Total", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth\_ref": { "r466" } }, "us\_gaap\_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Lease obligation - operating, short term", "verboseLabel": "Short-term lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth\_ref": { "r466" } }, "us\_gaap\_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease obligation - operating, long term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth\_ref": { "r466" } }, "us\_gaap\_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Right of Use Asset", "terseLabel": "Right of use lease assets - operating, net", "verboseLabel": "Short-term lease asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth\_ref": { "r465" } }, "us\_gaap\_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "lang": { "en-us": { "role": { "verboseLabel": "Reduction in carrying value of operating right of use lease assets", "terseLabel": "Reduction in carrying value of operating right of use lease assets", "label": "Operating Lease, Right of Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right of use asset from operating lease." } } }, "auth\_ref": { "r808" } }, "us\_gaap\_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostAndOtherInformationOfOperatingLeaseLiabilitiesDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate - operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth\_ref": { "r474", "r684" } }, "us\_gaap\_OperatingLeaseWeightedAverageRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostAndOtherInformationOfOperatingLeaseLiabilitiesDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term - operating leases", "documentation": "Weighted average remaining lease term for operating lease, in PnYnMnDnTnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth\_ref": { "r473", "r684" } }, "scph\_OperatingLeasesExpirationYear": { "xbrltype": "gYearItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "OperatingLeasesExpirationYear", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "documentation": "Operating leases expiration year.", "label": "Operating Leases Expiration Year", "terseLabel": "Operating leases expire" } } }, "auth\_ref": { } }, "us\_gaap\_OrganizationConsolidationAndPresentationOffinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth\_ref": { } }, "us\_gaap\_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails", "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth\_ref": { "r56" } }, "us\_gaap\_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss.", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth\_ref": { } }, "us\_gaap\_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "lang": { "en-us": { "role": { "label": "Unrealized gain (loss) on short term investments", "label": "OCI, Debt Securities, Available for Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "verboseLabel": "Unrealized loss on short term investments", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale." } } }, "auth\_ref": { "r150", "r151", "r249" } }, "scph\_OtherLeaseInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "OtherLeaseInformationAbstract", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostAndOtherInformationOfOperatingLeaseLiabilitiesDetails", "lang": { "en-us": { "role": { "documentation": "Other lease information.", "label": "Other Lease Information [Abstract]", "terseLabel": "Other information" } } }, "auth\_ref": { } }, "us\_gaap\_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "label": "Other current liabilities", "label": "Other Liabilities, Current", "totalLabel": "Other Liabilities, Current, Total", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth\_ref": { "r56", "r685" } }, "us\_gaap\_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth\_ref": { "r60" } }, "us\_gaap\_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense), Total", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth\_ref": { "r78" } }, "ecd\_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth\_ref": { "r750" } }, "ecd\_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth\_ref": { "r712", "r722", "r732", "r764" } }, "ecd\_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth\_ref": { "r715", "r725", "r735", "r767" } }, "ecd\_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth\_ref": { "r715", "r725", "r735", "r767" } }, "us\_gaap\_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaidInKindInterest", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "lang": { "en-us": { "role": { "label": "Paid-In-Kind Interest", "terseLabel": "Paid-In-Kind Interest", "documentation": "Interest on debt securities or other financial instruments that is paid in kind, rather than in cash." } } }, "auth\_ref": { } } }

[illegible]

"Proceeds from Maturities, Prepayments and Calls of Short-Term Investments", "terseLabel": "Maturities of short-term investments", "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short term." } } }, "auth\_ref": { "r20", "r70" } }, "us-gaap-ProceedsFromRepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfDebt", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "totalLabel": "Proceeds from (Repayments of) Debt, Total", "label": "Proceeds from (Repayments of) Debt", "terseLabel": "Proceeds from (Repayments of) Debt, Total", "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings." } } }, "auth\_ref": { "r2", "r14" } }, "us-gaap-ProceedsFromRevenueParticipationAgreementNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "ProceedsFromRevenueParticipationAgreementNet", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from revenue participation agreement, net", "label": "Proceeds from Revenue Participation Agreement, Net", "documentation": "Proceeds from revenue participation agreement, net." } } }, "auth\_ref": { "r1" } }, "us-gaap-ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited": { "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the exercise of vested stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth\_ref": { "r2", "r14" } }, "us-gaap-ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited": { "lang": { "en-us": { "role": { "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from employee stock purchase plan", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth\_ref": { "r2" } }, "us-gaap-ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF STOCKHOLDER EQUITY Unaudited": { "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth\_ref": { "r133", "r152", "r154", "r164", "r172", "r179", "r185", "r188", "r189", "r250", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r403", "r406", "r408", "r411", "r412", "r425", "r452", "r520", "r533", "r561", "r595", "r611", "r612", "r671", "r672", "r700", "r806", "r841" } }, "us-gaap-PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth\_ref": { "r90", "r126", "r130" } }, "us-gaap-PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentScheduleOfPurchasedPropertyAndEquipmentDetails": { "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross", "totalLabel": "Property, Plant and Equipment, Gross, Total", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth\_ref": { "r90", "r138", "r532" } }, "us-gaap-PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentScheduleOfPurchasedPropertyAndEquipmentDetails": { "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": { "r476" } }, "us-gaap-PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentScheduleOfPurchasedPropertyAndEquipmentDetails": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDBALANCESHEETS Unaudited": { "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth\_ref": { "r6", "r476", "r521", "r532", "r685" } }, "us-gaap-PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentTables": { "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Purchased Property and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth\_ref": { "r6" } }, "us-gaap-PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentScheduleOfPurchasedPropertyAndEquipmentDetails": { "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth\_ref": { "r00", "r476" } }, "us-gaap-PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentScheduleOfPurchasedPropertyAndEquipmentDetails": { "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "ESTIMATED USEFUL LIFE", "documentation": "Useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth\_ref": { "r1" } }, "us-gaap-PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosurePropertyAndEquipmentScheduleOfPurchasedPropertyAndEquipmentDetails": { "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life, Term, Description [Extensible Enumeration]", "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value." } } }, "auth\_ref": { "r832" } }, "seph-PurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "PurchasePrice", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Purchase price", "label": "Purchase Price", "terseLabel": "Purchase price" } } }, "auth\_ref": { "r1" } }, "seph-PurchasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "PurchasesMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Purchases", "label": "Purchases [Member]", "terseLabel": "Purchases" } } }, "auth\_ref": { "r1" } }, "ecd-PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": { "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth\_ref": { "r739" } }, "ecd-PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth\_ref": { "r739" } }, "xbrl-RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationAdditionalInformationDetails": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "auth\_ref": { "r279", "r280", "r281", "r282", "r343", "r350", "r378", "r379", "r380", "r388", "r431", "r487", "r496", "r513", "r541", "r543", "r551", "r565", "r566", "r618", "r621", "r622", "r623", "r628", "r633", "r634", "r653", "r660", "r666", "r676", "r677", "r681", "r682", "r688", "r693", "r837", "r843", "r879", "r901", "r902", "r903", "r904", "r905" } }, "xbrl-RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationAdditionalInformationDetails": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "auth\_ref": { "r279", "r280", "r281", "r282", "r343", "r350", "r378", "r379", "r380", "r388", "r431", "r487", "r496", "r513", "r541", "r543", "r551", "r565", "r566", "r618", "r621", "r622", "r623", "r628", "r633", "r634", "r653", "r660", "r666", "r676", "r677", "r681", "r682", "r688", "r693", "r837", "r843", "r879", "r901", "r902", "r903", "r904", "r905" } }, "ecd-RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth\_ref": { "r707", "r717", "r727", "r759" } }, "seph-RelativeFairValueOfDetachableWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "RelativeFairValueOfDetachableWarrants", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Relative fair value of detachable warrants", "label": "Relative Fair Value of Detachable Warrants", "terseLabel": "Relative fair value of detachable warrants" } } }, "auth\_ref": { "r1" } }, "us-gaap-RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS Unaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Principal payments on term loan", "label": "Repayments of Long-Term Debt", "totalLabel": "Repayments of Long-Term Debt, Total", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth\_ref": { "r81", "r559" } }, "srt-RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "auth\_ref": { "r172", "r174", "r298", "r327", "r479", "r497", "r522", "r643", "r644" } }, "us-gaap-ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONS AND COMPREHENSIVE LOSS Unaudited": { "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth\_ref": { "r390", "r635", "r651", "r906" } }, "us-gaap-ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth\_ref": { "r1" } }, "us-gaap-ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-DisclosureSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Research and Development Expense Policy [Policy Text Block]", "terseLabel": "Research and Development Costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical



"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationTables"}}, "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock Based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth-ref": { "r40" } }, "us-gaap\_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFairValueOffinancialInstrumentsTables"}}, "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Assets Measured at Fair Value on Recurring Basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."} } }, "auth-ref": { "r76", "r77" } }, "us-gaap\_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureInventoryTables"}}, "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth-ref": { "r16", "r70", "r71", "r72" } }, "us-gaap\_ScheduleOfMaturitiesOffLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOffLongTermDebtTableTextBlock", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesTables"}}, "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long Term Debt [Table Text Block]", "terseLabel": "Schedule of Future Principal Payments Due", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long term debt." } } }, "auth-ref": { "r7" } }, "us-gaap\_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationTables"}}, "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of RSU Activity", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth-ref": { "r101" } }, "us-gaap\_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosurePropertyAndEquipmentScheduleOfPurchasedPropertyAndEquipmentDetails"}}, "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth-ref": { "r6", "r46" } }, "us-gaap\_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails"}}, "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfRSUActivityDetails"}}, "lang": { "en-us": { "role": { "label": "Schedule of Share Based Compensation Arrangements by Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share based payment arrangement." } } }, "auth-ref": { "r352", "r354", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381" } }, "us-gaap\_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationTables"}}, "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Information about Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth-ref": { "r12", "r13", "r98" } }, "us-gaap\_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationTables"}}, "lang": { "en-us": { "role": { "label": "Schedule of Share Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Estimated Fair Value of Options Valuation Assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk free rate(s), and (e) discount for post vesting restrictions." } } }, "auth-ref": { "r103" } }, "us-gaap\_SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"}}, "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable rate leg." } } }, "auth-ref": { "r873" } }, "dei\_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DocumentDocumentAndEntityInformation"}}, "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth-ref": { "r702" } }, "dei\_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DocumentDocumentAndEntityInformation"}}, "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth-ref": { "r704" } }, "us-gaap\_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"}}, "lang": { "en-us": { "role": { "totalLabel": "Selling, General and Administrative Expense, Total", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, General and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth-ref": { "r76" } }, "us-gaap\_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"}}, "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "documentation": "Amount of noncash expense for share based payment arrangement." } } }, "auth-ref": { "r4" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails"}}, "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Award Vesting Period", "terseLabel": "Stock option vesting term", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth-ref": { "r667" } }, "seph\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEffectiveDate", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails"}}, "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award effective date", "label": "Share Based Compensation Arrangement By Share Based Payment Award Effective Date", "terseLabel": "Stock option and incentive plan effective date" } } }, "auth-ref": { } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfRSUActivityDetails"}}, "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "RSUs Forfeited", "negatedLabel": "RSUs Forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth-ref": { "r372" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfRSUActivityDetails"}}, "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "RSUs Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."} } }, "auth-ref": { "r370" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfRSUActivityDetails"}}, "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance", "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance", "periodEndLabel": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth-ref": { "r367", "r368" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails"}}, "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance", "periodEndLabel": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth-ref": { "r370" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": {  
"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails"}}, "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Number of restricted stock units outstanding", "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance", "periodEndLabel": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth-ref": { "r367", "r368" } }, "seph\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfRSUActivityDetails"}}, "lang": { "en-us": { "role": { "negatedLabel": "RSUs Released", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Released in Period",

"documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, released in period" } } }, "auth\_ref": [ ] },

"seph\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageReleasedFairValue": { "xbrltype": "perShareItem", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageReleasedFairValue", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfRSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AVERAGE GRANT DATE FAIR VALUE, Released", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Weighted Average Released Fair Value", "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, weighted average released fair value." } } }, "auth\_ref": [ ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "xbrltype": "dateItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option and incentive plan expiration date", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date", "documentation": "Date the equity-based award expires, in YYYY-MM-DD format." } } }, "auth\_ref": [ "r847" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } }, "auth\_ref": [ ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFinancialLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price", "terseLabel": "Exercise price per warrant", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth\_ref": [ ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth\_ref": [ "r379" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFinancialLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth\_ref": [ "r378" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth\_ref": [ ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth\_ref": [ ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFinancialLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth\_ref": [ "r380" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth\_ref": [ ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth\_ref": [ ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfRSUActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Equity awards granted under the inducement, Granted", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": [ "r352", "r354", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments", "terseLabel": "Equity awards granted under the inducement, Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth\_ref": [ "r11" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfRSUActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding", "terseLabel": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth\_ref": [ "r99", "r100" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of common shares authorized for issuance", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth\_ref": [ "r669" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Stock options, available for issuance", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth\_ref": [ "r39" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "AGGREGATE INTRINSIC VALUE", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth\_ref": [ "r361" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise prices, vested and exercisable ending balance", "documentation": "The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth\_ref": [ "r361" ] }, "seph\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeited": { "xbrltype": "sharesItem", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeited", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award options forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award Options Forfeited", "terseLabel": "Number of options forfeited" } } }, "auth\_ref": [ ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of shares forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth\_ref": [ "r365" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Additional options granted", "verboseLabel": "Number of

shares granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth\_ref": { "r363" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails"}, {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfOptionsValuationAssumptionsDetails"}, {"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value", "verboseLabel": "Fair market value per share of common stock", "documentation": "The weighted average grant date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth\_ref": { "r373" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "order": "debit", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails"}, {"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, outstanding ending balance", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth\_ref": { "r39" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails"}, {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails"}, {"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of shares outstanding, ending balance", "periodStartLabel": "Number of shares outstanding, beginning balance", "terseLabel": "Stock option, number of shares outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth\_ref": { "r359", "r360" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails"}, {"en-us": { "role": { "terseLabel": "Weighted exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price", "documentation": "Change in the weighted average exercise price of options outstanding." } } }, "auth\_ref": { "r359", "r360" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails"}, {"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding (Roll Forward)", "terseLabel": "NUMBER OF SHARES", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth\_ref": { "r359", "r360" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails"}, {"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise prices, outstanding ending balance", "periodStartLabel": "Weighted average exercise prices, outstanding beginning balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth\_ref": { "r359", "r360" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails"}, {"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (Abstract)", "terseLabel": "WEIGHTED AVERAGE EXERCISE PRICE" } } }, "auth\_ref": { "r359", "r360" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "order": "debit", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails"}, {"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value, vested and expected to vest ending balance", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth\_ref": { "r375" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails"}, {"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest, ending balance", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth\_ref": { "r375" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails"}, {"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise prices, vested and expected to vest ending balance", "documentation": "Weighted average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth\_ref": { "r375" } }, {"seph\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "xbrltype": "stringItem", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails"}, {"en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award options weighted average remaining contractual term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award Options Weighted Average Remaining Contractual Term (Abstract)", "terseLabel": "WEIGHTED-AVERAGE REMAINING CONTRACTUAL TERM" } } }, "auth\_ref": { "r359", "r360" } }, {"seph\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTerm": { "xbrltype": "sharesItem", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTerm", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails"}, {"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise prices, forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth\_ref": { "r365" } }, {"us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionActivityDetails"}, {"en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise prices, granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth\_ref": { "r363" } }, {"us-gaap\_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"}, {"en-us": { "role": { "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth\_ref": { "r377" } }, {"us-gaap\_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"}, {"en-us": { "role": { "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth\_ref": { "r377" } }, {"us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails"}, {"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Term of option granted", "documentation": "Period from grant date that an equity-based award expires, in 'PnYmNdTnHmNs' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth\_ref": { "r668" } }, {"us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFinancialLiabilitiesAdditionalInformationDetails"}, {"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Contractual life", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYmNdTnHmNs' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth\_ref": { "r377" } }, {"us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1", "order": "debit", "presentation": "http://www.sepharmaceuticals.com/20



"http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSOCKHOLDERSEQUITYUnaudited", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders' equity as of 2019 equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "auth\_ref": {"r64", "r67", "r68", "r88", "r577", "r593", "r614", "r615", "r685", "r701", "r811", "r831", "r891", "r941", "1"}, "us-gaap\_StockholdersEquityAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "lang": {"en-us": {"role": {"documentation": "Line items represent stockholders' equity note.", "label": "Stockholders' Equity Note [Line Items]", "terseLabel": "Stockholders' Equity Note [Line Items]", "auth\_ref": {"1}}, "us-gaap\_StockholdersEquityNoteDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquity", "lang": {"en-us": {"role": {"label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity.", "auth\_ref": {"94", "r171", "r324", "r326", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r338", "r340", "r422", "r616", "r617", "r630", "1}}, "seph\_StockholdersEquityNoteLineItems": {"xbrltype": "stringItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "StockholdersEquityNoteLineItems", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquityAdditionalInformationDetails", "lang": {"en-us": {"role": {"documentation": "Line items represent stockholders' equity note.", "label": "Stockholders' Equity Note [Line Items]", "terseLabel": "Stockholders' Equity Note [Line Items]", "auth\_ref": {"1}}, "seph\_StockholdersEquityNoteTable": {"xbrltype": "stringItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "StockholdersEquityNoteTable", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquityAdditionalInformationDetails", "lang": {"en-us": {"role": {"documentation": "Disclosure of information about stockholders' equity note.", "label": "Stockholders' Equity Note Table", "terseLabel": "Stockholders' Equity Note Table", "auth\_ref": {"1}}, "seph\_StraightLineBasisMember": {"xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "StraightLineBasisMember", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "lang": {"en-us": {"role": {"verboselabel": "Straight Line Basis Member", "documentation": "Straight-line basis.", "label": "Straight Line Basis [Member]", "terseLabel": "Short-term Leases Recognized on Straight-line Basis", "auth\_ref": {"1}}, "us-gaap\_SubleaseIncome": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostAndOtherInformationOfOperatingLeaseLiabilitiesDetails", "lang": {"en-us": {"role": {"label": "Sublease Income", "negatedLabel": "Sublease income", "documentation": "Amount of sublease income excluding finance and operating lease expense.", "auth\_ref": {"r471", "r684", "1}}, "us-gaap\_SubsequentEventMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "lang": {"en-us": {"role": {"label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "auth\_ref": {"r459", "r480", "1}}, "us-gaap\_SubsequentEventTypeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "lang": {"en-us": {"role": {"label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "auth\_ref": {"r459", "r480", "1}}, "us-gaap\_SubsequentEventTypeDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "lang": {"en-us": {"role": {"label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "auth\_ref": {"r459", "r480", "1}}, "us-gaap\_SubsidarySaleOfStockAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSOCKHOLDERSEQUITYUnaudited", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock", "documentation": "Information by type of sale of the entity's stock", "auth\_ref": {"1}}, "us-gaap\_SupplementalCashFlowInformationAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "lang": {"en-us": {"role": {"label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information", "auth\_ref": {"1}}, "us-gaap\_SupplierConcentrationRiskMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierConcentrationRiskMember", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": {"en-us": {"role": {"label": "Supplier Concentration Risk [Member]", "terseLabel": "Supplier Concentration Risk", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "auth\_ref": {"r87", "1}}, "seph\_SupplierOneMember": {"xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "SupplierOneMember", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": {"en-us": {"role": {"documentation": "Supplier one.", "label": "Supplier One", "auth\_ref": {"1}}, "seph\_SupplierThreeMember": {"xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "SupplierThreeMember", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": {"en-us": {"role": {"verboselabel": "Supplier Three", "label": "Supplier Three Member", "documentation": "Supplier three.", "auth\_ref": {"1}}, "seph\_SupplierTwoMember": {"xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "SupplierTwoMember", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "lang": {"en-us": {"role": {"documentation": "Supplier two.", "label": "Supplier Two", "auth\_ref": {"1}}, "ecd\_TabularListTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": {"en-us": {"role": {"label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List Table", "auth\_ref": {"r757", "1}}, "seph\_TaxesPaid": {"xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TaxesPaid", "crdr": "credit", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "lang": {"en-us": {"role": {"documentation": "Taxes paid.", "label": "Taxes Paid", "terseLabel": "Taxes paid", "auth\_ref": {"1}}, "seph\_TermLoanMember": {"xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TermLoanMember", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfChangesInFairValueOfLevel3DerivativeLiabilitiesDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesScheduleOfFairValueOfDebtBalanceDetails", "lang": {"en-us": {"role": {"terseLabel": "Term Loan", "label": "Term Loan [Member]", "documentation": "Term loan.", "auth\_ref": {"1}}, "ecd\_TotalShareholderRtnAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": {"en-us": {"role": {"label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount", "auth\_ref": {"r749", "1}}, "ecd\_TotalShareholderRtnVsPeerGroupTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": {"en-us": {"role": {"label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group", "auth\_ref": {"r756", "1}}, "us-gaap\_TradeAndOtherAccountsReceivablePolicy": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPolicies", "lang": {"en-us": {"role": {"label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable", "documentation": "Disclosure of accounting policy for accounts receivable.", "auth\_ref": {"r119", "r120", "r121", "r823", "r824", "r825", "1}}, "ecd\_TradingArrAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": {"en-us": {"role": {"label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement", "auth\_ref": {"r776", "1}}, "ecd\_TradingArrByIndTable": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": {"en-us": {"role": {"label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual", "auth\_ref": {"r778", "1}}, "doi\_TradingSymbol": {"xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "TradingSymbol", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DocumentDocumentAndEntityInformation", "lang": {"en-us": {"role": {"label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange.", "auth\_ref": {"1}}, "seph\_TrailingOfNetSales": {"xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TrailingOfNetSales", "crdr": "credit", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": {"en-us": {"role": {"documentation": "trailing 12-month net sales.", "label": "Trailing of net sales", "auth\_ref": {"1}}, "seph\_TrancheALoanMember": {"xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TrancheALoanMember", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "lang": {"en-us": {"role": {"documentation": "Tranche A Loan", "label": "Tranche A Loan [Member]", "verboselabel": "Tranche A Loan", "auth\_ref": {"1}}, "seph\_TrancheBLoanMember": {"xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TrancheBLoanMember", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "lang": {"en-us": {"role": {"documentation": "Tranche B Loan", "label": "Tranche B Loan [Member]", "terseLabel": "Tranche B Loan", "auth\_ref": {"1}}, "seph\_TrancheBWarrantMember": {"xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TrancheBWarrantMember", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "lang": {"en-us": {"role": {"terseLabel": "Tranche B Warrant", "label": "Tranche B Warrant [Member]", "documentation": "Tranche B Warrant", "auth\_ref": {"1}}, "seph\_TransferOfIssuanceCostsFromOtherCurrentAssetsToEquity": {"xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TransferOfIssuanceCostsFromOtherCurrentAssetsToEquity", "crdr": "credit", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "lang": {"en-us": {"role": {"label": "Transfer of issuance costs from other current assets to equity", "documentation": "Transfer of issuance costs from other current assets to equity.", "auth\_ref": {"1}}, "seph\_TransferOfIssuanceCostsFromOtherNoncurrentAssetsToEquity": {"xbrltype": "monetaryItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TransferOfIssuanceCostsFromOtherNoncurrentAssetsToEquity", "crdr": "credit", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "lang": {"en-us": {"role": {"documentation": "Transfer of issuance costs from other noncurrent assets to equity.", "terseLabel": "Transfer of issuance costs from other noncurrent assets to equity", "label": "Transfer of issuance costs from other noncurrent assets to equity", "auth\_ref": {"1}}, "us-gaap\_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureInvestmentsSummaryOfAvailableForSaleClassifiedInvestmentsDetails", "lang": {"en-us": {"role": {"label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "auth\_ref": {"r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "1}}, "ecd\_TrdArrAdoptionDate": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": {"en-us": {"role": {"label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date", "auth\_ref": {"r779", "1}}, "ecd\_TrdArrDuration": {"xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": {"en-us": {"role": {"label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration", "auth\_ref": {"r780", "1}}, "ecd\_TrdArrExpirationDate": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": {"en-us": {"role": {"label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date", "auth\_ref": {"r780", "1}}, "ecd\_TrdArrIndName": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": {"en-us": {"role": {"label": "Trading Arrangement, Individual Name", "terseLabel": "Name", "auth\_ref": {"r778", "1}}, "ecd\_TrdArrIndTitle": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": {"en-us": {"role": {"label": "Trading Arrangement, Individual Title", "terseLabel": "Title", "auth\_ref": {"r778", "1}}, "ecd\_TrdArrSecuritiesAggAvailAmt": {"xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": {"en-us": {"role": {"label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available", "auth\_ref": {"r781", "1}}, "ecd\_TrdArrTerminationDate": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate",

"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terselabel": "Termination Date" } } }, "auth\_ref": { "r779" } }, "seph\_TwentyTwentyFourATMAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TwentyTwentyFourATMAgreementMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquityAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terselabel": "2024 ATM Agreement", "label": "Twenty twenty four ATM agreement [Member]", "documentation": "Twenty twenty four ATM agreement" } } }, "auth\_ref": { } }, "seph\_TwentyTwentyOneATMAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TwentyTwentyOneATMAgreementMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquityAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Twenty twenty one ATM agreement", "label": "Twenty Twenty One A T M Agreement [Member]", "terselabel": "2021 ATM Agreement" } } }, "auth\_ref": { } }, "seph\_TwoThousandAndSeventeenEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TwoThousandAndSeventeenEmployeeStockPurchasePlanMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terselabel": "2017 Employee Stock Purchase Plan", "label": "Two Thousand and Seventeen Employee Stock Purchase Plan [Member]", "documentation": "Two thousand and seventeen employee stock purchase plan" } } }, "auth\_ref": { } }, "seph\_TwoThousandFourteenStockPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TwoThousandFourteenStockPlanMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Two thousand fourteen stock plan", "label": "Two Thousand Fourteen Stock Plan [Member]", "terselabel": "2014 Stock Plan" } } }, "auth\_ref": { } }, "seph\_TwoThousandNineteenATMAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TwoThousandNineteenATMAgreementMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquityAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen ATM agreement", "label": "Two Thousand Nineteen A T M Agreement [Member]", "terselabel": "2019 ATM Agreement" } } }, "auth\_ref": { } }, "seph\_TwoThousandNineteenLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TwoThousandNineteenLoanAgreementMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen loan agreement", "label": "Two Thousand Nineteen Loan Agreement [Member]", "terselabel": "2019 Loan Agreement" } } }, "auth\_ref": { } }, "seph\_TwoThousandSeventeenLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TwoThousandSeventeenLoanAgreementMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Two thousand seventeen loan agreement", "label": "Two Thousand Seventeen Loan Agreement [Member]", "terselabel": "2017 Loan Agreement" } } }, "auth\_ref": { } }, "seph\_TwoThousandSeventeenStockPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TwoThousandSeventeenStockPlanMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Two thousand seventeen stock plan", "label": "Two Thousand Seventeen Stock Plan [Member]", "terselabel": "2017 Stock Plan" } } }, "auth\_ref": { } }, "seph\_TwoThousandTwentyFourPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TwoThousandTwentyFourPublicOfferingMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquityAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "2024 public offering", "label": "Two Thousand Twenty Four Public Offering [Member]", "terselabel": "2024 Public Offering" } } }, "auth\_ref": { } }, "seph\_TwoThousandTwentyThreeEmploymentInducementAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "TwoThousandTwentyThreeEmploymentInducementAwardPlanMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Two thousand twenty three employment inducement award plan", "label": "Two Thousand Twenty Three Employment Inducement Award Plan [Member]", "terselabel": "2023 Employment Inducement Award Plan" } } }, "auth\_ref": { "us-gaap-TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquityAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue generating activity or operations" } } }, "auth\_ref": { "r407" } }, "us-gaap-USGovernmentCorporationsAndAgenciesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFairValueOffinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureInvestmentsSummaryOfAvailableForSaleClassifiedInvestmentsDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "United States Government Agency securities", "label": "US Government Corporations and Agencies Securities [Member]", "terselabel": "United States Government Agency Securities", "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)" } } }, "auth\_ref": { "r908" } }, "us-gaap-USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureFairValueOffinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureInvestmentsSummaryOfAvailableForSaleClassifiedInvestmentsDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "United States Treasury securities", "label": "US Treasury Securities [Member]", "terselabel": "United States Treasury Securities", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)" } } }, "auth\_ref": { "r647", "r663", "r665", "r673", "r909" } }, "seph\_UnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "UnderwritingAgreementMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquityAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Underwriting agreement", "label": "Underwriting Agreement [Member]", "terselabel": "Underwriting Agreement" } } }, "auth\_ref": { } }, "seph\_UnderwrittenPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "UnderwrittenPublicOfferingMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetails", "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquityAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Underwritten public offering", "label": "Underwritten Public Offering [Member]", "terselabel": "Underwritten Public Offering" } } }, "auth\_ref": { "ecd-UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terselabel": "Underlying Security Market Price Change" } } }, "auth\_ref": { "r775" } }, "us-gaap-UnrealizedGainLossOnInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureInvestmentsTables" }, "lang": { "en-us": { "role": { "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "terselabel": "Summary of Available for Sale Classified Investments", "documentation": "Tabular disclosure of unrealized gains and losses on investments" } } }, "auth\_ref": { "us-gaap-UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crd": "credit", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terselabel": "Potential interest and penalties associated with uncertain tax positions, accruals", "totallabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return" } } }, "auth\_ref": { "r393", "r670" } }, "seph\_UnvestedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "UnvestedRestrictedStockUnitsMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Unvested Restricted Stock Units Member", "documentation": "Unvested restricted stock units", "label": "Unvested Restricted Stock Units [Member]", "terselabel": "Unvested Restricted Stock Units" } } }, "auth\_ref": { "us-gaap-UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terselabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles" } } }, "auth\_ref": { "r28", "r29", "r30", "r123", "r124", "r127", "r128" } }, "us-gaap-ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueAxis", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique" } } }, "auth\_ref": { "r429", "r430", "r676", "r880" } }, "us-gaap-ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Discounted Cash Flow", "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows" } } }, "auth\_ref": { "r676", "r878", "r879", "r880" } }, "us-gaap-ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDomain", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique" } } }, "auth\_ref": { "r429", "r430", "r676", "r880" } }, "us-gaap-VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "terselabel": "Variable Rate", "documentation": "Information by type of variable rate" } } }, "auth\_ref": { "us-gaap-VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "terselabel": "Variable Rate", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index" } } }, "auth\_ref": { "ecd-VstngDtFrValOfEqtyAwrdsGrntdAndVstnInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstnInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terselabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth\_ref": { "r745" } }, "us-gaap-WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terselabel": "Warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount" } } }, "auth\_ref": { "r691", "r692", "r695", "r696", "r697", "r698" } }, "us-gaap-WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/DisclosureFinancialLiabilitiesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terselabel": "Warrants exercise period", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days" } } }, "auth\_ref": { "r878", "r879", "r880" } }, "seph-WarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sepharmaceuticals.com/20240930", "localname": "WarrantsToPurchaseCommonStockMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails" }, "lang": { "en-us": { "role": { "documentation": "Warrants to purchase common stock", "label": "Warrants to purchase common stock [Member]", "terselabel": "Warrants to Purchase Common Stock" } } }, "auth\_ref": { "srt-WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "WeightedAverageMember", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureStockholdersEquityAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terselabel": "Weighted Average", "documentation": "Weighted Average" } } }, "auth\_ref": { "r431", "r496", "r633", "r634", "r676", "r900", "r902", "r905" } }, "us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": { "http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role\_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareOfCommonStockDetails",

```

"en-us", {"role": {"totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Weighted average common shares outstanding - diluted", "terseLabel": "Weighted average shares used in computing net loss per share, diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, {"auth_ref": ["r192", "r197"] }, {"us_gaap_WeightedAverageNumberOfSharesOutstandingBasic": {"xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": {"http://www.sepharmaceuticals.com/20240930/taxonomy/role/Role-StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", {"lang": "en-us", {"role": {"totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Weighted average common shares outstanding - basic", "terseLabel": "Weighted average shares used in computing net loss per share, basic", "documentation": "Number of basic shares or units after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, {"auth_ref": ["r191", "r197"] }, {"ec_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {"xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localName": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure", {"lang": "en-us", {"role": {"label": "Year-End Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested (Member)", "terseLabel": "Year-End Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "auth_ref": ["r743"] } } } } }, {"std_ref": {"r0": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1", "r1": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r2": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14", "r3": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15", "r4": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r5": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r6": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1", "r7": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1", "r8": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1", "r9": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r10": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2", "r11": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r12": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r13": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r14": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A", "r15": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1", "r16": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1", "r17": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14", "r18": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A", "r19": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5", "r20": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12", "r21": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14", "r22": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15", "r23": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4", "r24": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1", "r25": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1", "r26": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18", "r27": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20", "r28": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4", "r29": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]



[illegible]

[illegible]



[illegible]



TSN9@!.\$84)-3I2 M/SMO&3LI^0G!%=[5.4 GA%5@.I7^Z7R/>A?>)OHO&X2:P^OJ^7Y+ \$T(M:N+!/:>#.@L1+ #G,RJ\$54 H&>>3!:H<3%A,V<5\$IO,H8"MI+7Y> \V12TU^9F/ZI=J  
Ml\_9 \*#\_.Z':>\$=J5^FQN+FWES,IGZ>S59W MIX&S=[Ts1\$VY09VZ-VSW!|AN29C7=)&\*G^S]2-&KV3 WS[=@+.G8!4(L MMULO@?

[illegible]

MD->CH-E6ZCUJQU7U->46W->#16#050MIMM->U3TTHU- W-F5S-M2U->Z75-M->5N2F-E O4KMGU\*Y-L BO'W+1-L=>-%V98R&+S-GW=O1HM<S<90MG.1 M4%  
 N6L1N2->XS-L1ZN%R3076 JGK=V-C<XB6O \*S<=JF6V T7I=65 M 1<8UW- PK6%FY.1013H.SLC-7L Z3C2CFJ9QUN?2 H/4D&3.SID->M2-V  
 =>J0Q&PALGPC1+U P&=RD3KN892CYG#P#G>M A713NXVZIGMR MXVPD#>BZ.SP(FB?7 HOM1)/L"/3/+1+AW<+>Al" M@COTY70HU.L MH2TF\$8/4729F9?

2XMKX 9.0 2CFM3V1L'ISG MC@8ZBA%'Z1/PW'IA'@RBH71=\$PZ4A%'\$APSSJKG7+0.-%#) \BS(> \$% 4IS MIUUR(R.SCU\_3@\_4Z'1=-I6#1=QOCGPI.%VA=M.IIHK4@OT6Z%'BA'+B..MLV2=  
 3S161>HW1L.FHT330%'#SX<-W2<->2BWZ320.>@+F7>5G\$BBS772GMO4L81M04R%'L%Z/ 22\$GPQ#Q%'70 810. JNZ/J /CU\_ POU2UAXU1..M.ZV1+1.CVI.  
 M1 VCKU1UT7B(R)H/0710=-VW<S>N1Z30?>1W7VU.UM5\$R.VD-23Y M=C6GF728 .3?1M0L 9HC#K.L1N8WOU=-WXU=@150@1 7 KA681IHLZ@M@P

[illegible]

6368R'72,MD8[S^C%?N]BVCW3 M "6="OG'WQ@Z"+DBRIT0WX9QXOC QIM=A&Y^1L%: [2SD/CR&6\*P(#+>DLQL736]6TFHUFUFI-P%VE0M6)&XKV=JDP4T81]GDI57-  
MYZFQOM7?#MPJ8,0+67H&4,NX5Z?#K721WFO 6\_7WJ0KEU!+=,RW&0\* MR@=Q! A!@0]FHM28R'FHV=RY+3+=N3L@1202,BUG6(1#+16+=Q!+8UVP"P"-\*7  
M22T40H+?+7-HG"+6 VB(XGFW,7G6TFVX?% W%N3L(SCIO'S%#-R,R M89TFC:ZXSX1#!N#N@Q!+G652+2YVA#;KO3L!+A?M2 ,H6S2I58D)T0T

MUPR;JMS:0700XB NR118163P>\*95\*Q:3L\*QSI-6\*28P>U@J&=3U. MPJP-8^&=2CW)K 7^YM.#R1&67?>9HX5?P1X74^4UO MHQ1KYVVV^#K9M  
 <@URXJP>.1G\_CXJM.H+@19W,OP@Q080=R7G7U+>70P MI<-BLCWH1@AEM1219S01^1-0I+>^BX8P8&4KSAWI/M:SI71HJ.M.N#%&ZS)AB1\_G?P?P  
 MSLF5<-1UHCJH1/I&:IH B8OP1?T4M\_NG:1P77U1-2^4MAWVPBA(>\_TMO:1M-2\_K 0#2XX5-HT&VXS^BXI5-1-BHBP7971X6^32W JOGP+O^WL<-VGPOH>UZO^YH&^+

MBH)XKPP04@!H4Q0D%#@=([+V+J]U)U\$!FISXUP03!ADM?)2=7MJK69<MJE+7A&HJ3&E44JLY472>+1/GIT038)C=0LQ(7F=VWDBYFO3N^Y4\$5\$M6<@OM5A+&5.5DZ?7HJ=VY0V7H7AXI/[775YVYVG1P5N60Q(PB+A(E+M)=(\*@)H01-XBC6PMH16PPY@4PDX+65(1H1\*3G-B TY(Z3RR5;9H%R+6 M5ERR551UR1+13=55MU^XJ@GVR04E-K157H7H2H<E=7C@VW-M041YBS=-W16+G+YSC@2SR2\$R+R+M=M=DP(C(2@)1MC@31OYX3V6R5V4YRKH=M=6&32M1R16L+4R=67@S^XJ

RMZ27PU4H-3/@.H.X.V.CBE.M=4G/#Q.L.NI=WRI#GWRU)K#3-BZYSB2?5LNG17Z?P\*O>?IB\$4.&1\$@A#B1<=70.9Y(\*?P.D?5.M.MO:IST+CX4.9&UF2;...1+0.MCGH6%#<=>79/BPZGH43B3=LQ1#GPD(60K\$S\$X.RK(4K.M+Q5.+8TAS.T).X!@+X4.HG-/%\$N.7JHS9R(P?B2Z85.YC.B4Y@K\VO=&=8<17>U&6R0%#<=>7.0B3Q3\*6^HDK.D.J  
2M8WV..2BE4\*Q5B?1?>5GS5SYX.RCB84UHUOH8J8S.=WD1\*P1/H+1XK4.M.N.TX7.2.=ZA.M?2B.T4FJL#FVRI@3T2.V+UI#.#\$1A=V?TNE<@>...@>1>V

N8U+NU8A4KJ2V1+(-C)V EU74+C0G9K96+2B+UEC+KH+2=J+M4H+1+M2AR3K9M+2#21H+4P2DSZLQ8V14+84 M81+372D49+0URF/ALEO /O#81338741%4%CLL+170=+GGC-6%N1H#0X0O M-K+1=-(U7JYV#8%P41SN1B)X5-MW#9KHJ=2+PIR#6J320HV5JQJ+UQ MW(T+X)+A4+AAWV9+2+HV8S85W=AGM9(O1FLF+GYOXM9H6+CVSR?+BYVN/7ZLEELYVTL+(-CMGN5RN7WYRLHFC#B4 HP -CZYH+U#3-KPIHQ.RBP/5Y+GCQ+FEI=ORTZG.MISZW0.0.0.3"W'G<S#A4B+O'HUJL=L-X'LNQ'623Y7L43GI=L'N1JH.HH

```
>0!4<2=<%H:/UL/IP96-8 AC"><#C-15G8Y4AN+GC@::8!^RZ$(4N-MZF))X0-0J7$ E)IRI96F(IGA'F+XG+&f>.9$NGY2GAFF?-(M9=N(GD-RB@ MYIV+IZ-  
04W713?0-T!!%NU4SD2INQ8Q?PV&FTL(2H)5%!HH+DNT-P/0-T0.26 M#@4FP(PV(O<4%$H$JD.A.(4.%E2=U3(X.K.PSI7MMX2SM K308 M-@)(KCM 15)G 26:ZRD=f  
047W2XKI0)>1%LUK8FI7VK2$5BT0-LB M-31HH&DNT-P/VZNVOO(R)G+6%~5/1-W666=UAUK'F(Z/OD'H%?&O95 RF M-SY21
```

1-1N0P7-MJ=A1=1:\$90@^XCL3@^8Y.6@OX.W> \$3 M.U.7>^78YUNNKVNHUORY%9MB(TO^A3)<4Z/P^A^>9(1H-1(H8RAW6B/2LJNJE10733/MW)@K0  
1-1N0K1WFT>R9(KK0+;+<1%G8^FM>:UW&WDHJ>+<R1+9>+I(7E43^3^X2 MKRO.#U FIV^\*(SA^M8)HW6,JY^D+H0&M2.14J/V3&35676/SN(D ANH  
M%4PM,D\*SX77:CH&TVTJ<EM&G&FM>B=)%VH>; 3 MV @CT#1&H=H/P&A^P^1+78NTP@#J \$9J;DSO(P<R\$R6XR9>+^1HN 1&T MJVJ<9GD2XXSS&K5L1>1SP 3D3(7F:Q@<Q@J

```

1408 L^100M10191048,MM11M101735M00K1047R1E100 AKZ25H038J2 VYTHR0399W00M-DT1VHE1AD0T1 MKR1VAC200F01
1409 L^100L^1ISC<G6>1J1U7P2Y1UQH1V5M<EQX1AVE> MY<NA125HX6308J149Z7<3DAMZK<=>GAK,23HK<=>|@|(#Z5RIA6V0A#1+Q<1^+QM
1410 L^100M1ZC7<=>@#137L1L^9T1M392TA#M<VN7F1Z1T,FI00B00Q>Y5(CM^M&610Q/5S&11NH1^Y2<B1GH11M1V7S)7>Z7D1Q^XOH1^1Y,Y616^EELMB-
1411 L^100L^1Q1N147L^100L^153282TA#-ML^1K40L1N,V1C1^3EY1L14EFLW14Q1N32_EKS_V1412<043%0PWBH16CM^HCH1AV200H<4C1GH<0_0"

```

```

@C@B5D9:531,+K7=-AM1FE=N^070)T^X0/8H14MK*=<52R0U^M@C^R^M)15J8-=<4C-C6;YKXX@1^R49&KJSWN>^VOJVPXSNZI+6.WSV^C<# MK1^5PK^Z(F5HP^HW*
-6s-2R1^DAKM^71^R^DHO^T04V49+8Q=1^DAGWS9^M2^813+7+IDJ5L^ENG&^BY6#G#Y1(%%0%ZK^&^6Y2I3I^TR^X^MRC^M4C51^G+XEV1^K5351^XQMFW^/Q
N1^KG5I1^&G&UHLH^Q3044)<M>=M50T&M^6HJ5^KWH1^G15^06F8I^T^W22^H^KX^N^PFS1V^LCRA&FEI9-29 MED5T^Y1^I02-1^U9A1T^>0^SI>->D^B^KZ

```

IP6-LEVO-4-AD-F6U1X%-7AT?7 MLH1T551Y-U%?7AQ-?%?XLUER\*MBF08-76-0.80H-X%-?U5ZG6Q(910)S7-M\*U2 -#M1W-(P=^?P?X=0-S\$2(1 MR-K=SC7KIAIF?LVI.S  
MM)99E-4-PA6IAGH+7AT?(XA-^+SOF,7JV16-W& MO)H%&H\*H-8I4-7L7D-3T1A?C3I62NR+1.60(KI?JAS-U+ UN271910Z\$(=P-  
MM@A'G'IN^?O!E=PM\*51C62LTS&S-R.7UH5Q9QN.Q??-F#1?<(G|X\$|RJ?^G-MAH-^?RIYPW=1^UDUR\*J5S4H?QXD!-&N+IHGH;NMMWYH\*-\* M-#1\$XT-KC5P?P7.\$EHEIH  
?A'G'IN^?O!E=PM\*51C62LTS&S-R.7UH5Q9QN.Q??-F#1?<(G|X\$|RJ?^G-MAH-^?RIYPW=1^UDUR\*J5S4H?QXD!-&N+IHGH;NMMWYH\*-\* M-#1\$XT-KC5P?P7.\$EHEIH

MCS<DPTH,\*22,C^HX+EB.%C\$6\$39,Ps.^2'8M'W.2%G73E2&I.VVOO<M V2HBGU^ NYC>L ^%+B^NZ,S5L^+15NMA SPMC %X%)HJSO.X\$7@(LX)? M^8\_5G<H^0SCI^=T.E6  
J9R1.DY6</JIHY81IR@8A.M<6^L^17U3^2A.W)^|RT.N.JB./OA>%D2P.S.C.^#00+2JPM.M^<VN ^+EWFT^,MBZLAPZ5E.L^#6^WBA7K1245?>EA/(^AYMM^)%#13  
M^B^K18&Z.E.SOG:0.V/OBX124^IRIVZ.M%OV^EY3S+11.&MGWSRVZ.KI.HL^U-H^dG0BK.%GVDSMF25\$E2\_XY+-R@B.M^#-B:0.=.-CSG4/AZ?

aB7M\$N,IMNBFKB&LOEA7GH^C^Z+|X917^LL.LF6S MF^%1LF^K:N.SIG.(ELWIM+|<=PVE147 SEGA;|W^Z%^V2R=8XV."Q9.196 M9S7-M5NPR"C-A KU)-  
 sYVKOP8C;TL9X27ADE6RX<C-A JK^T^LL.XM>+7W@|UT9D1<QG,W6B-1.8I:PV.E9X\$%9<AWG 5<^RSU7=>+&1+M^JF7WCQ&006>VN3IH;|J70^0:DJG5<|65+1L9%7  
 N(04)60S7J7-1H^M2>1|BLB7E7^OFF# VF7?0IQ=50+|0I99;OFEKYWB#(0<@YP3;|V@|0WRV9 S((=0^4^7B| MBKXWQ&Q0532

[illegible]

IRGF=NV1@^@.M26%O.)4M1(8?JC)9=M-R\*LB+B\*D5V6(O\$4~1R.5^KAX=? M(TN ICFX!\$D^W915K; &3=-MPR3?/\_ MOG+BK5^\$(XF-SW&9&CHZNS#+2 PGF(^!8)-0TY(Z5-  
V2L1 MJ1VBZ/IZ/Y MO.DY F7D0=0#914.61:4D12E\*^&3=Z\$WWD(DIKH2L2RE@.ZYC@.6MRJMG^AE M^@^UXYJ08E^Bj0f1VQV37@~NHRVX.8C.B;JS=H\$&JKXV^ L1=GM(G!  
M\$S=KHE^!u7F4@ (WULO 6.DKBU1CJ^IE^HE^0:0\$W64AIAZ?G5Y8VYUQZBSZ\$!)3V^~\$U!L-9PK M7IT E74B PU505718~7^~(20PQF&U.87.KET7159)C00102HWE-

BDW3V1%0M453%+JRN#HFNQWZDJHB3I2P%V7<3(C)K2M2V1-A6G#ATTT1UAPL2V2G%R%SH2<#8\*3%K9\*RM&ST+GMKNI-C5X3+51UPlM%=>V+3(E9%0)-  
EW7+P51z0I2P145K9R3V1U(H)BL=I4RE#E%FTT#ZW%K6M2T#PB1I7U01s6%5MPBPV4Z<7#9%G92P%1P1CPH#N0.P%AFJTN8ZC.SI+MY2SH6G4DAD+D+D+MFTF  
2%??->@PAJGO+Y%#WA5%5Q>IC|P0&M+HF#EEJ5XA&M8\$W%0V\$Y:Y.MI7>53M2\_VL1K9\$IQ&#AHZ%5H5FY-&\_I9O>S2FF.(UYS\$12Z>9?5Y#I MKD%\*2(\$+HAY&FIPN-

KPHHl@Q\$M+N@LB6\$%&+!X\$X"MU'X4.HV-X2A2-BYMD8..lVJ5-Z-COW#++5V0'IS=H#F.(\$H@MHQ05/IGU?>Q99Y04A2-M.VKI'9=>44R#@AQ<D)F3."LMK@G2EM<\$;S8;MM#H\$12.26XG2K+LX?>LQFG."@AOPBYB03323304G/+M419R77/OK-Z5=I6MI"++&+R-K%Z?XQI?F;ENY.SI.00X#88R47953<ZT4\$E'U>8&K&R5M+H?>P&FC2I?G2.MH0KI.RFV2Z7FIP%<+H&PM+!\$U3"-349.60#-6049S2?CP&SFLA.D/LUHW.6T-DUW@7IG9370#P#H\$5M.VTVHSFED=8RUZF&X&M.MN=H4VY.0M+&+V?<+H2

11:..RIB=9Q@8Y.Q98?F>=S)85DUY.F@C.YYQ.0^HE2Z.K#F.Q5^?iG:::MNA(0715S6.M=%]BFI.06N^:::WG#@.U5F'H'AT=0G0B.AMFYFY+7A.C+O::@=T3+F0.M-YB1K3K.OV4U1AGB>2,?;B5QIG.Z61..M0GX0D1.L3P<4F1EIR)P6D=Z.MB=28HY.H5G(Z.R.K)5479.6J5635UE^..F1^&[.NWJZMP0U3>9LP.(4QA=K60.M.5B9JW.R)G61K5761&EYTOPT.H25.6E=S837>D/Q(A71).H3L1&L1P<5F2.MU=D/10V.Q14BWYV=R.CF1&2UL0B.J5\$BXY'W'D\*3.7RH2&+SX#IP0Q(4WQY.M.H.VXG6A0+>.

PL[AT5HK,52%)1:1CYWYRAB,61/B-(GV)NFC=^1:M661Q4GV5YLP^1-DHAM DRUJ.WD)P^VJ=WJXA:3 ZHFKAKJSLS^1-MVYX9:  
Q17VIGLJA..NIEWL270X.84FBX^PY:RH.UE^20H.6.^7^0LIV.F22N1L MU6.^76K(8 HB241.2.OX.9Y1+6K^G1T0T1K1S1302?CP8+OC61.3s4V7>M^S3D9NCFNSI9/6^FS6  
K.TA.Q.2V(2#2^R1H5259^H^IV MHP.WF6<2^2^P42)ASB1+HQGT.7Q.1+V=QN.ZHRD.^1X3Q^T.9KGVYHPBD.M5(61.^1H.NU.10^1)WNWNU^DQNGN..IMVIL.5E)5+SG-  
2^1^3N0N0^H15.M6.^01582.FE0QT.071L..H5^E4A.DSC16U.^1.N8H1H141QYU.96.A6A764.G66.^1V.C1HEWYR.DR.DH41.E4.766P.M2P.2.G1U41OXIYD.

3:3XM>@H-WB9<-HEL|QV.N|A\*-C0:0|HZ~B3-M\$>@R@-L=G.E#%32L&S2T-FLGWRM~@OKI-@X.S@H'L'Q@-PWU4J.9E3>~W-M@2.1%SFEA-SU?\_??  
 @GK\*GW,ETH|LOI@-RW=T16|Q/GI-8\_0X>?0\_X1X%#M-@-|YSM|A|NTBR3|XVTZ3H|AD?&6H(CM|H@85YC'<8.5#3)R'|CH'~MG&G|GB|OUPPEG8>+XUHU9GZ 54#|  
 @FNKXATJ|BLDA#Z&4A2N0- TUV<N|MY(ZYXKXZ|@.T9#P|Y|0.>1|A1.1.BN3J L|J>:AD?T.E.S)>~?S70|HS-MT>|BBE 7|Q?|KITWV|J|J:H2G<FC N9M?H%<FU\_&P5\$%#|

M5B, ZQC~?2M,6/OU&T8B\~ZZV~412~#SW(I{#J08LK:NP~#T60NQIYQW#V8?7U5\*~M~1%2~B0,~#I~B1\*%>C~CBT&T~\*4~\*37?C1:2I(SO&F5~F~@3PGIAE{  
 MMBPB~ZQ1~N,IALED&TB\I{S5U{L55%52/6~E~#~5RD8H~#V,8V8I~>9~B6F?7~MLD8D&~#Y,~DB,01~#666G(RC{S~M~%XJ8?>1~4EQR&F5~M5~&56,668,~R{5}UPP~3TNI~R  
 RPN6GOF~#~MMI~L~2N,%~#RNC#U\$;CVE,E,D)@KX1,50A6(30~\$S~\$X52J9E,I~O~MAD4B~VY>XP<6)DIY4Z\$~F~LHPW>SC>4B~\$5;AE0;H,~ETI~X#6~\$~DI1T1~R#~M(ACS!%D4ZI

[illegible]

MMS30ICXDI.F46D1%16Z\ON=;1A4\MC\KP;"C8"@=4LSKYI2\//L#;"HE-1W#1\MC6<2NSTRFQ>Z>R\;AC73&4\$6?YBS>"/LK+CY-5EXN\CI4A8-D/L-0\
 MUB<6">K\KX1.84>ULIB3I26<8?>2\;"ZY&T"1\FOQIE.YEV-D"MPB7-IN:1%:/R5J00PH1ZL=8D6<@ZR\T<7GR&+&@"Z2W\YAFD9B-B\ZK-M;
 +B-O\MI-R>U"R<4AA.FS>GUAIM+408K<6&IAFK\ KLG-71BYI<7QDM4M+2M14TKZD+H1;1ZL=;C9M-98JO<+2MW71D180\YVQ4PHPPW2\I/#=8R

[illegible]

C5-TK85NAU& B\*7(!)2L<#>>AN(AC) MT6W7i>3A ZMPNB9B2H3O !0/4-Z4272M0BK<X9.0<<>J(DF> @J7.9:9H\*?I8 M8Q8,(W %B=IHCR6VU\*&Y!+0 MP; ?R).P(X 2  
M!E!0GWf,+I7<+0JONJ7VH<@!9T.&V10)O(C)&L!P6XIMJ7Z+D.Y<=OX3! M09X!BEORP25<><K\*!EP !00HZA LK\*Q2 M&<+F0!H14Q47H?M-Z5A!+5<+!+4FGHZ  
/1HL<+Y. B4YH. P!8MR8 M8FM5<@.V30?DBU<12<+D8\*NTGSHN<DRL.GTLH!>.>+!@V.6V7ZGZD MO4G<+L.PD?YBNO34G<ZP70.Z.O!47H!G8BER!>?MO?O9V5SD5P!

06\_KHK\_KQ:MGPYGIEH,V@:S42F1ARM4:D6S2\$@@C:M950:M7U~X\_JK?-A:G2Q+@GOY/S\*HZS\*8A\*6J\_KJGBHKK\*P36G1STGDA\_M8^-(B-C=OP5DP2CABAB2Y>@LH07ON  
 M\$~Jm8S,Q3L2(W\$1N.HYZM:.5A!MSV=.%7(XEL6P6740W#+23~1Q2!V%F2\_M7+YH1WBA=@2HC+QV1\*~dS769F8Y8I3L2\_AZBGC=KJ7&+<8R+>  
 M\$~Jm8S,Q3L2(CD9+4V#1B!HY@AG3+IR\$2-R-74~C:N36P.BJ=@M>>1YW%J29+@4&+HPV9M3=23D2B.+3&3!T5J\_L626#2H19+LRDGM16\$@G\_MR-7JL:9?

[illegible]









scph:TwoThousandTwentyFourPublicOfferingMemberscpsh:UnderwritingAgreementMember 2024-08-132024-08-13 0001604950 scph:CustomerTwoMember-  
gaap:RevenueFromContractWithCustomerMembers-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001604950 scph:CustomerTwoMembers-  
gaap:RevenueFromContractWithCustomerMembers-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0001604950 us-gaap:AccountsPayableMember 2023-  
01-012023-12-31 0001604950 scph:CowenAndCompanyLLCMemberus-gaap:CommonStockMemberscpsh:TwentyTwentyOneATMAgreementMember 2024-01-012024-09-30  
0001604950 scph:WarrantsToPurchaseCommonStockMember 2024-01-012024-09-30 0001604950 us-  
gaap:CommonStockMemberscpsh:TwoThousandTwentyFourPublicOfferingMemberscpsh:UnderwritingAgreementMember 2024-08-132024-08-13 0001604950  
scph:WarrantsToPurchaseCommonStockMember 2024-07-012024-09-30 0001604950 scph:PurchasesMembers-  
gaap:SupplierConcentrationRiskMemberscpsh:SupplierTwoMember 2023-01-012023-09-30 0001604950 scph:CowenAndCompanyLLCMembersrt:MaximumMembers-  
gaap:CommonStockMemberscpsh:TwentyTwentyOneATMAgreementMember 2023-01-03-232021-03-23 0001604950 scph:OaktreeAgreementMember 2024-08-092024-08-09  
0001604950 us-gaap:CommonStockMember 2024-09-30 0001604950 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001604950 us-  
gaap:CommonStockMember 2024-04-012024-06-30 0001604950 us-gaap:ComputerEquipmentMember 2023-12-31 0001604950 us-gaap:CommonStockMember 2024-07-  
012024-09-30 0001604950 us-gaap:FairValueInputsLevel3Memberscpsh:RevenuePurchaseAndSaleLiabilityMember 2024-01-012024-09-30 0001604950  
scph:OaktreeAgreementMember 2023-12-31 0001604950 2024-11-12 0001604950 2023-01-012023-12-31 0001604950 us-gaap:AdditionalPaidInCapitalMember 2022-12-31  
0001604950 us-gaap:MeasurementInputDiscountRateMembers-gaap:ValuationTechniqueDiscountedCashFlowMember 2024-09-30 0001604950  
scph:OaktreeAgreementMember 2022-10-132022-10-13 0001604950 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001604950  
scph:CustomerTwoMembers-gaap:AccountsReceivableMembers-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001604950  
scph:TwoThousandTwentyFourPublicOfferingMemberscpsh:UnderwritingAgreementMember 2024-08-13 0001604950 scph:TermLoanMember 2024-09-30 0001604950  
scph:TwoThousandTwentyThreeEmploymentInducementAwardPlanMember 2024-09-30 0001604950 us-gaap:CommonStockMember 2023-01-012023-03-31 0001604950 2024-  
01-012024-03-31 0001604950 scph:CustomerOneMembers-gaap:RevenueFromContractWithCustomerMembers-gaap:CustomerConcentrationRiskMember 2023-01-012023-  
09-30 0001604950 srt:MaximumMemberscpsh:TwoThousandSeventeenStockPlanMember 2024-01-012024-09-30 0001604950 us-gaap:FairValueInputsLevel3Members-  
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001604950 2024-01-012024-09-30 0001604950 us-gaap:AccountsReceivableMember 2023-01-012023-12-31  
0001604950 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001604950 scph:CowenAndCompanyLLCMembersrt:WeightedAverageMembers-  
gaap:CommonStockMemberscpsh:TwentyTwentyOneATMAgreementMember 2024-09-30 0001604950 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-  
30 0001604950 srt:MaximumMember 2024-01-012024-09-30 0001604950 srt:MaximumMemberscpsh:OaktreeAgreementMember 2022-10-13 0001604950 us-  
gaap:FairValueInputsLevel3Memberscpsh:RevenuePurchaseAndSaleLiabilityMember 2024-09-30 0001604950 scph:CustomerThreeMembers-  
gaap:AccountsReceivableMembers-gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0001604950 scph:TermLoanMember 2024-08-09 0001604950  
scph:WarrantsToPurchaseCommonStockMember 2023-07-012023-09-30 0001604950 scph:CreditAgreementMembers-gaap:CommonStockMember 2024-08-092024-08-09  
0001604950 2023-03-31 0001604950 scph:TermLoanMember 2024-09-30 0001604950 us-gaap:RetainedEarningsMember 2024-03-31 0001604950 us-  
gaap:AccountsReceivableMember 2024-01-012024-09-30 0001604950 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001604950 us-gaap:RetainedEarningsMember  
2023-01-012023-03-31 0001604950 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001604950 us-gaap:CommonStockMember 2023-03-31 0001604950 us-  
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001604950 scph:CreditAgreementMembers-gaap:WarrantMember 2024-08-092024-08-09 0001604950  
scph:TwoThousandSeventeenStockPlanMember 2024-09-30 0001604950 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001604950 2024-08-13  
0001604950 scph:UnvestedRestrictedStockUnitsMember 2023-07-012023-09-30 0001604950 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30  
0001604950 us-gaap:FairValueInputsLevel3Memberscpsh:TermLoanMember 2024-01-012024-09-30 0001604950 us-gaap:FairValueMeasurementsRecurringMember 2023-12-  
31 0001604950 scph:CreditAgreementMemberscpsh:FranchiseWarrantMember 2024-08-092024-08-09 0001604950  
scph:BorrowingsOneMemberscpsh:OaktreeAgreementMember 2022-10-13 0001604950 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001604950  
us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001604950 2023-12-31 0001604950 2024-04-012024-06-30 0001604950 2024-09-30 0001604950  
scph:CowenAndCompanyLLCMembersrt:MaximumMembers-gaap:CommonStockMemberscpsh:TwentyTwentyOneATMAgreementMember 2021-03-23 0001604950 2023-06-30  
0001604950 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0001604950 scph:CreditAgreementMember 2024-08-092024-08-09 0001604950  
us-gaap:FurnitureAndFixturesMember 2023-12-31 0001604950 us-gaap:RevenueFromContractWithCustomerMember 2023-07-012023-09-30 0001604950 us-  
gaap:AdditionalPaidInCapitalMember 2024-03-31 0001604950 scph:PurchasesMember 2023-07-012023-09-30 0001604950 scph:CowenAndCompanyLLCMembers-  
gaap:CommonStockMemberscpsh:TwentyTwentyFourATMAgreementMember 2024-01-012024-09-30 0001604950 scph:OaktreeAgreementMembers-gaap:WarrantMember  
2022-10-132022-10-13 0001604950 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001604950 us-  
gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001604950 scph:BorrowingsOneMemberscpsh:CreditAgreementMember 2024-08-09 0001604950 us-  
gaap:CorporateBondSecuritiesMember 2023-12-31 0001604950 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001604950 us-  
gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001604950 scph:PurchasesMember 2024-01-012024-09-30 0001604950 2023-09-30 0001604950  
scph:OaktreeAgreementMember 2024-07-012024-09-30 0001604950 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001604950  
scph:CreditAgreementMember 2024-08-09 0001604950 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001604950 scph:CreditAgreementMembers-  
gaap:SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember 2024-08-092024-08-09 0001604950 scph:OaktreeAgreementMember 2024-01-012024-09-30  
0001604950 us-gaap:OfficeEquipmentMember 2024-09-30 0001604950 scph:RevenuePurchaseAndSaleAgreementMember 2024-08-092024-08-09 0001604950  
scph:TwoThousandFourteenStockPlanMember 2024-01-012024-09-30 0001604950 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001604950 2023-12-292023-12-29  
0001604950 scph:StockOptionsToPurchaseCommonStockMember 2023-07-012023-09-30 0001604950 scph:CowenAndCompanyLLCMembersrt:MaximumMembers-  
gaap:CommonStockMemberscpsh:TwentyTwentyFourATMAgreementMember 2024-03-13 0001604950 2023-04-012023-06-30 0001604950 us-gaap:RetainedEarningsMember  
2023-09-30 0001604950 scph:WarrantsToPurchaseCommonStockMember 2023-01-012023-09-30 0001604950 scph:OaktreeAgreementMember 2023-01-012023-09-30  
0001604950 us-gaap:FairValueInputsLevel3Memberscpsh:TermLoanMember 2024-09-30 0001604950 scph:PurchasesMembers-  
gaap:SupplierConcentrationRiskMemberscpsh:SupplierOneMember 2023-07-012023-09-30 0001604950 us-gaap:OfficeEquipmentMember 2023-12-31 0001604950 us-  
gaap:CommonStockMemberscpsh:TwoThousandTwentyFourPublicOfferingMemberscpsh:UnderwritingAgreementMember 2024-08-13 0001604950 2024-03-31 0001604950 us-  
gaap:RevenueFromContractWithCustomerMember 2024-07-012024-09-30 0001604950 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001604950 us-  
gaap:FairValueInputsLevel1Members-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001604950 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-  
09-30 0001604950 us-gaap:CommonStockMember 2024-01-012024-03-31 0001604950 us-gaap:CommonStockMember 2023-07-012023-09-30 0001604950 us-  
gaap:FairValueInputsLevel2Members-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001604950 us-gaap:CommonStockMember 2024-03-31 0001604950  
scph:StockOptionsToPurchaseCommonStockMember 2024-01-012024-09-30 0001604950 us-gaap:CommercialPaperMembers-  
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001604950 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001604950 us-gaap:RetainedEarningsMember  
2023-04-012023-06-30 0001604950 scph:StockOptionsToPurchaseCommonStockMember 2023-01-012023-09-30 0001604950 us-gaap:RetainedEarningsMember 2023-12-31  
0001604950 us-gaap:CommercialPaperMember 2023-12-31 0001604950 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001604950 us-gaap:RetainedEarningsMember  
2024-09-30 0001604950 us-gaap:RevenueFromContractWithCustomerMember 2024-01-012024-09-30 0001604950 us-  
gaap:USGovernmentCorporationsAndAgenciesSecuritiesMembers-gaap:FairValueInputsLevel2Members-gaap:FairValueMeasurementsRecurringMember 2023-12-31  
0001604950 scph:TwoThousandSeventeenStockPlanMember 2024-01-012024-09-30 0001604950 scph:StockOptionsToPurchaseCommonStockMember 2024-07-012024-09-30  
0001604950 scph:DerivativeLiabilityMembers-gaap:FairValueInputsLevel3Member 2023-12-31 0001604950 us-gaap:RetainedEarningsMember 2022-12-31 0001604950 us-  
gaap:CommonStockMember 2023-12-31 0001604950 scph:OaktreeAgreementMembers-gaap:WarrantMember 2022-10-13 0001604950  
scph:UnvestedRestrictedStockUnitsMember 2023-01-012023-09-30 0001604950 us-gaap:CommonStockMember 2023-09-30 0001604950  
srt:MaximumMemberscpsh:OaktreeAgreementMembers-gaap:WarrantMember 2022-10-132022-10-13 0001604950 srt:MaximumMember 2023-01-012023-09-30 0001604950  
2024-07-012024-09-30 0001604950 scph:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember 2024-09-30 0001604950 scph:DerivativeLiabilityMembers-  
gaap:FairValueInputsLevel3Member 2024-01-012024-09-30 0001604950 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001604950 us-  
gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001604950 scph:PurchasesMembers-  
gaap:SupplierConcentrationRiskMemberscpsh:SupplierTwoMember 2024-01-012024-09-30 0001604950 scph:UnvestedRestrictedStockUnitsMember 2024-01-012024-09-30  
0001604950 scph:TermLoanMember 2024-01-012024-09-30 0001604950 scph:TwoThousandFourteenStockPlanMember 2024-09-30 0001604950  
scph:UnvestedRestrictedStockUnitsMember 2024-07-012024-09-30 0001604950 us-gaap:USTreasurySecuritiesMembers-gaap:FairValueInputsLevel1Members-  
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001604950 us-gaap:CommercialPaperMembers-gaap:FairValueInputsLevel2Members-  
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001604950 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001604950 us-  
gaap:USTreasurySecuritiesMember 2023-12-31 0001604950 us-gaap:FairValueInputsLevel1Members-gaap:FairValueMeasurementsRecurringMember 2023-12-31  
0001604950 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0001604950 srt:MinimumMember 2023-01-012023-09-30 0001604950  
scph:RevenuePurchaseAndSaleAgreementMember 2024-09-30 0001604950 scph:PurchasesMembers-gaap:SupplierConcentrationRiskMemberscpsh:SupplierTwoMember  
2024-07-012024-09-30 0001604950 scph:CreditAgreementMemberscpsh:FranchiseWarrantMember 2024-08-09 0001604950 us-  
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0001604950 scph:StraightLineBasisMember 2024-09-30 0001604950 us-  
gaap:RestrictedStockUnitsRSUMemberscpsh:TwoThousandSeventeenStockPlanMember 2024-09-30 0001604950  
scph:TwoThousandTwentyThreeEmploymentInducementAwardPlanMember 2024-01-012024-09-30 0001604950 scph:OaktreeAgreementMember 2023-07-012023-09-30  
0001604950 scph:CreditAgreementMembers-gaap:WarrantMember 2024-01-012024-09-30 0001604950 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-  
012023-03-31 0001604950 us-gaap:AccountsPayableMember 2024-01-012024-09-30 0001604950 scph:TwoThousandAndSeventeenEmployeeStockPurchasePlanMember 2024-  
01-012024-09-30 0001604950 scph:CreditAgreementMembers-gaap:CommonStockMember 2024-08-09 0001604950 2023-01-012023-03-31 0001604950 us-  
gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001604950 us-gaap:RevenueFromContractWithCustomerMember 2023-01-012023-09-30 0001604950 us-  
gaap:FairValueInputsLevel3Members-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001604950 us-  
gaap:InterestRateFloorMemberscpsh:CreditAgreementMembers-gaap:SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember 2024-08-092024-08-09  
0001604950 2024-06-30 0001604950 us-gaap:CorporateDebtSecuritiesMembers-gaap:FairValueInputsLevel2Members-gaap:FairValueMeasurementsRecurringMember  
2023-12-31 0001604950 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001604950 scph:RevenuePurchaseAndSaleAgreementMember 2024-08-09 0001604950 us-  
gaap:AccountsPayableMembers-gaap:SupplierConcentrationRiskMemberscpsh:SupplierThreeMember 2024-01-012024-09-30 0001604950 us-gaap:CommonStockMember  
2023-06-30 0001604950 scph:CreditAgreementMembers-gaap:WarrantMember 2024-08-09 0001604950 us-gaap:RetainedEarningsMember 2024-07-012024-09-30  
0001604950 scph:PurchasesMember 2024-07-012024-09-30 0001604950 us-gaap:CommonStockMember 2024-06-30 0001604950 us-gaap:CommonStockMember 2022-12-31  
0001604950 us-gaap:RetainedEarningsMember 2023-06-30 0001604950 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001604950 2022-12-31 0001604950  
scph:TwoThousandTwentyThreeEmploymentInducementAwardPlanMember 2023-02-012023-02-01 pure-iso4217:USD shares shares scph:Customer scph:Supplier  
iso4217:USDQ3--12-31false0001604950 http://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-  
gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#PureFullLifeTermOffLeaseMemberhttp://fasb.org/us-  
gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-  
gaap/2024#OtherNonoperatingIncomeExpense2017-11-302027-11-302017-11-30P1Y10-Other2024-09-302024false001-382935CPHARMACEUTICALS INC.DE46-518407525  
Mail.RoadSuite.20301803BurlingtonMA617517-0730Common.stock.par.value\$.0.0001.per.shareSCPHNASDAQYesYesNon-accelerated  
Filtertruefalse50040134468140009148400029199000448900092170008840000181070002436000337300011600001148000929380001233290005800051000140100013300  
281346000-347649000-  
100037218000307990009447900012506900037960001062600074970002418200010790003311000203800073960000342100035410008471000894400014135000213200003712  
14839000-18146000-40139000-48433000-13032000-1303200029540002954000001830001830000-  
360001804000119300035870001301000903000397900024440002060000185000060310006085000-15634000-35105000-40998000-66303000-0.41-0.41-0.75-0.75-1.07-1.07-  
1.6-1.6387608953768095465584744655847438421676384216761516917415169174000-340001000-15630000-35105000-41032000-66302000359685104000318561000-  
281346000-100037218000-14108000-141080003275418100018100053145-166000-16600014400001440000100010003605449000320016000-32554540002566000-  
17999000-179990008539328300028300014910001491000361398024000321790000-3255440009250000-35105000-  
3510500017440001744000138750001000535460005354700021792470004700035401226000122600050401345000378353000-

[illegible]

width:fit-content;">99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> of revenue, respectively. For the three and nine months ended September 30, 2023,</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap,min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> customers represented</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap,min-width:fit-content;">92</span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">% and</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap,min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> customer represented</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap,min-width:fit-content;">88</span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">% of revenue, respectively.</span></p><p><span style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">The Company has a limited number of suppliers and contract manufacturers utilized in the production of its product. As of December 31, 2023 and September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">,</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap,min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> supplier represented</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap,min-width:fit-content;">47</span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">% and</span><span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap,min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> suppliers represented</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap,min-width:fit-content;">49</span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">% of accounts payable, respectively. For the three and nine months ended</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">,</span><span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap,min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> suppliers represented</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap,min-width:fit-content;">45</span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">% and</span><span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap,min-width:fit-content;">49</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">% of purchases, respectively. For the three and nine months ended September 30, 2023,</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap,min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> supplier represented</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap,min-width:fit-content;">29</span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">% and</span><span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap,min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> suppliers represented</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap,min-width:fit-content;">40</span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">%</span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">% of purchases, respectively.</span></p><p><span style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">The Company depends on suppliers for raw materials, active pharmaceutical ingredients, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers may take a substantial period of time, as suppliers must be approved by the FDA. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture its products, it could have a materially adverse effect on the Company's business, financial condition and results of operations.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Calibri,sans-serif,min-width:fit-content;"></span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">Investments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">Company invests excess cash balances in available-for-sale debt securities. The Company determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company reports available-for-sale investments at fair value at each balance sheet date and includes any unrealized gains and losses in accumulated other comprehensive income (loss), a component of stockholders' equity. Realized gains and losses are determined using the specific identification method and are included in other income. If any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">adjustment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is "other than temporary," including the intention to sell and, if so, marks the investment to market through a charge to the Company's consolidated statements of operations and comprehensive loss</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></span><span style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">Inventory</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company began capitalizing inventory costs following U.S. Food and Drug Administration ("FDA") approval of FUROSCIX on October 7, 2022. Inventory is sold on a first in, first out ("FIFO") basis. The Company periodically reviews inventory for expiry and obsolescence and writes it down accordingly, if necessary. Prior to FDA approval of FUROSCIX, the Company expensed all inventory-related costs, including that used for clinical development, to research and development ("R&D") costs in the period incurred.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use ("ROU") lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">Debt Issuance Costs</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">Debt issuance costs have been amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheet as of December 31, 2023.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">Fair Value Option</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">As permitted under Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 825, Financial Instruments ("ASC 825"), the Company elected the fair value option to account for the Credit Agreement and the Revenue Purchase and Sale Agreement (collectively, the "Perceptive Financing"). In accordance with ASC 825, the Company records these instruments at fair value with changes in fair value recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the Perceptive Financing were expensed as incurred and were not deferred.</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">The Company elected to account for the Perceptive Financing using the fair value option, which allows for valuing the Credit Agreement and the Revenue Purchase and Sale Agreement in their entirety versus bifurcation of the embedded derivatives.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">Revenue Recognition</span></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, Revenue from Contracts with Customer ("Topic 606"), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. The Company has identified one performance obligation, the delivery of FUROSCIX to its customers. The Company has not incurred any incremental costs associated with obtaining contracts with customers. The Company's revenues consist solely of the sale of FUROSCIX to customers in the United States.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic,min-width:fit-content;"></span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic,min-width:fit-content;">Product Net Sales</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic,min-width:fit-content;"></span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">FUROSCIX was approved by the FDA on October 7, 2022. The Company launched sales of FUROSCIX in the first quarter of 2023 and its customers consist of specialty pharmacies ("SPs") and specialty distributors ("SDs"). The Company recognizes revenue from product sales at a point in time, typically upon receipt of product at the SPs and SDs, the date at which the rights, title, interest and risk of loss are transferred. Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration that result from (a) sales discounts, (b) rebates (c) co-pay assistance, and (d) product returns. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves for variable consideration are reflected as either as a reduction to the related account receivable or as an accrued liability, depending on how the consideration is settled. The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results vary from its estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></p></div>

[illegible]

style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">The Company has a limited number of suppliers and contract manufacturers utilized in the production of its product. As of December 31, 2023 and September 30, 2024,</span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">,</span></span><span style="font-size:10pt;font-family:Arial;color:#000000:white-space:pre-wrap,min-width:fit-content;">one</span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">supplier represented</span></span><span style="font-size:10pt;font-family:Arial;color:#000000:white-space:pre-wrap,min-width:fit-content;">47</span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> and</span></span><span style="font-size:10pt;font-family:Arial;color:#000000:white-space:pre-wrap,min-width:fit-content;">three</span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">suppliers represented</span></span><span style="font-size:10pt;font-family:Arial;color:#000000:white-space:pre-wrap,min-width:fit-content;">49</span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> of accounts payable, respectively. For the three and nine months ended</span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">September 30, 2024,</span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">,</span></span><span style="font-size:10pt;font-family:Arial;color:#000000:white-space:pre-wrap,min-width:fit-content;">two</span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">suppliers represented</span></span><span style="font-size:10pt;font-family:Arial;color:#000000:white-space:pre-wrap,min-width:fit-content;">45</span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> of purchases, respectively. For the three and nine months ended September 30, 2023,</span></span><span style="font-size:10pt;font-family:Arial;color:#000000:white-space:pre-wrap,min-width:fit-content;">one</span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">suppliers represented</span></span><span style="font-size:10pt;font-family:Arial;color:#000000:white-space:pre-wrap,min-width:fit-content;">49</span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> of purchases, respectively.</span></p><p><span style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company depends on suppliers for raw materials, active pharmaceutical ingredients, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers may take a substantial period of time, as suppliers must be approved by the FDA. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture its products, it could have a materially adverse effect on the Company's business, financial condition and results of operations.</span></p><p><span style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Investments</span></p><p><span style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company depends on suppliers for raw materials, active pharmaceutical ingredients, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers may take a substantial period of time, as suppliers must be approved by the FDA. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture its products, it could have a materially adverse effect on the Company's business, financial condition and results of operations.</span></p><p><span style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Company invests excess cash balances in available-for-sale debt securities. The Company determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company reports available-for-sale investments at fair value at each balance sheet date and includes any unrealized gains and losses in accumulated other comprehensive income (loss), a component of stockholders' equity. Realized gains and losses are determined using the specific identification method and are included in other income. If any,</span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">adjustment</span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is "other than temporary," including the intention to sell and, if so, marks the investment to market through a charge to the Company's consolidated statements of operations and comprehensive loss</span></p><p><span style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Inventory</span></p><p><span style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company began capitalizing inventory costs following U.S. Food and Drug Administration ("FDA") approval of FUROSCIX on October 7, 2022. Inventory is sold on a first in, first out ("FIFO") basis. The Company periodically reviews inventory for expiry and obsolescence and writes it down accordingly, if necessary. Prior to FDA approval of FUROSCIX, the Company expensed all inventory-related costs, including that used for clinical development, to research and development ("R&D") costs in the period incurred.</span></p><p><span style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Leases</span></p><p><span style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use ("ROU") lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets.</span></span><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term</span></p><p><span style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Debt Issuance Costs</span></p><p><span style="color:#000000:white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic,min-width:fit-content;">Fair Value Option</span></p><p><span style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As permitted under Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 825, Financial Instruments ("ASC 825"), the Company elected the fair value option to account for the Credit Agreement and the Revenue Purchase and Sale Agreement (collectively, the "Perceptive Financing"). In accordance with ASC 825, the Company records these instruments at fair value with changes in fair value recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the Perceptive Financing were expensed as incurred and were not deferred.</span></p><p><span style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Revenue Recognition</span></p><p><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, Revenue from Contracts with Customer ("Topic 606"), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. The Company has identified one performance obligation, the delivery of FUROSCIX to its customers. The Company has not incurred any incremental costs associated with obtaining contracts with customers. The Company's revenues consist solely of the sale of FUROSCIX to customers in the United States.</span></p><p><span style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Product Net Sales</span></p><p><span style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Sales Discounts</span></p><p><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">Sales discounts are agreed-upon discounts, from negotiated contracts, taken directly off the Company's sales invoices. Sales discounts are recorded as an offset to revenue based on contractual terms at the time revenue from the sale is recognized.</span></p><p><span style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Rebates</span></p><p><span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">Allowance for rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare Part D prescription drug benefit, TRICARE program and contractual rebates with commercial payers. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or statutory requirements. The allowance for rebates is based on contracted or statutory discount rates and expected utilization by benefit plan participants. The Company's estimates for expected utilization of rebates are based on utilization data received from the SPs since product launch. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the

amount expected to be incurred for the current quarter's activity, plus an accrual balance for prior quarters' unpaid rebates. If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.

Research and Development Costs

Research and development costs are expensed as incurred. Nonrefundable advance payments, if any, for goods or services used in research and development are initially recorded as an asset and then recognized as an expense as the related goods are delivered or services are performed. Research and development expenses include contract services, consulting, salaries, materials and supplies and overhead.

Income Taxes

Income Taxes

Deferred tax assets and liabilities are recorded to reflect the impact of temporary differences between amounts of assets and liabilities for financial reporting purposes and such amounts as measured under enacted tax laws. A valuation allowance is required to offset any net deferred tax assets if, based upon the available evidence, it is more likely than not that some or all of the deferred tax asset will not be realized.

The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions. The tax benefits recorded are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is "more likely than not" to be realized following resolution of any uncertainty related to the tax benefit, assuming that the matter in question will be raised by the tax authorities. Potential interest and penalties associated with such uncertain tax positions are recorded as a component of income tax expense.

At September 30, 2024, the Company had no such accruals.

As part of the Tax Cuts and Jobs Act of 2017 ("TCJA"), beginning with the Company's fiscal year ended December 31, 2022, the Company is required to capitalize research and development expenses, as defined under section 174 of the Internal Revenue Code of 1986, as amended. For expenses that are incurred for research and development in the United States, the amounts will be amortized over 5 years.

The following table sets forth the computation of basic and diluted net loss per share of common stock (in thousands, except share and per share data):

Net Loss per Share Attributable to Common Stockholders	
Three Months Ended September 30,	
2023	2024
Basic	
Diluted	

Net Loss per Share Attributable to Common Stockholders

Three Months Ended September 30,

2023

2024

Basic

Diluted







[illegible]





[illegible]

[illegible]





```
<div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></span></p></div>
```

[illegible]

[illegible]

[illegible]

[illegible]

active; or for which all significant inputs are observable, either directly or indirectly.

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 3—Valuations that require inputs that reflect the Company's own assumptions that are both significant to the fair value measurement and observable.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The carrying values of the Company's cash, prepaid expenses and deposits approximate their fair values due to their short-term nature.

The following tables summarize the Company's assets that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands).

Asset	Level 1	Level 2	Level 3
Auto	37.84%	62.16%	0.00%
Box-sizing: content-box	11.68%	88.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.68%	98.32%	0.00%
Box-sizing: content-box	1.74%	98.26%	0.00%
Box-sizing			



[illegible]



[illegible]





[illegible]

[illegible]



[illegible]



[illegible]







size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial,min-width:fit-content;"></span></p></tr><tr style="height:10pt;background-color:#fffff0;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial,min-width:fit-content;">Change in fair value of the term loan</span></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial,min-width:fit-content;"></span></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial,min-width:fit-content;"></span></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.954</span></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffff00;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial,min-width:fit-content;"></span></p></td></tr><tr style="height:10pt;background-color:#ff00f0;word-break:break-word;"><td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial,min-width:fit-content;">Total fair value of the term loan</span></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial,min-width:fit-content;"></span></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial,min-width:fit-content;">\$</span></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">51.099</span></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial,min-width:fit-content;"></span></p></td></tr></table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">On the Closing Date, the Company entered into the Credit Agreement. The Credit Agreement establishes a \$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> million term loan facility, consisting of (i) \$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> million funded on the Closing Date ("Tranche A Loan") and (ii) subject to satisfaction of certain conditions, \$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> million (together with the Tranche A Loan, collectively, the "Term Loan") that the Company may borrow in a single borrowing on or prior to March 31, 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">Borrowings under the Term Loan bear interest at a rate per annum equal to the one-month term SOFR (subject to a</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> floor), plus an applicable margin of</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">%, payable</span><span style="font-size:10pt;font-family:Arial;"></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> monthly</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> in arrears. There will be</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> scheduled repayments of outstanding principal on the Term Loan prior to</span><span style="font-size:10pt;font-family:Arial;"></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">August 9, 2029</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> and (i)</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">% of the principal amount of the Term Loan prepaid, if prepaid on or prior to the first anniversary of the Closing Date, (ii)</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">% of the principal amount of the Term Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, (iii)</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">% of the principal amount of the Term Loan if prepaid after the second anniversary of the Closing Date through and including the third anniversary of the Closing Date, with</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> prepayment premium due after the third anniversary of the Closing date through the Maturity Date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">On the Closing Date, the Company was required to issue to the Lenders of such Term Loan warrants to purchase</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">300,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> of shares of the Company's common stock, in the aggregate (the</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial,min-width:fit-content;">Warrant</span>), at an exercise price of \$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5902</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> Upon the completion of the sale of common stock on August 13, 2024 (Note 10), the exercise price of the warrants was adjusted to \$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> according to the terms of the agreement. Upon inception, the Company evaluated the warrants and determined that they met all the requirements for equity classification under ASC Topic 815</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> ("ASC 815"). This transaction was accounted for as a detachable warrant at its fair value, using the residual method, and is recorded as an increase to additional paid-in capital on the consolidated statement of stockholder's equity in the amount of \$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> million. The Company used the Black-Scholes option pricing model to determine the fair value of the warrants. Assumptions included the fair market value per share of common stock on the valuation date of \$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.33</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">, the exercise price per warrant equal to \$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">, the expected volatility of</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">87.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">%, the risk-free interest rate of</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> years and the absence of a dividend. The Warrant is immediately exercisable, and the exercise period will expire</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6 years</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> from the date of issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">In addition to the Warrant, the Company will be required to issue to the Lenders warrants to purchase</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">200,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> of shares of the Company's common stock (the "Tranche B Warrant") upon the draw down of the second tranche of the Term Loan on or prior to March 31, 2026. These warrants were accounted for using the residual method and were recorded on a relative fair value basis, resulting in an increase to additional paid-in capital on the consolidated statement of stockholder's equity in the amount of \$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> million. The Company used the Black-Scholes option pricing model to determine the fair value of the warrants. Assumptions included the fair market value per share of common stock on the valuation date of \$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.33</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">, the exercise price per warrant equal to \$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">, the expected volatility of</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">82.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">%, the risk-free interest rate of</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.87</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">%, the contractual term of</span><span style="font-size:10pt;font-family:Arial;"></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">7.64</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> years and the absence of a dividend. The Tranche B Warrant will expire</span><span style="font-size:10pt;font-family:Arial;"></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">6 years</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"> from the date of issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">The Company's obligations under the Credit Agreement and the other Loan Documents (as defined in the Credit Agreement) will be guaranteed by any domestic subsidiaries of ours that become Guarantors (as defined in the Credit Agreement), subject to certain exceptions. The Borrowers' and the Guarantors' (collectively, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Loan Parties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;">) respective obligations under the Credit Agreement and the other Loan Documents are secured by first priority security interests in substantially all assets of the Loan Parties, subject to certain customary thresholds and exceptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial,min-width:fit-content;"></span></p></tr></table></div>

contains customary representations, warranties and affirmative and negative covenants, including financial covenants requiring the Company to (i) maintain certain levels of cash and cash equivalents in accounts subject to a control agreement in favor of the Agent of at least \$5.0 million at all times after the Closing Date and (ii) meet minimum quarterly net sales targets described in the Credit Agreement.

On the Closing Date, the Company also entered into the Revenue Purchase and Sale Agreement with the Purchaser. Under the Revenue Purchase and Sale Agreement, in exchange for the Purchaser's payment to the Company of a purchase price of up to \$50.0 million, in the aggregate, the Company has agreed to sell to the Purchaser its right to receive payment in full of a tiered single digit percentage of net sales of FUSOCIX. The initial sale of the Revenue Payment under the Revenue Purchase and Sale Agreement in the amount of \$25.0 million took place on the Closing Date. The Purchaser's right to receive the Revenue Payment terminates and the Company no longer has the obligation to pay Purchaser Revenue Payments once the Purchaser receives 200.0% of the Revenue Payments received by such dates of the Purchase Price. The Company may also buy-out the Purchaser's rights to receive the Revenue Payments by paying Purchaser a tiered multiple on the Purchaser Price.

The Revenue Purchase and Sale Agreement contains various representations and warranties, including with respect to organization, authorization, and certain other matters, certain covenants with respect to payment, reporting, intellectual property, in-licenses, out-licenses, and certain other actions, indemnification obligations and other provisions customary for transactions of this nature.

The fair value of the Term Loan and the Revenue Purchase and Sale Agreement were \$48.1 million, respectively. As of September 30, 2024, the fair value of the Term Loan and the Revenue Purchase and Sale Agreement were \$25.0 million, respectively. Refer to Note 8 of the Financial Instruments for additional details regarding the fair value measurement.

The following table presents the carrying value of the Company's debt balance as of December 31, 2023 (in thousands).

Debt Instrument	Carrying Value as of December 31, 2023 (in thousands)
Term Loan	\$48.1
Revenue Purchase and Sale Agreement	\$25.0
<b>Total</b>	<b>\$73.1</b>

The following table presents the carrying value of the Company's debt balance as of December 31, 2023 (in thousands).

Debt Instrument	Carrying Value as of December 31, 2023 (in thousands)
Term Loan	\$48.1
Revenue Purchase and Sale Agreement	\$25.0
<b>Total</b>	<b>\$73.1</b>

[illegible]

[illegible]

(the "2024 ATM Program"). The offering and sale of the 2024 ATM Shares will be made pursuant to the Company's shelf registration statement on Form S-3, which was declared effective by the SEC on March 22, 2024 (the "2024 Registration Statement"). There were <span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span></span> shares issued under the 2024 ATM Program as of September 30, 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Sale of Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On August 13, 2024, the Company completed an underwritten public offering of</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,875,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of its common stock,</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"> par value per share (the "2024 Offering Shares"), and, in lieu of shares of common stock to certain select investors, pre-funded warrants to purchase up to an aggregate of</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock at an exercise price equal to</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.00</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> per share, pursuant to the 2024 Registration Statement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The 2024 Offering Shares were sold at an offering price of</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.00</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> per share. The pre-funded warrants were sold at an offering price of</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.999</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> per underlying share, which was equal to the price per share of common stock being sold in this offering, minus</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> per share, which is the exercise price per share of the pre-funded warrants. The pre-funded warrants were accounted for as equity instruments. Net proceeds of the offering were</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">53.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, after deducting underwriting discounts, commissions and offering expenses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"></span></p><p>035000000017260439.011520000050000000138750000.00015000000.00143.99990.00153500000<span style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">11. Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Stock Options</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company's 2017 Stock Option and Incentive Plan (the "2017 Stock Plan") became effective in</span><span style="font-size:10pt;font-family:Arial;">sec-ix</span><span style="font-size:10pt;font-family:Arial;min-width:fit-content;">November 2017</span><span style="font-size:10pt;font-family:Arial;min-width:fit-content;">upon the closing of the Company's initial public offering and will expire in</span><span style="font-size:10pt;font-family:Arial;">sec-ix</span><span style="font-size:10pt;font-family:Arial;min-width:fit-content;">October 2027</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Under the 2017 Stock Plan, the Company may grant incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units ("RSUs") and other stock-based awards. The Company's 2014 Stock Incentive Plan (the "2014 Stock Plan") was terminated in</span><span style="font-size:10pt;font-family:Arial;">sec-ix</span><span style="font-size:10pt;font-family:Arial;min-width:fit-content;">November 2017</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">effective upon the completion of the Company's initial public offering and</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> further options will be granted under the 2014 Stock Plan. At</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">September 30, 2024, there were</span><span style="font-size:10pt;font-family:Arial;min-width:fit-content;">555,427</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ions outstanding under the 2014 Stock Plan.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of September 30, 2024, there we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">8,769,977</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of the Company's common stock authorized for issuance under the 2017 Stock Plan, including</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">366,823</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> options that have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">been forfeited from the 2014 Stock Plan.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">At September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">there were</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,206,310</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> options available for issuance under the 2017 Stock Plan,</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,775,676</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> options outstanding and</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">721,766</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> RSUs outstanding.</span></p><p style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"><span style="font-size:10pt;font-family:Arial;min-width:fit-content;">As of September 30, 2024, the Board of Directors of the Company adopted the 2023 Employment Inducement Award Plan (the "Inducement Plan") and, subject to the adjustment provisions of the Inducement Plan, reserved</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of the Company's common stock for issuance pursuant to equity awards granted under the Inducement Plan. At</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">there were</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">385,628</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> options available for issuance under the Inducement Plan, and</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">114,372</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> options outstanding.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Awards granted under the 2017 Stock Plan and the Inducement Plan have a term of</span><span style="font-size:10pt;font-family:Arial;">ten years</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">vesting of awards under the 2017 Stock Plan and Inducement Plan is determined by the board of directors, but is generally over</span><span style="font-size:10pt;font-family:Arial;">sec-ix</span><span style="font-size:10pt;font-family:Arial;min-width:fit-content;">

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

family:Arial;min-width:fit-content;">					
	<td style="vertical-align:top;"></td> <td><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"></span>Weighted-average remaining lease term - operating leases</td> <td></td> <td style="vertical-align:bottom;"></td>		<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p> <span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"></span> Weighted-average remaining lease term - operating leases		
	<span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"></span>				
		<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p>	<span style="font-family:Arial;"></span>	<span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"></span> 5.5	
		<span style="font-family:Arial;"></span>	<span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"></span> years		
		<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p>	<span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"></span>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p>	
		<span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"></span>			
		<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p>	<span style="font-family:Arial;"></span>	<span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"></span> 4.8	
		<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p>	<span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"></span>		
		<span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"></span>			
		<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p>	<span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"></span> Weighted-average discount rate - operating leases		
		<span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"></span>	<span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"></span>		
		<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p>	<span style="font-family:Arial;min-width:fit-content;"></span>		
		<span style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></span>	<span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"></span> 11.6		
		<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p>	<span style="font-family:Arial;min-width:fit-content;"></span>		
		<span style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></span>	<span style="color:#000000;font-family:Arial;min-width:fit-content;"></span> %		
		<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p>	<span style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></span>		
		<span style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></span>	<span style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></span>		
		<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p>	<span style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></span>		
		<span style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></span>	<span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"></span> 12.1		
		<span style="white-space:nowrap;vertical-align:bottom;"></span>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p>		
		<span style="color:#000000;font-family:Arial;min-width:fit-content;"></span> %			

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--